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For proteins the link between their structure and their function is a central tenet of 
biology. A common approach to understanding protein function is to ‘solve’ its 
structure and subsequently probe interactions between the protein and its binding 
partners. The first part of this approach is non-trivial for proteins where localised 
regions or even their entire structure fail to fold into a three-dimensional structure 
and yet they possess function. These so called intrinsically or inherently disordered 
proteins (IDP’s) or intrinsically disordered regions (IDR’s) constitute up to 40% of 
all expressed proteins. IDPs which have crucial roles in molecular recognition, 
assembly, protein modification and entropic chain activities, are often  dynamic with 
respect to both conformation and interaction, so in the course of a protein’s ‘lifespan’ 
it will sample many configurations and bind to several targets. For these proteins, 
there is a need to develop new methods for structure characterization which exploit 
their biophysical properties. The solvent free environment of a mass spectrometer is 
ideally suited to the study of intrinsic interactions and how they contribute to 
structure. Ion mobility mass spectrometry is uniquely able to observe the range of 
structures an IDP can occupy, and also the effect of selected binding partners on 
altering this conformational space. 
This thesis details the technique of ion mobility mass spectrometry and illustrates its 
use in assessing the relative disorder of p53 protein. The tumour suppressor p53 is at 
the hub of a plethora of signalling pathways that maintain the integrity of the human 
genome and regulate the cell cycle. Deregulation of this protein has a great effect on 
carcinogenesis as mutated p53 can induce an amplified epigenetic instability of 
tumour cells, facilitating and accelerating the evolution of the tumour. Herein mass 
spectrometry provides a compelling, detailed insight into the conformational 
flexibility of the p53 DNA-binding domain. The plasticity of the p53 DNA-binding 
domain is reflected in the existence of more than one conformation, independent of 
any conformational changes prompted by binding. The in vacuo conformational 




the second-site suppressor mutation from loop L1, H115N, is probed whether it 
could trigger conformational changes in p53 hotspot cancer mutations. The structural 
basis of the binding promiscuity of p53 protein is investigated; of particular interest 
is the molecular interaction of the p53 N-terminus with the oncoprotein murine 








Proteins are fundamental components of all living cells and are necessary for the 
proper functioning of an organism. The building blocks of proteins are called amino 
acids. Proteins differ from one another primarily in their sequence of amino acids, 
dictated by the nucleotide sequence of their genes, which usually results in folding of 
the protein into a specific three-dimensional shape that determines its activity. 
However proteins are not entirely rigid molecules. Proteins may transit between a 
number of related structures while they execute their functions. In the context of 
these functional rearrangements, these structures are usually referred to as 
conformations, and transitions between them are termed conformational changes. 
This work is devoted to protein p53 that is a tumour suppressor, which in humans is 
encoded by the TP53 gene. More than fifty percent of human tumours contain a 
mutation or deletion of the TP53 gene. These mutations can cause errors in protein 
amino acid sequence, producing partially or completely non-functional proteins. 
Each cell, in order to function correctly, is dependent on a myriad of proteins to 
function in the right places at the right times. When a mutation affects a protein that 
plays a critical role in the body, a disease can develop. Mutant p53, however, does 
not function properly, allowing the cancer cells it routinely would target to slip 
through control mechanisms and proliferate. For this reason, the protein is a key 
target of research on cancer therapeutics. Here the various forms of p53 protein are 
captured and the conformational changes associated with binding to DNA and other 
interacting proteins are described. The diverse shapes of most common mutant 










ATD   arrival time distribution 
AMBER assisted model building with energy refinement 
ATM  atomic force microscopy 
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MoRF  molecular recognition feature 
MS   mass spectrometry 
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Physical Constants and Quantities 
 
e   elementary charge   
E   electric field strength   
K   mobility    
K0  reduced mobility   
kB  Boltzmann constant   
L  drift cell length    
m   mass      
MR  relative molecular weight  
m/z  mass to charge ratio 
N   number density    
P  pressure     
T  temperature    
t0  dead time    
ta  arrival time    
td  drift time    
v   velocity     
V   potential difference   
vd   drift velocity     
z  nominal charge 
μ   reduced mass    
ν   RF     








Table of Contents 
Declaration ................................................................................................................... i 
Acknowledgements ..................................................................................................... ii 
Abstract ...................................................................................................................... iii 
Lay Summary ............................................................................................................. v 
Abbreviations ............................................................................................................ vi 
Physical Constants and Quantities .......................................................................... ix 
 
1. Introduction and Motivation ........................................................................ - 1 - 
1.1. The Rules of Disorder and Why Disorder Rules ................................ - 1 - 
1.2. Intrinsically Disordered Proteins: definition, detection and beyond - 2 - 
1.2.1. Definition and Unique Properties of IDPs ...................................... - 2 - 
1.2.2. Functions of IDPs: the D2 Concept ................................................. - 5 - 
1.2.3. Experimental Identification and Prediction Methods ..................... - 6 - 
1.3. The Tumour Suppressor p53: Puzzle and Paradigm......................... - 8 - 
1.3.1. The Bigger Picture: Quaternary Structure of p53 ......................... - 12 - 
1.3.2. Post-translational Modifications of p53 ........................................ - 15 - 
1.4. p53:Mdm2 - the Affair that Never Ends ........................................... - 16 - 
1.5. The Case for Mass Spectrometry as a Tool to Study IDP’s ............ - 17 - 
1.6. Ion Mobility Mass Spectrometry - to determine Conformation(s) . - 19 - 
1.6.1. Drift Tube Ion Mobility Mass Spectrometry ................................ - 22 - 
1.6.2. Travelling Wave Ion Mobility Mass Spectrometry ...................... - 25 - 
1.6.3. Field Asymmetric Waveform Ion Mobility Mass Spectrometry .. - 27 - 
1.7. Summary .............................................................................................. - 28 - 
1.8. References ............................................................................................ - 29 - 
 
Chapter Two 
2. Experimental Methods ............................................................................... - 43 - 
2.1. Reagents ............................................................................................... - 43 - 
2.2. Sample Introduction - Ionisation ....................................................... - 43 - 




2.4. Drift Tube based IM-MS - the MoQToF .......................................... - 46 - 
2.4.1. Instrument Layout ......................................................................... - 46 - 
2.4.2. Drift Tube Architecture ................................................................. - 50 - 
2.4.2.1. Drift Gas .................................................................................... - 52 - 
2.4.2.2. Pressure and Temperature Regulation ...................................... - 52 - 
2.4.3. Instrument Tuning Parameters ...................................................... - 52 - 
2.4.4. Data Acquisition and Analysis: an example ................................. - 54 - 
2.4.4.1. Multiple ATD Peak Fitting ....................................................... - 60 - 
2.5. Travelling Wave based IM-MS - Synapt HDMS ............................. - 62 - 
2.5.1. Instrument Layout and Operation ................................................. - 62 - 
2.5.1.1. Travelling Wave Ion Guide Topology ...................................... - 63 - 
2.5.1.2. Instrument Tuning Parameters and Typical Pressures .............. - 65 - 
2.5.2. Calculation of CCS using TW IM-MS data .................................. - 68 - 
2.6. Mass Calibration ................................................................................. - 69 - 
2.7. Optimization of experimental conditions .......................................... - 70 - 
2.8. Estimation of collision cross sections from PDB structures ............ - 71 - 
2.8.1. Projection Approximation Method ............................................... - 72 - 
2.8.2. Exact Hard Sphere Scattering Method .......................................... - 73 - 
2.8.3. Trajectory Method ......................................................................... - 73 - 
2.8.4. Projected Superposition Approximation Method.......................... - 73 - 
2.9. References ............................................................................................ - 75 - 
 
Chapter Three 
3. p53 DNA-binding domain in vacuo ........................................................... - 80 - 
3.1. Introduction ......................................................................................... - 80 - 
3.2. How p53 binds DNA............................................................................ - 82 - 
3.3. Methodology ........................................................................................ - 84 - 
3.3.1. Protein Expression and Purification .............................................. - 84 - 
3.3.2. Sample Preparation ....................................................................... - 84 - 
3.3.2.1. DNA Oligonucleotides .............................................................. - 85 - 
3.3.3. Mass Spectrometry and Ion Mobility Mass Spectrometry ............ - 85 - 
3.3.4. Theoretical Measurements of collision cross sections .................. - 86 - 




3.4. Insights into Structure(s) and Dynamics of WT p53-DBD by MS and 
IM-MS .............................................................................................................. - 87 - 
3.4.1. MS of WT p53-DBD in buffered solution conditions .................. - 87 - 
3.4.2. MS of WT p53-DBD in denaturing solution conditions ............... - 89 - 
3.4.3. MS of WT p53-DBD in high buffer solution conditions .............. - 90 - 
3.4.4. Conformational Landscapes occupied by WT p53-DBD ............. - 91 - 
3.4.4.1. Collision Cross Sections of WT p53-DBD ............................... - 97 - 
3.5. Interactions of WT p53-DBD with its consensus DNA binding site - 99 - 
3.5.1. WT p53-DBD dimer bound to ds 12 mer DNA ............................ - 99 - 
3.5.2. WT p53-DBD tetramer bound to ds 20 mer DNA ...................... - 104 - 
3.6. Summary ............................................................................................ - 106 - 
3.7. References .......................................................................................... - 107 - 
 
Chapter Four 
4. Common p53 Cancer Mutants ................................................................. - 112 - 
4.1. Mapping Cancer Mutations on the DNA-binding Domain ........... - 112 - 
4.2. Structural Classes of p53 Core Domain Cancer Mutants ............. - 113 - 
4.2.1. DNA-contact Mutations .............................................................. - 113 - 
4.2.2. Structural Mutations in the L3 loop ............................................ - 114 - 
4.2.3. Disruption of the Zinc-binding Region ....................................... - 114 - 
4.2.4. Structural Mutations at the Periphery of the DBD ...................... - 115 - 
4.2.5. β-sandwich Mutations ................................................................. - 115 - 
4.3. Rescue of p53 Mutants by ‘Conformational’ Drugs ...................... - 116 - 
4.4. Methodology ...................................................................................... - 118 - 
4.4.1. Site-directed Mutagenesis, p53 Expression and Purification ...... - 118 - 
4.4.2. Sample Preparation ..................................................................... - 119 - 
4.4.3. Mass Spectrometry and Ion Mobility Mass Spectrometry .......... - 120 - 
4.4.4. Production of Waterfall Plots for data obtained via TW IM-MS - 121 - 
4.4.5. Production of Waterfall Plots for data obtained via DT IM-MS - 121 - 
4.5. Insights into the Diverse Conformational Nature of Common p53 
Cancer Mutants ............................................................................................. - 122 - 
4.5.1. Structural Mutation in the L3 loop - R249A ............................... - 122 - 




4.5.3. K292I Mutation ........................................................................... - 126 - 
4.5.4. A276Y Mutation ......................................................................... - 128 - 
4.5.5. Disruptions of the Zinc-binding Region - R175H ...................... - 130 - 
4.6. Mechanism of Rescue of Common p53 Cancer Mutants by Second-site 
Suppressor Mutations ................................................................................... - 132 - 
4.6.1. Cold Spot Mutations used as Second-site Suppressors ............... - 133 - 
4.6.2. Engineered Mutation in the L1 loop - H115N ............................ - 133 - 
4.6.3. DNA-binding properties of H115N Mutant ................................ - 136 - 
4.6.4. Double Mutant R249A/H115N ................................................... - 142 - 
4.6.5. Double Mutant R273H/H115N ................................................... - 144 - 
4.6.6. Double Mutant R248Q/H115N ................................................... - 145 - 
4.7. Summary ............................................................................................ - 147 - 
4.8. References .......................................................................................... - 149 - 
 
Chapter Five 
5. Promiscuous Interactions of p53 ............................................................. - 155 - 
5.1. Methodology ...................................................................................... - 156 - 
5.1.1. Protein Expression and Purification ............................................ - 156 - 
5.1.2. Sample Preparation ..................................................................... - 157 - 
5.1.3. Mass Spectrometry and Ion Mobility Mass Spectrometry .......... - 158 - 
5.2. Highly Disordered p53-N-Terminal Region ................................... - 158 - 
5.2.1. MS of p53-N-Terminus in buffered solution conditions............. - 160 - 
5.2.2. Conformational Flexibility of p53-N-Terminal Region .............. - 161 - 
5.3. Molecular Architecture of p53-N-DBD ........................................... - 163 - 
5.3.1. MS of p53-N-DBD in buffered solution conditions ................... - 164 - 
5.3.2. Conformational Landscapes adopted by p53-N-DBD ................ - 165 - 
5.4. The Quest for Stable p53 - Quadruple Mutant of p53-DBD: 
M113/V203/N239Y/N268D ........................................................................... - 168 - 
5.4.1. MS of SS p53-DBD in buffered solution conditions .................. - 170 - 
5.4.2. Conformational Populations occupied by SS p53-DBD ............. - 172 - 
5.5. Architecture of p53:Mdm2 Complex .............................................. - 175 - 
5.5.1. Mdm2 N-terminal - MS and IM-MS perspective ....................... - 176 - 
5.5.2. Interactions of p53-Mdm2 probed by IM-MS ............................ - 180 - 




5.6.1. MS of BcL-xL∆L∆C in buffered solution conditions ................. - 188 - 
5.6.2. Collision cross sections of BcL-xL∆L∆C ................................... - 189 - 
5.6.3. Molecular Interaction of N-terminal Domain of p53 with anti-
apoptotic BcL-xL ........................................................................................ - 192 - 
5.7. Summary ............................................................................................ - 193 - 
5.8. References .......................................................................................... - 195 – 
 
Chapter Six 
6. Conclusions ................................................................................................ - 201 - 
 
Appendices 
Appendix 1: Amino Acid Abbreviations ............................................................ - 204 - 
Appendix 2: Amino Acid R Groups.................................................................... - 205 - 
Appendix 3: Properties of Drift Gases ................................................................ - 206 - 
Appendix 4: Metric System Unit Prefixes .......................................................... - 207 - 
Appendix 5: Physical Constants, Symbols and Units ......................................... - 208 - 













Introduction and Motivation 
The very idea of structural disorder threatens the dogma of structural biology. The 
relevance of dynamically structured proteins in all kingdoms of life, in a myriad of 
cell functions and their significance in pathology means that conformational 
flexibility cannot be ignored. Mass spectrometry and ion mobility mass spectrometry 
can examine these heterogeneous flexible structures and their dynamics in the 
solvent free environment of a mass spectrometer. These techniques offer a capability 
to probe the conformational flexibility, binding and folding on binding and could 
also be adopted as a screening tool to assess the effects of interacting ligand 
molecules, or post transitional modifications, on intrinsically disordered protein 
conformations. 
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1. Introduction and Motivation 
1.1. The Rules of Disorder and Why Disorder 
Rules 
The name protein is derived from the Greek ‘proteos’ meaning ‘of first importance’ 
or ‘primary’. According to Greek mythology, Proteus was a prophetic god of the sea 
who could change his form at will. ‘Proteus modo se tenuabit in undas, Nunc leo, 
nunc arbor, nunc erit hirtus aper’ Like Proteus will melt into a sea wave, or will 
appear as a lion, or a trea, or a bristly wild boar (Ars Amatoria, 1, 755‐766 di 
Ovidio). From this feature of Proteus comes the adjective ‘protean’ which is used to 
describe something extremely flexible, versatile or capable of assuming many forms. 
These connotations extremely well define the nature of the class of proteins that lack 
a unique three-dimensional structure, known as intrinsically disordered proteins 
(IDPs), which indeed are very ‘protean’ proteins. The intriguing protein family of 
natively unfolded proteins contradicts one of the cornerstones of molecular biology, 
that is, the structure-function paradigm: the concept that well-defined structure is the 
prerequisite of function. This notion, formulated by Fisher et al. (1) in 1894 as a 
lock-and-key model for explaining the remarkable specificity of the enzymatic 
hydrolysis of glucosides, has proved to be exceptionally fruitful. Uversky et al. (2) 
even considered the protein-structure paradigm as the big bang, forming the universe 
of modern protein science. The finding that a large fraction of proteins (over 30%) in 
eukaryotic cells lack a tertiary structure but are functional has forced the scientific 
community to review its understanding of the structure-function paradigm (3). The 
involvement of many of these intrinsically unstructured proteins (IUPs) in 
intracellular signalling and regulatory processes as well as their central positioning 
(as interaction hubs) in recently mapped protein interaction networks is particularly 
intriguing (4). The existence of IDPs has ‘raised eyebrows’ for a decade, but it is 
now becoming evident that a radical transition is taking place by ‘unstructural’ 
biology getting into the mainstream of molecular biology. Rapid growth of the field 
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has been marked by several excellent recent reviews (4-7) including a textbook of 
comprehensive coverage (8). 
1.2. Intrinsically Disordered Proteins: definition, 
detection and beyond 
1.2.1. Definition and Unique Properties of IDPs 
Generally, IDPs can be defined as polypeptide chains that lack a unique fold, either 
entirely or in parts (9). Instead, they populate several heterogeneous conformations 
of similar energy that interconvert on a number of timescales and are more dynamic 
than folded globular proteins (7). IDPs and intrinsically disordered regions (IDRs) 
can be either collapsed (as a native molten globule), or extended (as a native coil or 
premolten globule) (10,11).  
A number of terms have been used to indicate the disordered characteristics of these 
proteins, such as natively denatured (12), natively unfolded (13), intrinsically 
unstructured (14), intrinsically denatured (12), intrinsically unfolded (13), 
intrinsically disordered (11), floppy (15), flexible (16), mobile (17), partially folded 
(18), vulnerable (19), chameleon (20), malleable (21), dancing proteins (22), protein 
clouds (23). The most often used expression is intrinsically disordered proteins in 
recent literature and by a ‘silent’ agreement is considered as the most appropriate 
descriptor of the phenomenon.  
A common trait of IDPs/IDRs is the low portion of bulky hydrophobic (Ile, Leu, and 
Val) and aromatic (Trp, Tyr, and Phe) groups, considered as ‘ordering’ amino acids 
(24). These order-promoting groups form and stabilise the hydrophobic cores of 
folded globular proteins that interact favourably with each other inside the fold, away 
from solvent. By contrast, IDPs are substantially enriched in polar (Arg, Gly, Gln, 
Ser, Pro, Glu, and Lys) and structure-breaking (Gly and Pro), amino acid residues 
considered as a source of disorder (9,25-27). These compositional differences 
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enabled a coarse prediction of disorder from primary sequence information alone via 
a numerous developed disorder predictors (28-30).  
The binding of IDPs contrast with that of ordered proteins since they interact with 
their target via short molecular recognition features (MoRFs) which are motifs (10-
70 amino acid residues) within unstructured segments, which undergo disorder-to-
order transition upon binding to their partner. It has also been suggested by 
Gunasekaran et al. (31,32) that IDPs provide larger surface areas for intermolecular 
interactions than globular proteins of similar size. Such large and flexible interaction 
surfaces can be a major advantage and assist the assembly of intertwined multimeric 
complexes (33).  Further, the high flexibility of intrinsically unstructured protein 
segments allows wrapping around their binding partners, thereby creating an 
extensive interaction surface (Figure 1.1). 
 
Figure 1.1: Folding only as needed, p27 (green) can wrap around many different partners. 
Illustration by AXS Biomedical Animation Studio (34). 
Many IDPs/IDRs fold upon binding to their physiological partner targets, a puzzling 
matter is whether folding occurs before binding or binding occurs before folding? 
Wright and Dyson et al. (35) proposed two extreme mechanisms: induced folding 
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and conformational selection (Figure 1.2). In the first process, the protein associates 
with its binding target in a disordered state and subsequently folds in association with 
the binding partner. In the conformational selection mechanism, the target protein 
‘selects’ a conformational isomer which closely resembles that of the bound form 
from the repertoire of conformations populated by the IDP (36). 
 
Figure 1.2: Schematic showing two possible mechanisms of coupled folding and binding: folding 
upon binding and conformational selection. Image taken from Wright and Dyson et al. (35). 
This concept is equivalent to the induced fit-fluctuation fit (conformational selection) 
duality of molecular recognition. In real systems, one or other or both mechanism(s) 
are likely to be favoured. For many IUPs, coupled folding upon binding forms 
complexes with relatively low affinities, notably though, these complexes are in most 
cases highly specific, as their formation is facilitated by MoRFs and modulated by 
specific post translational modifications. The manifestation of these highly 
specific/low-affinity complexes could be invaluable for signalling proteins that need 
to be able to associate specifically to transmit a signal but also dissociate easily when 
conditions are altered (5,37). In contrast, according to Tompa et al. (38) many IDPs 
hardly ever become fully ordered even in the bound state, but show a significant 
amount of structural disorder or polymorphism in protein complexes. This 
phenomenon termed ‘fuzziness’ represents the extension of the paradigm of structural 
disorder to the functional-bound-state. 
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1.2.2. Functions of IDPs: the D2 Concept 
Intrinsic disorder is prevalently associated with human diseases, including cancer, 
cardiovascular disease, amyloidoses, neurodegenerative diseases, and diabetes, 
giving rise to the D
2
 (disorder in disorders) concept (39). In 2002 Iakoucheva et al. 
(40) applied a neural network predictor of disorder to several data sets of proteins 
related to various diseases. 79% of cancer-related and 66% of cell-signalling proteins 
were found to contain predicted regions of disorder that were 30 residues or longer. 
The overall findings of another analysis performed by Uversky et al. (39) for 
proteins associated with cancer, cardiovascular disease and diabetes are shown below 
in Figure 1.3, which represents percentage of proteins with at least 30 consecutive 
amino acid residues predicted to be disordered.  
 
Figure 1.3: Abundance of intrinsic disorder in disease-associated proteins. Percentages of 
disease-associated proteins with 30 - 100 consecutive residues predicted to be disordered. The 
error bars represent 95% confidence intervals and were calculated using 1000 bootstrap 
resampling. Corresponding data for signalling and ordered proteins are shown for comparison. 
Analysed sets of disease-related proteins included 1786, 487, 689, and 285 proteins for cancer, 
CVD, neurodegenerative disease, and diabetes, respectively. Figure and caption taken from 
Uversky et al. (39). 
Chapter 1: Introduction and Motivation 
- 6 - 
 
The high abundance of intrinsic disorder in diseases is due to the unique structural 
and functional peculiarities of IDPs and IDRs. IDPs perform crucial biological 
functions; they are among major cellular regulators, recognizers, and signal 
transducers. Their functions are tightly regulated via extensive post translational 
modifications and many IDPs can fold upon interaction with corresponding binding 
partners (partially or completely), ensuring low-affinity/high-specificity binding. 
They are promiscuous binders, they possess multiple binding specificity and 
participate in one-to-many and many-to-one signalling interactions (binding 
plasticity) (41).  
1.2.3. Experimental Identification and Prediction 
Methods 
Intrinsic disorder in proteins can be identified and characterised by using a wide 
arsenal of experimental methods (42,43). Naturally, the lack of a well-defined 
structure in disordered proteins complicates their investigation, since the 
determination of the unique high resolution structure(s) of IDPs is extremely 
difficult. Only a strategic combination of complementary structural and biophysical 
techniques would allow one to decipher their mode of action at the structural level. 
The main techniques are briefly specified below: 
Disordered states of proteins, being highly heterogeneous and dynamic, are not 
accessible to X-ray crystallography, however this method repeatedly defines missing 
electron density in many structures, which may correspond to disordered and 
dynamic region(s) of the protein. The increased flexibility of atoms in such region(s) 
leads to the non-coherent X-ray scattering, making them unobserved (9). 
Heteronuclear multidimensional Nuclear Magnetic Resonance (NMR) spectroscopy 
is by far the most powerful technique for determination of high resolution three-
dimensional structural information in solution and for the portrayal of protein 
dynamics. The backbone motions (in the NMR timescale) throughout the polypeptide 
chain can be revealed by this technique. Recent advances in NMR spectroscopy have 
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allowed the complete assignment of several unfolded and partially folded proteins, as 
well as the disordered fragments of folded proteins (2,44).  
Small angle X-ray scattering (SAXS) and the small angle neutron scattering (SANS), 
on the other hand typically provides information on the hydrodynamic behaviour and 
topology of the polypeptide chain (45).  
Low content of secondary structure in partially intrinsically disordered proteins can 
be provided by a number of spectroscopic techniques including far-ultraviolet (UV) 
circular dichroism (CD) (46), Fourier transform infrared spectroscopy (FTIR), 
Raman optical activity and deep UV Raman spectroscopy (47). 
Additional data of on the intramolecular mobility and compactness of the protein can 
be detected via the analysis of different fluorescence methods, including fluorescence 
resonance energy transfer (FRET) (48). 
Mass spectrometry based techniques (reviewed by Beveridge et al. (49)) can also be 
applied to the study of IDPs, including hydrogen-deuterium exchange (HDX) (50), 
limited proteolysis (51-53), proteomics (54) and ion mobility mass spectrometry 
(IM-MS), which is described in detail later in this chapter.  
Bioinformatic predictions still play a decisive role in studies of structural disorder. 
Based on the compositional bias of IDPs, many of different predictor programs have 
been developed in recent years (28-30,55), including PONDR (26) (predictor of 
naturally disordered regions), charge-hydropathy plots (CH-plots) (24), and IUPred 
(56), to name a few. The available predictors can be classified into two categories 
(8,57): (i) predictors that are based on the amino acid sequence, (ii) machine learning 
algorithms that are trained on the existing experimental data sets which indicate the 
disorder (e.g. missing electron density in crystallographic data). One of the key 
findings of these computational approaches to the completely sequenced genomes is 
that eukaryotes exhibit a significantly larger portion (up to 30%) of their proteome 
that is intrinsically disordered than prokaryotes (3).  
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Even if feasible, determination of a single set of three-dimensional atomic 
coordinates, may not be instructive for a highly disordered protein. Rather, the 
objective is to identify the rules that define the dynamic conformational behaviour, 
particularly in terms of an ensemble description of interconverting structures and 
determining timescales that are involved in the conformational transitions in order to 
develop a complete picture. IDPs inhabit a vast conformational landscape, and 
mapping of this intricate conformational energy landscape requires an exploitation of 
complementary experimental techniques.  
1.3. The Tumour Suppressor p53: Puzzle 
and Paradigm 
p53 belongs to the growing family of loosely folded or partially unstructured native 
proteins (58). Research on the p53 protein is at fever pitch. In the past couple of 
years it has become evident that inactivation of its tumour-suppressor activity is an 
almost universal step in the formation of human cancers (59). But even thirty years 
after its discovery by Levine et al. (60), the multi-functional tumour suppressor p53 
is still somewhat of an enigma. p53 nicknamed the ‘guardian of the genome’ is at the 
hub of a plethora of signalling networks by a multitude of protein-protein 
interactions that regulate the cell cycle and maintain the integrity of the human 
genome, and modulated by extensive post translational modifications. In response to 
oncogenic or other cellular stress stimuli, p53 is activated and prompts up- or down 
regulation of genes involved in cell cycle arrest, DNA repair, senescence, or 
apoptosis (61-63). It is therefore not surprising that this functional complexity is 
mirrored in its structure. 
p53 protein has been extensively studied leading to a significant number of 
discovered protein-protein interactors; so far 485 partners according to BioGRID 
database, 266 direct protein interactors according to the Human Protein Reference 
Database, 303 according Interologous Interaction Database (SwissProt ID: P04637, 
315 from POINeT database, have been brought forward by different experimental 
methods (Figure 1.4). Both transactivation and C-terminal domain are particularly 
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multi-functional binding sites for many interacting proteins. For instance among 
many others, N-terminal TAD interacts with CBP/p300, TFIID, TFIIH, Mdm2, RPA, 
and CSN5/Jab1 and the C-terminal domain interacts with TAF1, TRRAP, hGcn5, 
TAF, GSK3β, PARP-1, 14-3-, S100ββ (64,65). 
 
Figure 1.4: Experimental human p53 non-redundant interactors build with POINeT whose 
protein-protein interaction data sources are from BIND, AfCS, HPRD, BioGRID, MPact, DIP, 
IntAct, NCBI interactions, MINT, MIPS databases (http://poinet.bioinformatics.tw). Figure and 
caption taken from Huart et al. (65). 
In response to various intracellular and extracellular stimuli stress, p53 is activated 
and induces up- or down-regulation of a variety of genes involved in cell cycle arrest, 
DNA repair, senescence, or apoptosis (Figure 1.5) (61-63). For example, in response 
to DNA damage ATM protein kinase is activated which triggers Chk2 kinase (66). 
ATM and Chk2 then both phosphorylate p53 at distinct sites leading to p53-
dependent cell cycle arrest or apoptosis (67). 
 
(a)
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Figure 1.5: p53 locating at the crossroads of complex networks of stress response pathways. 
Various intercellular or extracellular stresses elicit cellular responses directly or indirectly 
through p53 activation. p53 activates its downstream targets to perform various functions 
including cell cycle arrest, DNA repair, apoptosis, and senescence. Figure and caption taken 
from Bai et al. (68). 
As a result of efforts to identify targets of p53 in various experimental systems, 
hundreds of physiologically p53 responsive genes have been reported, such as genes 
for p21Waf1/Cip1, Gadd45 (growth arrest and DNA-damage-inducible protein and 
genes of the Bcl-2 family (63). Elevated levels of p53 can also cause repression of 
genes which include cyclin B1, MAP4, bcl-2, bcl-x, and survivin, some of them are 
negative regulators of apoptosis (63). The functions of p53 target genes are diverse, 
corresponding to p53’s activity as a multifunctional protein. 
 
p53 functions as a homotetramer comprising 4 x 393 amino acid residues. It has a 
modular domain structure, consisting of independently folded DNA-binding and 
tetramerization domains, flanked by natively unfolded regions at both the amino- and 
carboxy-termini, which poses a challenge to the structural biologists (Figure 1.6). 
The N-terminal region consists of an intrinsically disordered transactivation domain 
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(TAD, residues 1-61) that induces transcriptional activation of genes regulated by 
p53, followed by a proline-rich region (PRR, residues 62-94), and a central folded 
DNA-binding domain (DBD, residues 94-292) that is responsible for recognition of 
the consensus sequences associated with p53 target gene promoters. This domain is 
linked to a tetramerization domain (TET, residues 325-356) that regulates the 
oligomerization state of p53. At its C-terminus (CT, residues 356-393) p53 contains 
a strongly basic regulatory domain (mainly lysines) which binds DNA non-
specifically. Although the core DBD forms a so called ‘ordered’ region of p53, and 
possesses many disordered loops and it is in these that most p53 inactivation 
mutations associated with nearly 50% of human cancer occur (69). Overall, 
approximately 70% of p53 interactions are mediated by intrinsically disordered 
regions (IDRs) (70). A bias toward intrinsic disorder is particularly expressed in the 
sites of posttranslational modifications, with 90%, 86%, and 100% of detected 
phosphorylation, acetylation,  and protein conjugation sites, respectively found in 
IDRs (70).  
 
Figure 1.6: Domain structure of full-length p53 consisting of an N-terminal transactivation 
domain (TAD), followed by a proline-rich region (PRR), the central DNA-binding domain 
(p53C), the tetramerization domain (TET), and the extreme C-terminus (CT). p53C, the domain 
where most cancer-associated p53 mutations are located, is highlighted with a rainbow color 
gradient from blue at its N-terminus to red at its C-terminus. The bars above the diagram 
indicate the relative frequency of oncogenic missense mutations at each residue according to 
version R11 (October 2006, N = 17,015) of the International Agency for Research on Cancer 
TP53 mutation database. Schematic and caption taken from Joerger et al. (71). 
In the mid-1990s, several pioneering studies elucidated structural details of 
individual modules of p53 structure, the first structures to be solved were the core 
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DBD in a complex with DNA (72), and the tetremerization domain (73-76). Shortly 
after, atomic structure of a transactivation domain in a complex was solved (77), and 
recently fragments of the C-terminal regulatory domain also in a complex with 
binding partners were determined (78-80). But in the decade that followed, relatively 
small progress was achieved in revealing the structural foundation of p53 
functionality or its inactivation in tumour, considering that the scientific literature 
has been inundated with p53-associated publications.  
1.3.1. The Bigger Picture: Quaternary 
 Structure of p53 
Only in recent years has a full grasp of the quaternary structure of p53 and its 
dynamic behaviour as a whole has become possible, owing to combination of 
sophisticated computational methods, innovative protein engineering and classical 
structural biology. Many structural studies on the full-length p53 have been hindered 
both by its intrinsic instability and the presence of large regions of intrinsic disorder. 
A rapidly growing number of identified proteins have globular domains connected by 
intrinsically disordered regions, and so solving such structures is a recurring 
problem. There are particular obstacles in tackling the full-length structure of tumour 
suppressor p53; the protein is too flexible for crystallographic measurements, and too 
big for conventional NMR spectroscopy. A multi-technique strategy was applied by 
Tidow (81) and Wells et al. (82). The quaternary structure of the stabilized full-
length p53 and different domain constructs in their free form and in complex with 
response element DNA was determined by using state-of-the-art NMR spectroscopy 
to identify domain-domain interfaces, SAXS experiments and electron microscopy 
(EM). The X-Ray crystal structures of individual p53 domains were modelled as 
rigid bodies to fit the SAXS and EM data, missing residues were modeled ab initio. 
Pivotal to this work was Nikolova’s design of an engineered stabilized variant of p53 
core domain M133L/V203A/N239Y/N268D that considerably improved the overall 
stability of the protein (83,84).  
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According to Tidow et al. (81), the free p53 protein in solution forms an elongated 
cross-shaped structure with the tetramerization domain at its center, loosely 
assembled core domain dimers and extended N and C termini (Figure 1.7). In this 
open conformation, the DBDs can interact freely with cognate DNA and partner 
proteins in the cell cycle.  
 
Figure 1.7: Rigid body models of free (a) and DNA-bound (b) p53 in solution from small-angle 
X-ray scattering data (81). Both models are shown in two different orientations. Core (blue and 
green) and tetramerization (red) domains are shown as cartoon representations, with core 
domains binding to the half-site in the same colour. Flexible connecting linkers (gray), N termini 
(pink), and C termini (yellow) are shown as semi-transparent space-filled models. Models of N 
and C termini in the free protein are approximations to illustrate the space occupied by these 
flexible regions, rather than representing defined conformations. Image and caption taken from 
Joerger et al. (71). 
EM images for full-length p53 are heterogeneous in shape and size, indicating an 
ensemble of different, predominantly open conformations (81). A radically different 
structural model of the unbound full-length murine p53 protein was proposed by 
(a) (b)
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Okorokov et al. (85). This cryo-electron microscopy study reported a closed, 
compact structure resembling a hollow skewed cube, in which the tetramer is formed 
through interactions via its N and C termini (Figure 1.8). Upon DNA binding (Figure 
1.7b), p53 wraps around the DNA double helix and becomes more compact. Domain 
rearrangements to allow DNA binding are facilitated via the flexible linker between 
the DNA-binding and tetramerization domain, and the overall structure becomes 
more rigid.  
 
Figure 1.8: Structural organization of p53. (a) The upper density layer of the p53 three-
dimensional map, with fitted structures of two core domains shown in green and orange. N and 
C represent positions of the N- (blue) and C-termini (magenta), respectively. (a) Cut away view 
of the lower density layer with the second pair of core domains (coloured red and yellow) fitted 
in. (c) Domain structures are fitted into the corresponding nodes of the tetramer. Image and 
caption adapted from Okorokov et al. (85).  
This process is in accord with the X-ray crystal structures of the tetrameric p53-DNA 
complexes by Kitayner et al. (86). The N termini are extended in both the free and 
DNA-bound p53 modeled structures by Tidow et al. (81), consonant with the fact 
that they interact with myriad of signaling proteins and are subjected to extensive 
post translational modifications (87,88). 
Not only is this complex (un)structural biology vital for full understanding the role of 
p53 in the cell cycle and in other activities, but the structures may also help in the 
design of drugs that affect the cell cycle.  
(a) (b) (c)
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1.3.2. Post-translational Modifications of p53 
In response to stress levels, p53 participates in complex networks of covalent post-
translational modification, including phosphorylation, acetylation, ADP-ribosylation, 
ubiquitylation, sumoylation, neddylation, and cytoplasmic sequestration (63,89). 
Post-translational modifications affect protein activity, stabilization, localisation, 
turnover, and interaction properties, governing fully the protein function. Recent 
studies have shown that most of these modifications occur in unstructured parts of 
proteins, mainly in the N- and C-terminal regions. Phosphorylation and acetylation 
are the key modifications improving the transcription activating ability of p53 
because these modifications result in p53 stabilization and accumulation in the 
nucleus, where p53 interacts with sequence-specific sites of its target genes (90). 
Most of the phosphorylation sites have been identified in the N-terminal domain at 
the Ser6, Ser9, Ser15, Thr18, Ser20, Ser33, Ser37, Ser46, Thr55, and Thr81 residues, 
but there are also other sites in the C-terminal domain at Ser315, Ser366, Ser371, 
Ser376, Ser378, Thr387, and Ser392, and also in the central core DNA-binding 
domain at Ser149, Ser150, Ser155 (89,91). Many protein kinases have been 
implicated in phosphorylating events of p53, including ATM, ATR, Chk1, Chk2, 
JNK and p38 (92-94). p53 is also targeted for degradation via Mdm2 via 
ubiquitination of specific lysine residues localised within its C-terminus.  In addition 
p53 can be modified by ubiquitin like proteins, NEDD8, and SUMO which regulate 
the p53-Mdm2 interaction and protein stability. Acetylation takes place on residues 
used for ubiquitination thus resulting in p53 stabilization as a consequence blocking 
Mdm2 catalyzed ubiquitination (95). Not only p53 is activated by blocking Mdm2 
ubiquitination, but acetylation induces conformational changes within p53 which 
stimulates its sequence-specific DNA binding activity (95,96). Two histone 
acetyltransferases are known to acetylate p53: p300 or/and CBP acetylates the C-
terminus of p53 at Lys305 at Lys305, Lys372, Lys373, Lys381, and Lys382, whereas 
PCAF (p300/CBP-associated factor) acetylates Lys320 (95,97). These various 
modifications form a ‘binding code’, as they alter the local charge density and 
hydrophobicity, affecting the structure and folding properties of the local chain and 
its surface (4). Generally, post-translational modifications provide dynamicity in the 
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protein-protein interactions and can adapt the function precisely in in space and time 
scales to achieve diverse and specific biological cell outcomes. 
1.4. p53:Mdm2 - the Affair that Never Ends 
The interaction between p53 and Mdm2 (murine double minute 2) represents the 
best-studied relationship between a tumour suppressor protein which acts as a 
transcription factor and an oncoprotein, which functions primarily as an E3 protein 
ligase (also called a ubiquitin ligase, that combines with a ubiquitin containing E2 
ubiquitin-conjugating enzyme, recognizes the target protein and causes the 
attachment of ubiquitin to a lysine on the target protein) (98). This intimate 
relationship is tightly regulated by a complex arsenal of post-translational 
modifications, which in turn dictates the stability and activity of p53 and Mdm2.  
Mdm2 down regulates the activity of p53 via a negative feedback loop through 
binding to the N-terminal transactivation domain of p53 (99). In addition to blocking 
the transcriptional activity of p53, Mdm2 also exports p53 from the nucleus into the 
cytoplasm and promotes it for proteasomal degradation via ubiquitination (100-102). 
The E3 activity of Mdm2 is centered within the RING finger domain (103). The 
ability of Mdm2 to associate with, and induce p53 degradation is highly dependent 
on the phosphorylation status of p53, as well as on the interaction of p53 with other 
cellular proteins. In response to cellular stress, when p53 phosphorylation occurs on 
multiple serine residues in its N-terminal transactivation domain, including those 
spanning Mdm2 binding, the association of p53 with Mdm2 is no longer possible 
(104,105).  Amplification of the Mdm2 gene is observed in approximately 7% of 
human cancers, with a much higher incidence in soft tissue tumours (20%), 
osteosarcomas (16%) and oesophageal carcinomas (13%) (106). Overexpression of 
Mdm2 effectively abolishes p53 function, and in turn tumours become less 
susceptible to chemotherapeutic agents and do not undergo programmed cell death, 
or apoptosis. The myriad of roles which p53 and Mdm2 play within the cell led to the 
realization that the p53-Mdm2 interaction is a ‘druggable’ target (77). A series of 
p53-Mdm2 antagonists have been developed including ‘stapled‘ peptides (107), cis-
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imidizalones (108), meta-chloro piperidinones (109), benzodiazepinediones (110) 
and chromenotriazol- pyrimidines (111).  
 
Mdm2 itself is a multi-domain 55 kDa protein consisting of 491 amino acids. Overall 
it is composed of an N-terminal domain with a hydrophobic pocket, a disordered 
central acidic domain containing a nuclear localization signal, a zinc finger, and a C- 
terminal really interesting new gene (RING) which is responsible for its ligase 
activity (112).  
1.5. The Case for Mass Spectrometry as a 
Tool to Study IDP’s 
Knowledge of the active conformation and interaction partners of proteins and their 
complexes is paramount to understanding their intercellular function. Many protein 
systems are dynamic with respect to both conformation and interaction, so in the 
course of a protein’s ‘lifespan’ it will sample many configurations and bind to 
several targets. This is particularly true for IDP’s which have crucial roles in 
molecular recognition, assembly, protein modification and entropic chain activities, 
but often intrinsic structural disorder until required to function. It is desirable 
therefore to observe the range of structures an IDP can occupy, and also the effect of 
selected binding partners on altering this conformational space. In the past 10 years, 
a substantial body of work on IDP’s has been performed in silico, but due to their 
flexibility and ‘fuzziness’ they have been less examined as a class of proteins by 
structural characterisation (39). Since the solvent free environment of a mass 
spectrometer is ideally suited to the study of intrinsic interactions and how they 
contribute to structure, it is a very exciting venue for the study of IDP’s. 
Mass Spectrometry has established itself as a bone fide method for structural biology 
(113-115). Pioneering work has shown that bioactive complexes of significant size 
can be transported intact into the controlled environment of a mass spectrometer for 
subsequent analysis (116). There is of course controversy about whether a solution 
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phase structure is retained in its entirety in the solvent free environment of a mass 
spectrometer, but for large macromolecular systems bound by many non-covalent 
interactions, there is evidence to suggest that macroscopic features of solution and 
even in vivo structures are retained (117). When applied to IDP’s, the fact that a 
range of conformations can be observed for a given protein system depending on the 
method by which it is ionised is a rather exciting prospect. This control and 
selectivity over the way in which a given protein that is intrinsically disordered can 
be studied means that its inherent stability and how that is affected by binding 
partners can be probed. The growth and success of studies of macromolecular 
complexes by mass spectrometry increasingly places biological mass spectrometry as 
the first step in structural analysis of an unknown protein and of its targets; in short, 
it now has a role as a rapid information rich predictive tool which has a particular 
suitability for IDP’s. 
Careful optimisation of the nano electrospray ionisation (n-ESI), source optic 
voltages and pressures allows for the non-covalent interactions to be preserved and a 
gentle transfer of intact macromolecules from solution into the solvent-free 
environment of a mass spectrometer. Following n-ESI, all proteins are present in a 
number of different charge states, commonly as (multiply) protonated species (for 
positive ionisation) or (multiply) deprotonated (negative ionisation) - this is termed a 
charge-state distribution (CSD). Structured, folded proteins with little conformational 
flexibility in solutions where the protein is buffered appropriate to its pI, give rise to 
gaseous ions carrying a relatively low number of charges, presenting a narrow charge 
state distribution centered on high values of m/z (118). By contrast, less structured or 
unfolded proteins can accommodate a larger variation in the number of protons 
related to the varied availability of ionisable sites on the protein surface, in turn a 
feature of the conformational flexibility in solution (119). Analysis of the relative 
intensities of ions in CSDs enables an indirect assessment of conformational families 
present in solution. Frimpong et al. (120) used CSD analysis following ESI-MS to 
determine the conformational heterogeneity of monomeric α-synuclein, a neuronal 
protein which has a special relevance for understanding Parkinsons disease (121). 
Although, this protein is highly disordered, it was found to populate four distinct 
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conformational states, ranging from a compact, highly structured one, to a random 
coil (120). IM-MS provides another dimension to gas-phase studies of biomolecules 
garnering more direct information on the molecular species  ‘shape’ (collision cross-
section, in Å
2
) along with the CSD, but does not provide atomic resolution compared 
to NMR and X-ray crystallography. IM-MS has been successfully applied to 
examine protein dynamics (118,120), protein-ligand and protein-protein interactions 
(122) and shows great promise for the structural characterisation of IDPs. Bernstein 
et al. (123) performed experiments on α-synuclein which combined n-ESI-MS with 
IM measurements. Their findings indicate the presence of compact structures when 
spraying from low pH solutions, while higher charge states occurring at 
physiological pH (6.8) have larger collision cross sections and are relatively 
unfolded. The transition from compact to extended conformations occurs from 
charge state z = -8 to z = -9 where a 50% increase in cross section is observed. IM-
MS has also been utilized to study the structure of the DNA binding domain of the 
tumour suppressor protein p53 with and without the functional zinc ion (124). Other 
research using IM-MS to study IDPs has examined changes in conformational 
equilibrium of the intrinsically disordered High Mobility Group A (HMGA) 
chromatin factors, due to post transitional modifications or sequence deletion (125), 
and the ability of IDPs to fold on binding to a partner using the salivary tannin 
binding proteins (126).  
A variety of configurations of IM instrumentation have been developed: drift tube 
(DT) IM-MS, travelling wave (TW) IM-MS and field asymmetric waveform ion 
mobility-spectrometry (FAIMS). These techniques are briefly described in the 
following section. 
1.6. Ion Mobility Mass Spectrometry - to 
determine Conformation(s) 
The start of the analytical technique termed ‘ion mobility spectrometry’ (IMS) can be 
traced to the beginnings of the 20
th
 century, when experimental (127,128) and 
theoretical  (129) physicists became interested in the movement of ions in gases. In 
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these early studies, as in all modern ion mobility methods, what was measured is the 
velocity of ions in a mass spectrometer where they ‘drift’ due to the presence of a 
weak electric field while experiencing collisions with a buffer gas. Following the 
experiments of Erikson (127) and Bradbury (128), in the 1950’s McDaniel (130,131) 
constructed low field drift tubes which bear a great resemblance to the Drift Time 
IMS mobility instrumentation still used today. In 1965 Kebarle coupled such a drift 
tube to a mass spectrometer creating the hybrid technique of ion mobility mass 
spectrometry (IM-MS) (132,133). This work prompted the development of different 
configurations of ion mobility and mass spectrometry instrumentation over the past 
40 years, and their application to an ever wider range of analyte species (134). 
Details of the early parallel development of ion mobility and of mass spectrometry 
and its applications to large macromolecules can be found in an excellent review by 
Uetrecht et al. (135) which focusses on applications, and one on instrumentation in a 
comprehensive summary by Kanu et al. (134). In the past 5 years commercial 
instrumentation for IM-MS (136) has been developed and the technique has become 
more widely applied as a research tool. Despite differences in the configuration of 
mobility devices there are some features common to all IM-MS experiments. A 
typical mobility experiment requires the injection of a pulse of ions into a chamber 
filled with a known gas at a known pressure across which is applied an electric field. 
The time taken for the ions to pass through the chamber is measured. Upon injection 
into the chamber or drift cell, the ions experience an electrostatic force pulling them 
through the cell; this force is countered by collisions between the ions and the buffer 
gas. The behaviour of an ion moving through a gas under the influence of an electric 
field (E) is dependent on its energy which is determined by the ratio of electric field 
strength to buffer gas number density, E/N (137). At low E/N the ions are said to be 
in the low field limit, under this regime the ions have low velocities which are 
independent of the field strength. At higher E/N the ions may align in the field and 
their motion becomes dependent on the field strength. In the low field limit, the 
motion of the ions can be described in more simple terms and most ion mobility 
measurements are therefore performed in the low field limit. Under these conditions 
the low field mobility is defined, (K) as the constant of proportionality between drift 
velocity, (vd) and electric field, E as shown by Equation 1.1.  
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          Equation 1.1 
For experiments performed at sufficiently high pressure, and low drift voltages, ions 
will quickly be thermally equilibrated and reach a constant drift velocity vd  which is 
determined by the magnitude of the electric field (E) and its influence on the charge 
of the ion as well as by the number of collisions that the ion makes with the buffer 
gas. Hence, the mobility, K, must contain terms relating to molecular shape, charge 
and the buffer gas pressure. These latter properties combine to provide the 
rotationally averaged collision cross section (Ω) for each ion which is critically 
dependent on the chosen buffer gas as well as on its temperature (see Equation 1.2). 
Hence determining vd   elucidates Ω which can be interpreted as the shape adopted by 
a given molecular ion under particular gas phase conditions. To determine vd, and 
hence K and Ω, accurately in ion mobility instrumentation, the length of the drift 
region must be known precisely and then the average arrival times of ions can be 
recorded at a detector post the drift region. In IM-MS instrumentation, detection will 
also provide mass resolution and so the arrival time for a given mass to charge ratio 
is found. Most laboratories will provide K in terms of the reduced mobility K0, 
normalised for pressure and temperature. In recent years IM-MS coupled with the 
soft ionisation technique electrospray ionisation (ESI) has gained importance as a 
tool for the analysis of macromolecules and particularly for its application in 
determining the conformations adopted by biological molecules (123,138-141). 
Efforts in commercial development have concentrated on improving the low duty 
cycle that can be significant in linear ion mobility experiments, and also on 
increasing the resolution obtained. Initial studies focused as much on structural 
measurements as on mixture separation, reflecting the growing potential of mass 
spectrometry as a tool to provide detailed conformational information on biological 
moieties (113). The use of IM-MS to study proteins and protein complexes has been 
particularly rapid. Figure 1.9 illustrates this, the number of publications as searched 
for in the ISI Web of Knowledge database containing the words ‘protein + ion 
mobility mass spectrometry’ was plotted versus the year of their publication.  
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Figure 1.9: Results from a search on ISI Web of Knowledge for the words protein + ion mobility 
mass spectrometry appearing in title or abstract fields. The number of published articles per 
year is plotted. The graph starts with the first hit (142). 
Of note on this figure are the inflections when Clemmer developed instrumentation 
in 1997 and then more recently when the Synapt instruments were launched in 2006. 
There are three principal types of ion mobility instrumentation that have been 
successfully combined with mass spectrometry.  
1.6.1. Drift Tube Ion Mobility Mass 
 Spectrometry 
Following from the apparatus used by Kebarle, the simplest configuration of IM-MS 
instrumentation consists of a tube located within a vacuum system filled with a 
buffer gas of interest across which is applied a weak electric field (5 - 100 Vcm
-1
). 
Ions are steered and injected into a small orifice at one end of the drift tube. They 
drift due to the field and collisions with the buffer gas until they exit through another 
small orifice. By measuring the drift velocity of an ion through such a linear drift 
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(CCS) with some degree of accuracy (137) according to the relationship in Equation 
1.2: 
    
   
   
 (
  
    
)
  ⁄  
 
  Equation 1.2 
where K0 is the reduced mobility (the measured mobility K standardised for pressure 
and temperature to 273.15 K and 760 Torr), z is the ion charge state, e is the 
elementary charge, N is the gas number density, µ is the reduced mass of the ion-
neutral pair (   
    
     
, where m1 is the mass of the ion, and m2 is mass of the drift 
gas) kB is the Boltzmann constant and T is the gas temperature. As shown here, the 
mobility of an ion is inversely related to its rationally-averaged collision cross 
section. In other words, a more compact ion will undergo fewer collisions and hence 
travel faster through the drift cell than a more extended ion (Figure 1.10). This is 
used to separate ions of the same mass but different conformations.  
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Figure 1.10: In the schematic, two ions of the coincident mass to charge ratios are resolved by 
DT IM-MS. The more extended conformer (blue) takes longer to traverse the drift cell because 
it collides more often with the buffer gas than the compact (green) conformer. Image adapted 
from the website of Ruotolo Research Group at the University of Michigan (143). 
This experimental CCS (Ω) which is buffer gas dependent (144) can be compared to 
cross sections derived from co-ordinates obtained from other structural investigations 
(for example crystal structure co-ordinates), or from computational predictions, to 
obtain atomically detailed conformational information. 
Several IM-MS instruments which incorporate drift cells over which a linear field 
gradient is applied have been reported. In particular there have been notable efforts 
made in the ‘modern’ era of IM-MS in designing and building DT IM-MS 
instrumentation by Bowers with Kemper (145,146), and by Jarrold (147,148), 
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Clemmer (149-154), and Hill (155,156). In a seminal early study, Clemmer and 
Jarrold used a modified ion mobility-time of flight (TOF) mass spectrometer 
equipped with an ESI source for analysis of small organic and biological molecules, 
in particular bradykinin as well as the larger proteins cytochrome c and ubiquitin. 
Another ESI capable IM-MS instrument IM-Quadrupole reported by Wyttenbach, 
Kemper and Bowers (157), has been applied to the study of an impressive range of 
biologically relevant molecules including the amyloidgenic proteins alpha-synuclein 
(123) and the amyloid β protein (158), PNA/dsDNA complexes (159) and a 
systematic study of variants of the hormone GnRH (160). The studies from this 
group are frequently accompanied by extensive MD simulations of the analytes of 
interest, allowing comparison between calculated and measured CCSs. The Clemmer 
group at Indiana University have been responsible for a number of notable advances 
in instrument and technique development for the study of large proteomic datasets, 
(161,162) including multidimensional ion mobility (149,163-165). In our group an 
ion mobility mass spectrometer, capable of performing temperature variable 
measurements of CCSs has been built and applied to the examination of the 
conformations of biological molecules and complexes (166). McLean et al. have 
coupled a DT IM- MS with imaging mass spectrometry (167) - the results show the 
spatial localization of lipids in biological tissues. 
1.6.2. Travelling Wave Ion Mobility Mass 
 Spectrometry 
Waters MS Technologies introduced the first commercially available integrated IM-
MS instrument the Synapt HDMS in 2006 (136). With its origins in the pioneering 
work of Gerlich (168) this mobility separator consists of three stacked ring ion 
guides (called the Triwave) with RF applied to consecutive electrodes; to propel ions 
through the device, a travelling wave (TW) comprising a series of transient DC 
voltages is superimposed on top of the RF voltage. In 2009, Waters launched the 
second generation Synapt G2 System which improves some of the design. In the 
short time these instruments have been available, they have made a significant 
impact on the use of IM-MS for the study of macromolecular systems and in 
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particular on the study of intact proteins and protein complexes. The mobility of ions 
through these travelling wave devices is not as directly related to collision cross 
section as in DT IM-MS instruments. Shvartsburg et al. (169) have made notable 
efforts to formally understand the relationship between collision cross section and 
mobility in a travelling wave device, but as yet there is no adoption of such an 
approach by the IM-MS community. Despite this, with a careful use of standards 
previously measured in helium via DT IM-MS, it is possible to convert mobilities 
measured with nitrogen as a drift gas in Synapt instrumentation into mass selected 
‘helium based’ collision cross sections  (170). Using Synapt HDMS system, Ruotolo 
et al. (171) have assessed conformations of multimeric proteins, and also the 
disassembly of complexes viewing the partial unfolding of monomer units whilst still 
retaining some of the integrity of the complex (172). Smith et al. (173) has used TW 
IM-MS methodology to examine prefibrillar aggregates of amyloidgenic proteins. 
Scrivens has applied Synapt technology to several applications for biomolecular 
science including a study of the protein haemoglobin, (174)  and with Bowers a study 
of the calcium binding protein calmodulin. Scrivens et al. (175) has also employed 
this technique to extract the spectra of N-glycans released with PNGase F from a 
serial titration of recombinantly expressed envelope glycoprotein, gp120, from the 
human immunodeficiency virus. Heck and co-workers have examined very large 
species with TW IM-MS including chaperonin complexes (176) and intact virus 
particles (177). Oldham has performed promising experiments which apply IM-MS 
to the stabilisation of proteins by ligands (178). As can be seen in Figure 1.7 the 
number of publications which employ IM-MS to examine proteins has grown 
significantly since the introduction of the Synapt instruments by Waters.  Only a 
flavour of the range of biological systems amenable to this analysis has been 
provided here, rather than an extensive list. 
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1.6.3. Field Asymmetric Waveform Ion 
 Mobility Mass Spectrometry 
The final type of ion mobility separation, commonly used in conjunction with mass 
spectrometry is field asymmetric waveform ion mobility spectrometry (FAIMS) or 
differential mobility spectrometry. First developed in the USSR in the early 1980’s, 
(179) it was successfully coupled with ESI-MS by Purves, Gruevremont and co-
workers in the late 1990’s (180,181). The FAIMS/MS platform was made 
commercially available in 2003 as a front-end device that could be coupled to a 
number of mass spectrometers. In this technique ions pass between two electrodes in 
the presence of a tangential gas flow. FAIMS devices are usually placed at the source 
end of mass spectrometers where the gas flow may well be due to the drying gas 
requirements of an electrospray source. The voltages applied to the electrodes and 
the speed of the gas flow can be tuned such that ions of a specific mobility K are 
transmitted successfully through the device. This said, separation in FAIMS is 
independent of the absolute value of K, ions are separated by the difference in their 
mobilites at high and low values of E. Ashcroft and co-workers have employed a 
front end mobility separator available from Thermo-Electron coupled to a 
quadrupole TOF instrument to examine conformers of β-microglobulin (182). The 
group of Smith have been extremely successful in both the implementation with 
respect to separation of complex mixtures (183) and the interpretation of FAIMS 
(184). From this group, of particular note is a recent report which discusses the 
pendular alignment of proteins in gases under the influence of electric fields which 
has great promise as a new analytical approach for studying protein unfolding and for 
conformer selection of large systems (185). Xuan et al. (186) has also used FAIMS 
to help separate proteomic mixtures, with an emphasis on elucidation of 
phosphopeptides. This latter study and the work of Smith et al. (183) probably best 
represent the strengths and future applications of the FAIMS approach to ion 
mobility as an analytical technique for separation of mixtures, essentially gas phase 
chromatography, rather than for precise conformational detail. 
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1.7. Summary 
Mass spectrometry is a technique that can sample the broad repertoire of structural 
and functional states occupied by IDP’s. MS informs on all levels of protein 
organization, and enables quantitative assessments of their intrinsic dynamics in the 
gas phase. The key advantages of MS are that it is a sensitive separation technique 
with wide applicability, and thereby allows the individual interrogation of transient 
conformers and oligomers comprising a heterogeneous ensemble. In this thesis MS 
and IM-MS is used to provide insights into the disordered nature of tumour 
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Instrumentation used in the experiments is described with schematic diagrams and 
typical operating and tuning parameters. The drift tube and travelling wave based 
ion mobility mass spectrometers are set out. Illustration of a typical workflow for ion 
mobility mass spectrometry data acquisition and analysis is given. Information on 
nano-electrospray ionisation conditions, reagents used and mass calibration 
procedure is provided. Theoretical approaches for calculating rotationally averaged 
collision cross sections are also explained. 
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2. Experimental Methods  
2.1. Reagents 
For all experiments high purity water was used, obtained from an Arium 611 water 
purification system (Sartorius, Göttingen, Germany) or supplied by Fisher Scientific 
Ltd (Loughborough, UK). All organic solvents were either LC-MS or HPLC grade 
and supplied by Fisher Scientific Ltd (Loughborough, UK) or by Sigma Aldrich 
(Dorset, UK).  Acids were provided by VMW International Ltd (UK). Ammonium 
acetate (77.08 g/mol, ≥99% purity) was purchased from Fisher Scientific Ltd 
(Loughborough, UK). Information on protein samples can be found in the relevant 
chapters. 
2.2. Sample Introduction - Ionisation 
Ionisation is a critical step in the transfer of intact biological molecules from solution 
into the vacuum environment of the mass spectrometer. Electrospray ionisation (ESI) 
was pioneered by Dole in 1968 (1) and advanced by a Nobel laureate Prof Fenn in 
2002 (2,3). The principle of the electrospray process is shown in Figure 2.1. ESI is an 
atmospheric pressure ionisation technique that can produce either positive or 
negative ions. The sample is introduced into the ionisation source via a metal 
capillary to which a strong electric potential is applied (2 - 5 kV). Charging leads to 
droplets with an elongated meniscus, a Taylor cone, and releases droplets containing 
charged sample ions (4). The charged droplets are directed away from the capillary 
by a co-axial flow of neublizing gas (usually nitrogen). Evaporation of the solvent 
from droplets is achieved via the heating of the source region and another flow of 
nitrogen gas, termed drying gas. The size of droplets gradually decreases and due to 
charge conservation, Coulombic forces overcome the liquid surface tension at a 
critical diameter, leading to fission of smaller charged droplets. Recurring 
evaporation and fission events lead to charged droplets which are the gas-phase ion 
precursors. The desolvated analyte ions pass into the mass spectrometer through the 
cone, propelled by decreasing potential and pressure gradient.  
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Figure 2.1: Schematic of a n-ESI source, illustrating Taylor cone formation, production of 
multiply charged droplets, droplet fission, and entry of sample ions into the source of a mass 
spectrometer via the sample cone. 
The mechanism by which a charged droplet forms a desolvated ion is believed to 
occur by one or two models (5). The charged residue model, proposed by Dole (1), 
whereby droplets undergo a sequential fission until a single analyte ion remains 
within a droplet. Total desolvation of this droplet leaves the gaseous ‘charged 
residue’. This model is widely accepted for large biological molecules such as 
proteins which are the topic of this thesis (6). Conversely, a competing process is the 
evaporation model, introduced by Iribarne and Thomson (7). This model is favoured 
by small ions, where analyte ion is ejected from droplets when coulombic repulsive 
forces increase as the droplet decreases in size.  
 
In large molecules, such as proteins, the charged observed is interrelated to the 
availability of ionisable sites, which links with the key mechanism of ESI; it 
produces multiply charged ions from large biomolecules due to charge accumulation 
in the droplets. However protons might not be necessarily localised, according to the 
prevailing mobile proton model (8). The model assumes that ionizing protons are 
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and histidine. Upon ion activation the ionising proton(s) can move from less basic 
sites on the polypeptide chain triggering various charge-site-initiated mechanisms.  
Miniaturisation of the ESI interface - nano-ESI by Wilm and Mann (9) has vastly 
expanded the area of application for this technique. n-ESI uses much lower flow 
rates, analyte volumes and concentrations. n-ESI employs glass capillaries with a 
micron-wide internal diameter, instead of the metal capillaries (typical internal 
diameter of 0.1 mm) utilised in ESI. Electric charge is provided to n-ESI capillaries 
via a conductive coating on the inside of the glass capillary, or to a metal wire 
inserted into the analyte solution. Droplets formed by n-ESI are an order of 
magnitude smaller than those produced by conventional ESI, following from that, the 
final droplets will contain less concentrated amounts of unwanted impurities or salts, 
resulting in a cleaner mass spectrum (10). n-ESI is a gentler desolvation process 
which preserves the non-covalent interactions (11,12).  
 
All MS and IM-MS instruments utilised in this research were fitted with n-ESI 
sources. n-ESI glass capillaries were prepared in-house from thin-walled borosilicate 
capillaries (Precision Instruments, Stevenage, UK) using a Flaming/Brown 
micropipette puller Model P‐97 (Sutter Instrument Company, Novato, CA, USA) 
and then filled with sample solution by means of gel micro-loading tips (Eppendorf, 
Hamburgh, Germany). Alternatively pre-pulled platinum coated glass capillaries 
were used (Waters nanoflow probe tips, long thin wall, M956232AD1-S). The filled 
capillary was placed onto a holder and a thin platinum wire was inserted in order to 
provide an electrical contact between sample solution and voltage supply. This was 
secured to an adjustable xyz-axes stage of a Z-spray source allowing the position of 
the capillary to be altered with respect to the sample cone. The Micromass Z-spray 
ion source derives its name from the approximate shape of trajectory taken by ions 
from sample capillary to orthogonally positioned sample and extraction cones 
(Figure 2.2). The off-axis geometry ensures an excellent separation of ions from 
neutral molecules or excess solvent so that they diffuse away toward the vacuum 
pump. This circumvents the problem of clogging the skimmers by neutral species 
thus preventing a frequent maintenance downtime for cleaning of the source 
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components. Spray potential was adjusted to provide optimum signal. The precise 
value of voltage used depended mainly on the solution composition and spray 
geometry but voltages were typically in the range of 1.0-2.0 kV.  In case of samples 
prone to aggregation a nitrogen backing gas was used to maintain a stable spray. 
Unless stated otherwise the source block was heated 80°C to aid desolovation 
process.  
2.3. Instruments 
All of the experimental work reported here was performed on either Micromass 
quadrupole time-of-flight mass spectrometer that has been significantly modified in-
house (13) or commercially available Synapt HDMS instrument (Waters, 
Manchester, UK) (14). 
2.4. Drift Tube based IM-MS - the MoQToF 
The MoQToF (Mobility Quadrupole Time-of-Flight) instrument was built in-house 
in 2006 in collaboration with Waters Micromass and Prof. Bowers (University of 
California, Santa Barbara, USA). It is a low resolution drift tube based ion mobility 
mass spectrometer capable of providing temperature dependant absolute collision 
cross section measurements. 
2.4.1. Instrument Layout 
The MoQToF is a Q-ToF mass spectrometer that has been modified by an inclusion 
of a vacuum chamber containing a copper drift cell and ancillary ion optics between 
the first transfer hexapole and the quadrupole analyser, as shown in Figure 2.2 (13). 
Typically the drift cell is filed with a buffer gas helium at a pressure of 3.5 - 4.0 Torr 
(4.7- 5.3 mBar) and a weak electric field is applied to propel ions to drift through. 
Although the temperature of the drift cell can be controlled by heating or cooling the 
buffer gas during operation, all measurements presented here were made at 300K 
(300 K ~ 27°C).  
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Ions are produced in the n-ESI source and transferred through the source to the first 
hexapole region (20 cm). From here they are focused into the drift cell using a three-
elemet Einzel lens stack. Design of the instrument allows for operation in both mass 
spectrometry (MS) and ion mobility mass spectrometry (IM-MS) modes. In MS 
mode, a continuous beam of ions drifts through the cell, whereas in the latter ion 
packets are released into the drift cell in discrete pulses. Ions are accumulated in the 
pre-cell hexapole by raising a potential on the top hat lens (TH1) located at the end 
of the pre-cell hexapole, immediately prior to the focusing lenses of the drift cell. 
This stopping voltage is lowered periodically for 40 µs (performed via a biopolar 
pulsar unit) to allow the stored ion packets to enter the drift cell. The frequency of 
operation of this pulse is regulated by a Stanford DG535 digital delay generator 
(Stanford Research Systems, Sunnyvale, CA, USA) which is to be one two-
hundredth of the frequency of the pusher pulse into the ToF region of the mass 
spectrometer. Typically, a pusher period of 115 µs is used to cover a mass to charge 
(m/z) range of 4000. Hence any two mobility events take place every 200 x 115 µs = 
23 ms, or at a frequency of 43.5 Hz (ν = 1/t = 1/23 ms = 43.5 Hz). 
Upon exiting the drift cell, ions are focused into 12.5 cm post-cell hexapole via a 
single lens (L4). Subsequently ions are transmitted into the next vacuum chamber 
which contains a quadrupole mass analyser, collision cell and a final transfer 
hexapole prior to reaching the ToF analyser. In a quadrupole mode ions are detected 
on a point detector and on the microchannel plate detector (MCP) when operating in 
ToF mode. In the ToF-MS, the velocity of an ion is inversely proportional to its m/z 
ratio.  Here the ions are pulsed down the flight tube by the pusher until they reach the 
reflectron, where focused and reflected towards the MCP detector. The signal from 
arriving ions at the detector is converted via 4 GHz time-to-digital card (TDC) into a 
total arrival time distribution (tATD) and processed by MassLynx software (version 
4.1, Waters, Manchester, UK). 
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Figure 2.2: Schematic of MoQToF instrument showing n-ESI source, ion optics, drift chamber, 
quadrupole and time-of-flight analysers. Ion flight path is shown in red dotted line. (A) sample 
cone, B - extractor cone, C - pre-cell hexapole, D - top hat lens, E -  drift cell, F - post-cell 
hexapole, G - quadrupole, H - collision cell , I - post-collision cell hexapole, J -  acceleration and 
focusing lenses, K - pusher lens stack, L - reflectron, M - point detector (for quadrupole 
analyser), N - MCP detector (for ToF analyser).  The non-standard part of a QToF is 
highlighted in yellow (drift chamber including drift cell, E and post-cell hexapole, F) 
All voltages applied to the original parts of MoQToF (i.e., the source, quadrupole, 
ToF, and ion optics) are generated by the original instrument power supplies and 
controlled via Masslynx software (version 4.1, Waters, Manchester, UK). Voltages 
required for the drift cell and associated ion optics are generated by an external in-
house built power supply.  
Typical operating vacuum readings attained in the MoQToF with the buffer gas in 
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out for each system investigated. The elevated source pressure was achieved by 
throttling of the source rotary pump (Edwards E28) through insertion of a 
Speedivalve in line isolation valve to the vacuum line or via presence of background 
argon gas in the source region. 
Region Pressure / mBar 
Source 3.3 
Analyser 1.7 x 10
-3
 
ToF 3.0 x 10
-7
 
Table 2.1: Typical MoQToF instrument pressures. 
The photograph of the MoQToF instrument (Figure 2.3) highlights the modified 
elements from standard Q-ToF and additional components required for the mobility 
experiments. 
 
Figure 2.3: Photograph of the in-house linear drift tube IM-MS instrument – the ‘MoQToF’. A -  
power supply, B -  Einzel lens stack controls, C -  bipolar pulsar unit, D -  drift cell temperature 
read out, E -  Stanford generator, F -  drift cell pressure read out, G - drift cell, H - baratron, I - 
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2.4.2. Drift Tube Architecture  
The low resolution drift tube is based on the design used by the Bowers group at 
UCSB first reported in 1990 (15). The cell is made from a copper block and a copper 
end cap separated by a ceramic space ring (photograph of the cell is shown in Figure 
2.4). The cell contains five copper drift rings spaced 5.5 mm apart, separated by 
ceramic spacers, and connected in series by 1 MΩ resistors. Figure 2.5 shows 
perspective cross sectional and sectional views of the drift cell used in the MoQToF 
instrument. Here the linear drift field is achieved by applying a potential difference 
between the cell body and the end cap with a total drift length being equal to 5.1 cm. 
Entrance and exit orifices are made from molybdenum discs (30.5 mm o.d. x 15.2 
mm i.d x 1.6 mm width) and held in place by copper retainer rings.  
 
Figure 2.4: Photograph of MoQToF drift cell showing the Einzel lens stack (L1, L2 and L3), gas 
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Figure 2.5: Cross sectional drawings for MoQToF drift cell. (I) 3D section through cell (II) 
section through cell viewed from side (III) front elevation (IV) rear elevation. Parts are labelled 
as follows: A - Baratron connection, B - gas in, C- drift rings,  D - exit lens (L4), E - end cap 
(C2); F - cell body (C1), G -Einzel lens (L1, L2 and L3); H - heater terminal block,  I - mounting 
brackets, J -  heaters; K - cooling line inlets,  L - feedthrough to drift rings, M - molybdenum 
orifice, N - thermocouple mounting, O - cell screws. 
As ions leave the top hat lens (TH1), they are focused and steered into the entrance 
orifice of the drift cell via an Einzel lens stack. The Einzel lens is used to focus ions 
without increasing their energy (16). The Einzel lens consists of three stainless steel 
cylindrical lenses (L1, L2 and L3). The first lens L1 is an initial guiding lens for ions 
travelling from the pre-cell hexapole, L2 is subdivided into four elements at the xy 
plane to allow for directional steering of the ion beam and L3 acts as a final focusing 
lens. Exiting ions are focused through the final post-cell lens L4 and transferred to 
the quadrupole chamber. 
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2.4.2.1. Drift Gas 
CP Grade helium gas (99.999% purity, BOC Specialty Gases Ltd, Guildford, UK) 
permeates through a moisture filter (Inert Gas Purifier, Mykrolis cooperation) and 
enters the drift cell through a flexible stainless steel bellow. To maintain a correct 
pressure with additional gas load in this vacuum region a 500 L/s Pfeiffer TMH520 
turbomolecular pump (Pfeiffer Vacuum Ltd, Newport Pagnell, UK) backed by the 
Edwards two‐stage E2M40 rotary vane pump (Edwards Vacuum, Crawley, UK) and 
also a mechanical booster pump is utilised.  
2.4.2.2. Pressure and Temperature Regulation 
The temperature of the drift cell is carefully monitored using three k-type 
thermocouples, one located on the cell body and two on the top and bottom of the 
end cap. The design of the cell enables the temperature to be varied between 80 and 
700 K.  Heating can be implemented via ceramic rods threaded with tantalum wire 
(0.25 mm diameter, Goodfellow Cambridge Ltd., Huntingdon, UK) which are 
located in the copper block of the cell. A current (supplied by two external variable 
transformers) is passed through the chain of heaters causing the wire to resistively 
heat the cell. Cooling of the cell can be achieved with a stream of a chilled nitrogen 
gas that passes through the channels inside the copper block. 
The pressure of the drift cell is measured using a MKS Baratron (MKS Instruments, 
Andover, Massachusetts, USA) attached to the top of the cell via a Swagelok VCR 
fitting. 
2.4.3. Instrument Tuning Parameters 
The voltages applied to the drift cell and associated ion optics are supplied via an 
external in-house build power supply.  
The required voltages and their grounds are presented in the schematic below (Figure 
2.6).  
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Figure 2.6: Schematic of MoQToF drift cell voltages with surrounding lenses. Horizontal lines 
indicate the ground for each voltage. Voltages shown in red dotted line are set manually and 
supplied by external power supply whereas voltages indicated by a blue line are supplied from 
the instrument and controlled via the software. H1 is the pre-cell hexapole, H2 the post-cell 
hexapole, TH1 and TH2 pre and post cell top hat lenses. L1, L2 and L3 pre-cell lenses, L4 post-
cell lens. C1 cell body one, C2 end cap voltage. CV is a collision voltage. 
All voltages float above the collision cell voltage (CV) i.e. increasing its value by 4 
Volts will in effect increase all other voltages by 4 Volts. Additionally the pre-cell 
lenses (H1, TH1, L1, L2 and L3) are referenced to cell body one (C1) and the post-
cell lens (L4) is referenced to the end cap voltage (C2). The voltage ranges of each 
tuning supply and typical settings used are tabulated in Table 2.2.  
Tuning 
Parameters 
Voltage Range / 
V 
Output Voltage / 
V 
Typical Setting 
H1 0 to 200 CV + C1+ H1 35 (on C1 – 105) 
TH1 0 to 200 CV + C1 + TH1 15 (on C1 – 85) 
L1 0 to -350 CV + C1+ L1 -40 (on C1 – 30) 
L2 0 to -350 CV + C1+ L2 -80 (on C1 – 30) 
L3 +50 to -50 CV + C1+ L3 20 (on C1 – 90) 
C1 0 to 200 CV + C1 70 (ref CV) 
C2 0 to 75 CV + C2 10 (ref CV) 
L4 +50 to -50 CV + C2+ L4 -9 (on C2 – 1) 
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Typical instrument settings used in the presented work are shown in Table 2.3. 
Instrument Parameters Settings 
Capillary / kV 1.0-2.0 
Cone  60 
Extractor 120 
RF Lens 1.35 
Source Temperature / °C 80 
Collision Energy 2.3 





Aperture 2 12.6 
Acceleration 200 
Focus 1 
Tube Lens 80 
Guard 64.3 
TOF / kV 7.20 
Reflectron 35.00 
Pusher Cycle Time / µs* 120 
Pusher Frequency / Hz 8333.3333 
Multiplier 651 
MCP 3000 
TDC Start / mV 300.0 
TDC Stop / mV 40.0 




Table 2.3: Typical settings for the MoQToF in positive polarity. Values are shown in volts, 
unless stated otherwise. Extractor and sample cone voltage settings are the read outs given at 
cell drift potential 60V. (*) The pusher cycle time value is adjusted according to m/z range. 
2.4.4. Data Acquisition and Analysis: an example 
The following experiment demonstrates the procedure for acquisition and analysis of 
IM-MS data on the in-house MoQToF instrument. Proof of concept is illustrated by 
study of holo-myoglobin protein in the presence of three different drift gases 
(helium, nitrogen, and argon) in the drift cell. 
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Mass spectra were obtained for myoglobin sprayed from buffered solution conditions 
(10 mM ammonium acetate, pH 6.8) in the presence of different drifts gases in the 
drift cell (Figure 2.7 shows a mass spectrum of myoglobin obtained in the presence 
of helium). Irrespective of the drift gas used, the resulting mass spectra were very 
similar. In the buffered solution, charge state distributions of the heme bound holo-
myoglobin monomer were recorded with 7 ≤ z ≤ 10 (MR = 17566.8 Da ± 0.7) and 
additional multimeric species were also observed. In all cases, the most intense peak 
corresponds to the monomeric [M + 8H]
 8+
 holo-myoglobin (m/z = 2197.0) 
 
Figure 2.7: n-ESI spectrum of myoglobin sprayed from buffered solution conditions (10 mM 
ammonium acetate, pH 6.8) obtained in helium.  
In mobility mode ion arrival time distributions (ATD) were recorded by 
synchronization of the release of ions into the drift cell with mass spectral 
acquisition. A total arrival time distribution (tATD) was generated once every 200 
scans, where each 200 scans sums to 200 ‘pushes’ of ToF pusher plate (Figure 2.8). 
A minimum of ten tATD (2000 scans) was acquired for myoglobin at eight different 
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drift voltages (the electric potential difference across the cell): 60 V, 50 V, 40 V, 35 
V, 30 V, 25 V, 20 V and15 V. 
 
Figure 2.8: Myoglobin total ion ATD at a drift voltage of 30 V recorded in helium. Each peak is 
a collation of 200 scans. 
The ion mobility experiment consisting of eight drift voltages requires approximately 
one hour to be completed due to software waiting times and the time needed to alter 
the drift voltage. From the tATD a mass spectrum can be produced (Figure 2.7) and 
from this a deconvoluted ATD of an individual m/z peak generated. Data for each 
drift voltage is copied from Mass Lynx software (version 4.1, Waters, Manchester, 
UK) into an Excel spreadsheet where, the average arrival time (ta) is obtained by 
multiplying the average scan number of selected species by the pusher period value 
for each drift voltage. 
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Figure 2.9: Arrival time distributions acquired for the [M + 8H]
 8+
 holo-myoglobin peak (m/z = 
2197.0) taken at a drift voltage of 30 V at 300K in helium, nitrogen and argon. 
ATDs acquired for the 8
+
 holo monomer (m/z = 2197.0) at a drift voltage of 30 V are 
shown in Figure 2.9. A single resolvable species is observed in each of the three 
buffer gases, although the actual time spent in the drift cell varies, due to the 
different pressures used, as well as the varying mobility in each gas. There are 
differences in the width of the ATD for each gas. This is best seen by comparing the 
ATD in helium with that in argon where the average drift times are similar but the 
width of the peaks differs; This observation may be attributed to different gas 
pressures in the drift cell and the surrounding chamber and/or the nature of the buffer 
gas dependent collisions on the conformational spread of the ions.  
The average arrival time, ta, combines the time taken to traverse the drift cell (td) and 
the time spent outside the drift cell until the ions reach the detector (known as the 
dead time t0).  
           Equation 2.1 
arrival time /s 
 [M + 8H]

 in He





 [M + 8H]

in Ar 
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Typically t0 are less than 1 ms. Average arrival times are plotted versus pressure/drift 
voltage (P/V) where an intercept is equal to t0 and the slope of gradient is inversely 
proportional to the mobility (1/K) (Figure 2.10). The pressure and temperature of the 
gas present in the drift cell is measured and recorded regularly, at the start and end of 
each mobility event each drift voltage and the average of each, is taken. The td can be 
calculated from the equation 2.2 where K0 is the reduced mobility, L is the length of 
the drift cell, and P and T are averaged experimental buffer gas pressure and 
temperature corrected to standard conditions of temperature (T0 273.15 K) and 
pressure (P0 760 Torr).  
         
     
      
  Equation 2.2 
 
Figure 2.10: Graph of P/V versus arrival time for the [M+8H]  8+ holo-myoglobin ion obtained in 
helium. 
The goodness-of- fit value R
2 
value should be above > 0.9995.  If the fit is good then 
the gradient can be used to detrmine the rotationally averaged CCS of the ion using 




















P/V / Torr Volt
-1
y = 13386x + 842.25
        R
2
 = 0.9999
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Equation 2.3. Ω is the rotationally averaged CCS, z is the integer ion charge, e is 
electron charge (1.602 x 10
-19
 C), N is the number density of the drift gas, µ is the 





), T is the effective temperature of the drift gas and K0 is reduced mobility. 
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 Equation 2.3 
Under buffered conditions where the charge state distribution of holo-myoglobin is 
centered on a lower m/z range (Figure 2.4), the corresponding values for CCS for 6 ≤ 
z ≤ 9 are shown in Figure 2.11.  
 
Figure 2.11: CCS of all of the observed charge states of holo-myoglobin obtained in three 
different drift gases (helium, nitrogen and argon) from pH 6.8 solution at 300 K. The error bars 
are the standard deviation values from an average of three replicates, referring to the maxima 
of the fitted peaks. 
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For conformations of myoglobin with charge states that are considered to be ‘native-
like’, the dominant factors in determining CCS are the mass and the polarizability of 
the buffer gas. The larger, diatomic more polarizable molecule effectively lengthens 
the drift time, resulting in correspondingly larger values of CCS. Diatomic nitrogen 
gas will interact more strongly at short distances with the molecular ion than argon or 
helium: each nitrogen atom is actually negatively charged, and the center of the 
nitrogen molecule is positively charged, molecular nitrogen is also larger than argon. 
In addition, it may be that the greater effects of momentum transfer into rotational 
and vibrational energy for the diatomic gas compared to the monatomic gas causes 
the increase in mobility for nitrogen. When we compare the CCS for each charge 
state the relationship of HeΩ < ArΩ < N2Ω is found. Where z = 6, the HeΩ shows two 
conformers, both of which indicate a collapsed state, whereas for z = 7, 8, and 9 there 
is little change in the values found for HeΩ, although a more extended form appears 
where z = 9. For the heavier gases, at all other charge states around the dominant [M 
+ 8H]
8+
 species, there is more than one conformer present. This is an interesting 
finding, suggesting that the stability of the holo- protein in a single resolvable fold is 
favoured for [M + 8H]
8+
 and starts to be more disrupted for other charge states. 
In summary, different drift gases provide different CCS for each observed charge 
state of the same protein. In addition different gases can reveal different 
conformations and populations of molecular ions present in the gas-phase, 
particularly for native forms. 
2.4.4.1. Multiple ATD Peak Fitting 
For many species, the presence of peak shoulders or individual peaks that are not 
base line resolved in ATD obtained is an indication of potential multiple conformers. 
In this case maxima for the resulting peaks (and hence the arrival times) can be 
achieved by fitting a Gaussian distribution using Origin 8.5.1 (OriginLab, 
Northampton, MA, USA). The Gaussian function used is specified in Equation 2.4, 
where y0 is the offset, A is the area, xc the centre of the fitted peak and w the peak 
width: 
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     Equation 2.4 
 
Figure 2.12: Experimental ATD of holo-myoglobin peak (m/z = 2510.7) taken at a drift voltage 
of 20 V at 300 K in nitrogen. Three species can be resolved. Gaussian fits (red, green and blue 
lines) allow the centre of each species to be calculated shown in a dashed line. 
The centre of the Gaussian fitted peak xc is then converted into average arrival time 





 > 0.90 is accepted. A plot of arrival time versus P/V is obtained as in Figure 2.10 
and the CCS are calculated. 
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2.5. Travelling Wave based IM-MS - Synapt 
HDMS 
Travelling wave ion mobility mass spectrometry (TW IM-MS) is a relatively new 
IMS method implemented in the Synapt HDMS mass spectrometer (Waters, 
Manchester, UK) (14). Despite a successful commercialisation in 2006, its 
fundamentals have been explained only qualitatively. Shvartsburg has explored the 
TW IM-MS operation using theoretical models and numerical simulations of ion 
dynamics to formally understand the relationship between collision cross section and 
mobility in a travelling wave device (17), but as yet there is no adoption of such an 
approach by the IM-MS community. In the absence of a physical model for TW IM-
MS, the mobilities (and hence collision cross sections) of ions need to be extracted 
via an external empiric calibration using a set of standards previously measured in 
helium by drift tube ion mobility mass spectrometry (DT IM-MS) (18-20). However 
in the short time Synapt technology has been available; it has made an attractive 
platform for applications to structural biology analysis (21-24) and complex mixture 
separations (25,26). 
2.5.1. Instrument Layout and Operation 
Ions are produced in the n-ESI source via a ‘Z-spray’ and transferred through the T-
wave ion guide into the quadrupole analyser. Three travelling wave ion guides 
(TWIGs), which form the Tri-wave, are placed between the quadrupole and time-of-
flight mass analyser. Ions arriving in the Tri-wave device are stored in the Trap T-
wave and then released into the IMS T-wave where the mobility separation occurs. A 
schematic representation of this instrument is shown in Figure 2.13.  The mobility-
separated packets of ions are then transferred via the Transfer T-wave to an 
orthogonal acceleration ToF mass analyser.  
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Figure 2.13: Schematic of Synapt HDMS instrument. Image taken from Waters website (27). 
2.5.1.1. Travelling Wave Ion Guide Topology 
The TWIG device comprises a series of ring electrodes arranged orthogonally to the 
ion transmission axis, as shown in Figure 2.14 (28). Opposite phases of an RF 
voltage are applied to consecutive electrodes to provide a radial confinement for ions 
(29). To propel ions through device a transient direct current (DC) pulse is 
sequentially superimposed on the top of RF potential. This provides a moving 
electric field of ‘travelling waves’ on which ions can ‘surf’, reducing their residence 
time in the device. 
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Figure 2.14: Schematic diagram of an RF-only stacked ring ion guide. Image taken from Giles et 
al. (28). 
The mobility TWIG device (also referred as the travelling wave IM separator 
TWIMS) consists of 122 electrodes supported between two printed circuit boards 
(PCBs). A photograph of the T-wave device is shown in Figure 2.15, which has an 
overall length of 185 mm.  
 
Figure 2.15: Photograph of T-wave device. A T-wave device consists of a sequence of ring-
shaped electrodes, supported on PCBs that deliver both RF and DC voltages. Image taken from 
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The entrance and exit apertures of the TWIMS are 2 mm in diameter.  The principle 
of operation is illustrated in Figure 2.16 by SIMION study, ions roll over the wave 
top. Mobility separation is achieved because ions of high mobility roll over the wave 
less often than species of low mobility so the transit time through the device is 
shorter. The IMS cell is operated at up to 1 mBar nitrogen gas.  
 
Figure 2.16: Traveling wave propelling ions in the Synapt system. SIMION plots show a packet 
of ions surfing on the front of the travelling wave as it passes along the SRIG.  Image taken from 
the Waters website (27). 
The Trap and Transfer TWIGs are 100 mm long and consist of 33 electrode pairs 




2.5.1.2. Instrument Tuning Parameters and Typical 
Pressures 
Typical instrument settings used in the presented work are shown in Table 2.4. 
Instrument Parameters Settings 
Capillary / kV 1.0-2.0 
Cone / V 60 
Extractor 2.0 
Source Temperature / °C 30 
Nanoflow Gas Pressure / Bar 0.2 
Aperture 1 1.0 
Pre-filter 2.0 
Ion Energy 2.0 
Direction of 
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Instrument Parameters Settings 
Trap Collision Energy 5.0 
Transfer Collision Energy 3.0 
Trap Gas Flow / mL/min 1.50 
Source Gas Flow / mL/min 0.00 
IMS Gas Flow / mL/min 10.00 
Detector  1800 
Pusher Interval / µs 
 
90 
Pusher Width 4 
Acceleration 1 70.0 
Acceleration 2 200.0 
Aperture 2 70.0 
Transport 1 70.0 
Transport 2 70.0 
Steering  0.0 
Tube Lens 75 
Pusher  925.0 
Puller 647.0 
 
TOF / kV 9.10 
Reflectron / kV 2.16 
Trap DC Entrance 3.0 
Trap DC Bias 13.0 
Trap DC Exit 0.0 
IM DC Entrance 2.0 
IM DC Exit 2.0 
Transfer DC Entrance  1.0 
Transfer DC Exit 1.0 
IMS Wave Velocity / m/s 250 
IMS Wave Height  13.0 
Transfer Wave Velocity / m/s  247 
Transfer Wave Height 4.0 
Trap Release Time / µs 500 
Trap Trap Height 30.0 





Table 2.4: Typical settings for Synapt HDMS in positive polarity. Values are shown in volts, 
unless stated otherwise. 
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Figure 2.17: Schematic of the potential gradient along the Synapt HDMS instrument and the 
potential differences defining the Trap and Transfer collision energies (CE) and the Bias 
potential. All potentials are referenced to the Static Offset voltage typically set to 120 V. Image 
and caption adapted from Michaelevski et al. (30). 
Typical operating vacuum readings attained in Synapt HDMS during mobility 
experiment are tabulated in a Table 2.5. 
Region Pressure / mBar 
Backing 4.38  
Source  3.53 x 10
-3
 
Quadrupole 3.42 x 10
-5
 
Trap 1.85 x 10
-2
 
IMS 1.05  
TOF 1.12 x 10
-6
 
Table 2.5: Typical Synapt instrument pressures.  
 
Sample Cone 
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2.5.2. Calculation of CCS using TW IM-MS data 
The mobility of ions through T-wave devices is not as directly related to collision 
cross section as in DT IM-MS instruments. Despite this, with a careful use of 
standards previously measured in helium via DT IM-MS, it is possible to convert 
mobilities measured with nitrogen  as a drift gas in Synapt instrumentation into mass 
selected ‘helium based’ collision cross sections. Several ion mobility cross-sectional 
calibration procedures have been described previously (18,21,22,31-35).  
In this thesis, where TW IM-MS was employed (in Chapters 3 and 4), ion mobility 
drift times were calibrated using multiply charged ions of cytochrome c (equine 
heart) and myoglobin (0.2 mg/mL, in 50/50 H2O/acetonitrile and 0.1% formic acid). 
The mobility drift times of the calibrant ions were corrected for their mass-dependant 
flight time (the time from when the ion exits the transfer T-Wave until it reaches ToF 
and is proportional to the√
 
 
 of the ion), using the following Equation 2.5: 




   
     Equation 2.5 




is the mass-to-charge ratio of the observed ion and   is the Enhanced Duty Cycle 
(EDC) delay coefficient;   is instrument-dependant  with a typical value between 1.4 
and 1.6 (here 1.5).  Using Clemmer’s Cross-Section Database (36), the calibrant CCS 
were corrected (Ω’) for both ion charge state (z) and reduced mass (µ) to generate: 
   




     Equation 2.6 
The corrected collision cross section values (Ω’) were plotted against the corrected 
mobility drift time (t’d) values of the calibrant ions and a power trend (y = Ax
N
) was 
fitted (plot is shown in Figure 2.18). The experimental CCS measurements for each 
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resolvable species at a given charge state were converted to estimated CCS by 
calculating: 
      
 
     (√
 
 
)  Equation 2.7 
Figure 2.18: Normalized collision cross sections vs corrected mobility drift times for equine 
myoglobin ions, z = 13 - 22 (0.2 mg/mL, in 50/50 H2O/acetonitrile and 0.1% formic acid). The 
plot is an example used to create a cross-section calibration for the Synapt instrument.  
2.6. Mass Calibration 
Calibration was performed using a 1 mg/mL solution of sodium iodide (Sigma 
Aldrich, Dorset, UK) dissolved in 50% isopropanol.  The metal salt calibrant 
provides a series of monoisotopic cluster peaks corresponding to Nan+1In ions, 
covering appropriate m/z range.  
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2.7. Optimization of experimental conditions  
The goal of native mass spectrometry is to preserve quaternary protein structures to 
investigate protein complex topology and dynamics.  The experimental parameters 
(voltages and pressures) were screened systematically to achieve an optimum signal 
and most importantly to avoid any instrument-induced structural transitions.  
Injection energy monitoring, where the potential pushing ions into the drift cell 
region is varied as well as heating of the drift cell (thermal unfolding) was used to 
explore the conformational space of proteins, beyond native conditions. The full 
tuning of MoQToF instrument parameters was performed for every experiment, 
including the drift cell voltages (L1, L2, L3, L4 and H1, TH1), sample and extractor 
cone potential. In Synapt HDMS instrument, particular attention was given to IMS 
wave height, IMS wave velocity and bias potential settings, as well as sample and 
extractor cone values. For both instruments used the source pressure was elevated 
systematically to obtain an improved transition of ions. The capillary potential was 
adjusted to provide optimum signal. The precise value of voltage used depended 
mainly on the solution composition and spray geometry but voltages were typically 
in the range of 1.0-2.0 kV. In case of samples prone to aggregation a nitrogen 
backing gas was used to maintain a stable spray. Unless stated otherwise the source 
block was heated 80°C to aid desolvation process.  
Aqueous ammonium acetate salt concentrations were used in range of 10 mM to 500 
mM, with neutral pH. From many biophysical studies it is clear that quaternary 
protein structures can often be preserved under these conditions. During the ESI 
process, the volatile buffer easily desolvates, rendering 'naked' protein ions, albeit 
substantially less charged than in organic ESI solvents as the surface is more 
compact in folded species. Salting out of the protein sample solutions was one of the 
essential steps in obtaining a clean mass spectrum. Dialysis method, either slide-A-
lyzer dialysis cassettes (Thermo Scientific, Inc) or micro bio-spin chromatography 
columns (Bio-Rad Laboratories, Inc), was used for the removal of unwanted salt. 
Dialysate (buffer) volume, number of dialysate changes, time, dialysate agitation 
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(stirring) and temperature were the factors that affected the dialysis rate and were 
optimised for every protein sample.  
In the subsequent results chapters the final optimised experimental conditions are 
specified in the relevant methodology section.  
2.8. Estimation of collision cross sections from 
PDB structures 
The mobility and buffer gas specific CCS could be accurately calculated for any set 
of coordinates (available from RCSB Protein Data Bank) for subsequent comparison 
with experimental values. This would involve evaluation of orientationally averaged 
cross sections with an approximate but appropriate treatment of ion-buffer gas 
collisions. Indeed this can be accomplished, and Jarrold (37-39) and Bowers (40) 
have made significant breakthroughs in this direction. Currently, MOBCAL (37-
39,41) developed by Shvartsburg and Jarrold is widely used to determine the 
theoretical CCS of biological molecules. This open source software program is based 
on three different treatments of the ion-buffer gas collision which calculate 
rotationally averaged cross sections from input coordinate files, derived from X-ray 
crystallography or NMR studies or from MD simulations. With the exception of 
some recent work by Shvartsburg (42), all computations rely on averaging the 
orientation of a set of coordinates and calculating the interaction with a chosen buffer 
gas. The contained models in MOBCAL are: the projection approximation (PA) (40), 
exact hard sphere scattering method (EHSS) (37,43),  trajectory method (TM) (39) 
and recently developed a novel projected superposition approximation (PSA) (44-
46). The above four methods determine the CCS with helium as the in silico buffer 
gas, which to date somewhat curtails the use of other gases in experiments. 
In this thesis only EHSS or TM values are reported and compared with experimental 
data. 
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2.8.1.  Projection Approximation Method 
A particularly simple approach is the projection method (PA) (40) which has been 
employed to obtain rotationally averaged cross sections of proposed molecular 
structures for over 80 years. The CCS is determined by averaging the geometric 
projection areas over all possible orientations (Figure 2.19). However this method 
ignores the long-range interactions and all the details of the scattering process 
between the ion and buffer gas. The CCS obtained from crystal structure coordinates 
of some monomeric peptides and small proteins using the PA method were found to 
be on average up to 20% smaller than those obtained from the other approaches, 
EHSS and TM (this difference was marginally greater for the larger molecules) (47). 
In order to address the inadequacy of the PA approach, Wyttenbach (40) 
implemented the use of scaled size parameters for all of the atoms in the molecule, 
however this still does not address the effects of multiple collisions, and hence for 
ions of masses greater than 2 kDa, or for particularly crenulated conformations of 
smaller molecules such as those found for crown ethers, this method will 
underestimate CCS and is of limited value for larger biomolecules. 
 
Figure 2.19: The projection approximation method finds the average ‘shadow’ as a test 
conformer is rotated through all possible orientations. Image was adapted from the website of 
the Indiana University Bloomington (36). 
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2.8.2. Exact Hard Sphere Scattering Method 
In the exact hard sphere scattering (EHSS), a CCS is calculated by averaging the 
momentum transfer cross section which is related to the scattering angles between 
the incoming and departing gas atom trajectory. This model takes into account 
scattering and the collision process but does not consider the effects of long range 
potentials between the buffer gas and the molecular ion. Overall the EHSS model 
was found to give values that are slightly higher, especially for smaller molecules, 
than those determined by TM. The EHSS model overestimates the cross sections for 
small ions simply because it (as well as PA) in MOBCAL has been parameterized for 
fullerenes and other large ions of similar size, and small ions form shallower ion 
molecule potentials that are effectively manifested as smaller collision radii, finally 
the long range interactions included in TM appear to be of less importance for larger 
ions, but TM properly accounts for the size dependent variation of the interaction 
potential (47). 
2.8.3. Trajectory Method 
The trajectory method (TM) (39) is considered to be the most reliable and accurate 
method for calculating the CCS especially for larger ions. This approach takes into 
account the long-range interactions and close collisions between the ion and buffer 
gas atom, as well as the effects of multiple collisions. To perform this calculation, the 
effective potential must be defined and then the trajectories are run within this 
potential to obtain the scattering angles. 
2.8.4.  Projected Superposition Approximation 
Method 
In the framework of a novel projected superposition approximation (PSA), molecular 
CCS are computed as a projection approximation method, however modified to 
account for collective size and shape effects (46). The PSA method is a much faster 
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than the trajectory method as recently demonstrated by Bleiholder and Bowers 
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p53 DNA-binding domain 
in vacuo 
The tumour suppresour p53 is at the hub of a plethora of signalling pathways that 
maintain the integrity of human genome and regulate the cell cycle. It is therefore 
not surprising that this is mirrored in the intricate structure of p53. The central core 
of protein, consisting of the DNA-binding domain, is the most highly conserved 
domain and is required for sequence-specific DNA binding. Herein, mass 
spectrometry and ion mobility mass spectrometry studies on the conformational 
diversity of wild-type p53 DNA-binding domain are reported. 
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3. p53 DNA-binding domain in vacuo 
3.1. Introduction 
The central p53 domain is responsible for specific DNA-binding and it is probably 
the most interesting and important independent domain of the p53 tumour suppressor 
protein. This domain, also commonly known as ‘the core’ due to its protease 
resistance (1,2), contains the most evolutionary conserved sequences of the protein 
(3). Ever since the first structure of the p53 core domain in a complex with a 21-
base-pair DNA was determined from high-resolution X-ray diffraction data in 1994 
(4), a multitude of structures of the core domain of p53 have been elucidated: X-ray 
crystal and NMR solution structure of p53 core domain in DNA-free form (5,6), 
structures of p53 in a complex with DNA (7,8), several mutants (9-12), and p53 core 
bound to signalling proteins (13-15).  
The structure of DNA-binding core domain (residues 94-292) consists of two anti-
parallels β-sheets of four and five twisted strands, forming a ‘β-sandwich’ (Figure 
3.1). This compact, barrel-like structure provides the basic platform for a loop-sheet-
helix motif which docks to the DNA major grove and for two large loops, L2 
(residues 163-195) and L3 (residues 236-251). The architecture of the L2/L3 region 
is stabilised by a zinc ion, which is tetrahedrally coordinated by a histidine and three 
cysteines residues (Cys176, His179, Cys238 and Cys242) (4-6). Mutations of these 
corresponding residues in mouse p53 inhibit DNA binding (16). The presence of 
single zinc ion molecule was found to be essential for retaining the WT conformation 
of p53. Hainaut et al. (17) and others (18,19) established that the use of copper and 
cadmium instead of zinc ion removes DNA-binding.  
Human p53 core domain is only marginally stable and rapidly unfolds just above 
body temperature with a half-life of 9 minutes (20-22). Evidence suggest that the low 
thermodynamic and kinetic stability of p53 may be a result of an adaptive 
evolutionary process (5,23,24), to allow for a rapid inter conversion between folded 
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and unfolded states providing an additional layer of control of cellular protein levels.  
 
Figure 3.1: The DNA-binding core domain of p53 (residues 94-312) showing a predominantly 
sheet-like structure (yellow), alpha helices (purple), loop regions (white) and coordinated zinc 
ion is shown in red. PDB 2FEJ file (5) was used to generate image in VMD software. 
Furthermore, the NMR structure of p53 deposited by Wang et al. (6) reveals a 
number of buried polar groups that could potentially be key elements contributing to 
p53’s inherent instability. Increasing the stability of the p53 protein has been deemed 
necessary for some biophysical and structural investigations, in which a stabilised 
quadruple mutant has been used (11,25). 
The core domain of p53 is also the main target for mutations as over 80% of the 
missense tumour-derived mutations are mapped to this region (26). 
Chapter 3: p53 DNA-binding domain in vacuo 
- 82 - 
  
3.2. How p53 binds DNA 
p53 is known to regulate the gene transcription by binding to over 100 different, 
naturally occurring DNA-binding sites or response elements (27). The emerging 
picture is that p53 is involved in these promiscuous interactions with genomic DNA 
via both its DNA-binding domain and C-terminal regulatory domain.  This chapter 
will solely focus on what is known about the involvement and regulation of the p53 
core domain in sequence-specific DNA binding. Isolated p53-DBD binds specifically 
to double-stranded DNA sequence of two tandem decameric elements 
PuPuPuC(A/T)(A/T)GPyPyPy (Pu = A/G, Py = T/ C) that can be separated by 0 -13 
nucleotide base pairs (28). Four core p53-DBDs bind to these response elements in a 
highly cooperative manner to give a complex with 4:1 stoichiometry, even in the 
absence of the tetramerization domain responsible for oligomerization of the full-
length protein. Rippin et al. (29) report this phenomenon to be partially mediated by 
core-core interactions. The binding can also induce bending and twisting of the DNA 
(30,31). 
X-Ray crystallographic measurements provide detailed information on the structural 
architecture of p53 tetramers bound to DNA (7). Two core domains bind to a half-
site DNA, forming a symmetrical dimer (e.g. the green and grey molecules shown in 
Figure 3.2). The core-core interface is formed by residues located in the L3 region 
and a helical fragment within L2, which includes Pro177, His178, Arg181, Met243, 
and Gly244, in accord with NMR results (29,32). Both hydrophobic and water 
mediated polar contacts are an integral part of the protein-DNA interface. p53 
molecules self-assemble on DNA half-sites to form a ‘dimer of dimers’, stabilized by 
core-core and base-pair stacking interactions (7). The nature of the core-core 
interface along the DNA fluctuates among the different DNA complexes, reflecting 
the transitory mode of this interface region and p53’s capability to bind to response 
elements with different spacer lengths between the two half-sites (33). For instance a 
10-base pair spacer would place p53-DBD dimers on the same face of the DNA-
double helix but a significant bending of DNA would be required for inter-dimer 
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interactions to occur, whereas a 5-base pair spacer would place p53 dimers on 
opposite faces of the DNA (34).  
 
 
Figure 3.2: Image of human p53-DNA binding domains (residues 94-293) bound to two 
palindromic DNA half-sites. Representation of PDB 2AC0 file (7) rendered orthographically 
using VMD software. 
 
The DNA major-groove contacts are facilitated by residues: Ala276, Cys277 and 
Arg280 from the carboxy-terminal helix and also Lys120 from the L1 region (7).  
The vast amount of research probing the functions of the p53-DBD has provided 
many insights into possible modes of regulation of DNA binding. Multiple protein-
protein interactions have also been mapped to this domain and may directly or 
indirectly affect the ability to interact sequence-specifically with DNA (35). 
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3.3. Methodology 
3.3.1.  Protein Expression and Purification 
Wild-type (WT) human p53-DBD (amino acid residues 94-312) was expressed and 
purified by Dr Penka V. Nikolova (King’s College London, UK) and Dr David J. 
Clarke (University of Edinburgh, UK) according to the method outlined below. 
Cloning of the protein was performed using pRSETA expression vector (Invitrogen) 
which was modified so that it did not contain the His tag (20,36,37). The protein was 
expressed at 37°C in Escherichia coli C41 cells and grown up to an OD600 of 0.8. The 
temperature was reduced to 22°C before cell cultures were induced with 1 mM 
isopropyl β-D-thiogalactopyranoside (IPTG) and grown overnight. Cells were 
harvested by centrifugation and lysed using Bug Buster Protein Extraction Reagent. 
Benzonase nuclease and EDTA-free protease inhibitor tablets were also used during 
this process. The soluble fraction was loaded on to an SP-Sepharose column eluted 
with NaCl gradient followed by gel-filtration chromatography using an HP26/60 
Superdex 200 column. 
3.3.2. Sample Preparation 
WT p53 DNA-binding domain protein samples were flash frozen in liquid nitrogen 
and stored in a -80°C freezer. Prior to mass spectrometry and ion mobility mass 
spectrometry measurements, protein samples were thawed and dialysed in 50 mM 
ammonium acetate for 2 h at 4°C using slide-A-lyzer dialysis cassettes (Thermo 
Scientific, Inc). Protein concentrations were measured spectrophotometrically 
(NanoDrop Spectrophotometer ND 1000 Thermo Scientific, USA) by using an 
extinction coefficient of ɛ280 = 17,130 cm
−1 M−1 calculated by the method of Gill and 
von Hippel (38). WT human p53-DNA binding domain amino acid sequence is 
shown below: 
SSSVPSQKTY QGSYGFRLGF LHSGTAKSVT CTYSPALNKM FCQLAKTCPV 
QLWVDSTPPP GTRVRAMAIY KQSQHMTEVV RRCPHHERCS DSDGLAPPQH 
LIRVEGNLRV EYLDDRNTFR HSVVVPYEPP EVGSDCTTIH YNYMCNSSCM 
GGMNRRPILT IITLEDSSGN LLGRNSFEVR VCACPGRDRR TEEENLRKKG 
EPHHELPPGS   TKRALPNNT 
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3.3.2.1. DNA Oligonucleotides 
Double-stranded DNA fragments used in this study were constructed by annealing 
purified synthetic oligonucleotides purchased from ATDBio (University of 
Southampton, UK). DNA oligomers used in this study contained the following 
palindromic sequences: GGAACATGTTCC and GAACATGTTCGAACATGTTC 
consensus binding site. Annealing was performed by heating the oligonucleotides at 
95°C for 5 minutes and gradual, slow cooling to room temperature to ensure an 
efficient hybridization. The final concentration of the double-stranded DNA used for 
the binding experiments is based on the assumption that all of DNA had annealed 
completely, however trace amounts of unbound DNA/hairpin structures might be still 
present. 
3.3.3.  Mass Spectrometry and Ion Mobility Mass 
Spectrometry 
The travelling wave based ion mobility mass spectrometry (TW IM-MS) 
experiments were performed on a Synapt HDMS system (39) (Waters Corporation, 
Manchester, UK) described in detail in Chapter 2, Section 2.5.1. Samples were 
introduced into the source region by nano-electrospray ionisation (n-ESI). The 
instrument was operated in a positive ionisation mode with a capillary voltage of 0.8 
-1 kV, cone voltage of 65 V and source temperature of 30 °C. Source backing 
pressure was elevated to 4 mBar for improved transmission of ions. Travelling wave 
heights of 13, 14 and 15 V and 250 m/s were employed. The ion mobility separator 
containing nitrogen gas was operated at a pressure of 1 mBar. During data 
acquisition, the parameters of the instrument were optimised to obtain the optimum 
ion mobility separation. Equine heart cytochrome c and myoglobin was analysed 
under denaturing conditions to create a calibration curve for cross-section 
measurements versus values obtained from drift tube ion mobility mass spectrometry 
(DT IM-MS) studies. Calibration procedure is described in Chapter 2, Section 2.5.2. 
Drift tube ion mobility mass spectrometry (DT IM-MS) experiments were performed 
on an in-house modified quadrupole time-of-flight mass spectrometer, the MoQToF 
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(40). More detailed description of this instrument can be found in Chapter 2, Section 
2.4.1. Ions were produced by positive n-ESI using Z-spray source, within a spray 
voltage range 1.0 to 1.8 kV and a source temperature of 80°C. The drift cell was 
filled with helium buffer gas at the average pressure of 3.5 - 4.0 Torr (4.7 - 5.3 mBar) 
and a temperature between 298 - 302 K. The electric potential across the cell was 
varied from 60 to 15 V and ATDs were recorded at eight drift voltages. The mobility 
of the ion of interest was calculated from a linear plot of average arrival time versus 
pressure/drift voltage (P/V) and from this the rotationally-averaged collision cross 
section (CCS) for each resolvable species at a given charge state were obtained. 
3.3.4. Theoretical Measurements of collision cross 
sections  
Using the input coordinate files from published X-ray crystallography measurements 
of p53 deposited by Wang et al. (6) (PDB: 2OCJ) the rationally-averaged CCS p53-
DBD monomer, dimer and extended linear form of monomer were calculated. 
Projection Approximation (PA) (41), Exact Hard Sphere Scattering (EHSS) (42) and 
Trajectory Method (TM) (43) were utilised, all implemented in MOBCAL. The TM 
provides the most accurate estimate of the CCS and has been used here for a 
comparison with the experimental values of CCS.  We have not employed it for the 
fully extended form of p53-DBD since the size of this molecule was too large for our 
compilation of the MOBCAL software. The less accurate EHSS method gives 
qualitatively similar results (44) and so the two values are comparable. 
Using methods established by Jarrold and co-workers (42,43), CCS from coordinates 
obtained from the X-ray crystallography measurements of p53-DBD dimer cross-
linked to 16-base-pair DNA fragment (deposited by Ho et al. (6)) were also 
calculated. 
The MOBCAL calculations were performed by Dr Massimiliano Porrini. 
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3.3.5. Production of Waterfall Plots for data obtained on 
TW IM-MS 
The waterfall plots for WT p53-DBD were produced in Origin 8.5.1 software 
(OriginLab, Northampton, MA, USA). Multi-curve waterfall charts were created by 
plotting estimated CCS values (x), calculated as described in Chapter 2, Section 
2.5.2, against peak intensity values (y) and charge (z). The intensities of the peaks 
were obtained from the Mass Lynx software (version 4.1, Waters, Manchester, UK). 
3.4. Insights into Structure(s) and Dynamics of 
WT p53-DBD by MS and IM-MS  
This chapter focuses on the isolated core DNA-binding domain of p53, as a 
monomer, as well as in partnership with DNA. IM-MS is used to probe the 
conformational landscapes of this protein. The experimental approach provides the 
general shape and population of conformations via the measurement of their m/z and 
collision cross sections. The conformational spread of p53-DBD under buffered and 
denaturing solution conditions is quantified. The extent of changes in conformational 
families associated with binding of the isolated p53-DBD to two different DNA 
constructs is also monitored. 
3.4.1.  MS of WT p53-DBD in buffered solution 
conditions 
From the buffered solution, a charge state distribution of wild-type (WT) p53 DBD 
monomer is observed with 8 ≤ z ≤ 18 and a few additional multimeric species 
(Figure 3.3). Each of the monomer charge states is attributable to the zinc bound 
form of the protein (calculated MR = 24615.5 Da, observed MR = 24612.4 Da) which 
suggests that all conformations present in solution retain the zinc binding site, and 
that it is not perturbed by the n-ESI desolvation process or by any subsequent 
coulombically driven unfolding. The most abundant species in the mass spectrum 




 indicative of a compact form 
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of the protein with a limited number of charge-accessible residues available for 
protonation. Peaks also display phosphate adducts at low charge density. Two unique 
m/z are present for a dimeric form of p53, [2M+zH]
 z+
 where z = 13 and z = 15, 
representing higher order multimeric association in solution, again zinc is bound 
stoichiometrically. Higher charged species, where 11 ≤ z ≤ 18 are observed at low 
abundance, evidence of a small population of more unfolded states of p53. Even 
under ‘near native’ conditions p53 displays a wide charge state distribution (8 ≤ z ≤ 
18), which is a signature behaviour of IDPs in vacuo as reported by mass 
spectrometry (45). 
 
Figure 3.3: n-ESI spectrum of 95 µM p53 DBD obtained via the TW IM-MS from buffered 
solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
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3.4.2.  MS of WT p53-DBD in denaturing solution 
conditions 
At low pH (Figure 3.4) the observed spectrum displays a wider charge state envelope 
over the acquired mass range (400 - 4000 m/z). Under these conditions the most 
dominant species of p53 observed is a monomer. The deconvoluted mass (MR = 
24547.9 Da) is less than the mass of the ‘native’ p53 monomer (MR = 24612.4 Da). 
This is due to the loss of the tetrahedrally coordinated zinc atom (MR = 65.4 Da) 
which destabilises the structure of protein. The observed charge states ranged from 9 
≤ z ≤ 34 attributable to facile protonation of solvent exposed basic residues. These 
sites are proposed to be basic residues - there are 19 arginine, 8 lysine and 9 histidine 
residues in the p53 molecule, as well as at the N-terminus where proton addition 
could potentially occur.  
 
 Figure 3.4: n-ESI spectrum of 95 µM p53 DBD obtained via the TW IM-MS from pH 1.5 
solution (50 mM ammonium acetate, containing 10% by volume propan-2-ol and 1% formic 
acid). 
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The spectrum displays a trimodal charge distribution with centres at z = 27, 18 and 
11, suggesting at least three conformational families are present in the solution and 
transferred into the gas phase. The distribution ranging from 22 ≤ z ≤ 34 is more 
populated than the one ranging from 12 ≤ z ≤ 22, and so it can inferred that the 
denatured protein favours more extended conformations. In summary, as Figures 3.2 
and 3.1 are compared, an addition of acid (lower pH) causes a shift in the most 
intense peaks to higher charge (lower m/z), and a decrease in intensity of lower 
charged (higher m/z) as the folded conformation is lost and the unfolded state is 
predominantly populated interactions. 
3.4.3.  MS of WT p53-DBD in high buffer solution 
conditions 
Under higher buffer conditions (500 mM ammonium acetate) the most dominant 
species of p53 detected is zinc bound monomer (Figure 3.5).  
 
Figure 3.5: n-ESI spectrum of 95 µM p53 DBD obtained via the DT IM-MS from a solution at 
high buffer concentration (500 mM ammonium acetate, containing 10% by volume propan-2-
ol). 
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Nonetheless the observed mass spectrum displays a much tighter charge state 
envelope for the monomeric ensemble over the acquired mass range. There is a clear 
depopulation in the higher charge states of p53 monomer. The highest charge state 
corresponds to z = 13 in contrast to z = 18 observed in the spectrum sprayed from the 
lower buffer solution conditions (Figure 3.3). This is not surprising as the high 
concentration of buffer tends to stabilize the protein’s structure driving p53 molecule 
to a more compact conformational isomer (with fewer charges). Additionally dimer 
population [2M+zH]
z+
 (again zinc is bound stoichiometrically) with the distribution 
ranging from 14 ≤ z ≤ 17 is more intense in higher buffer solution conditions. A new 
unique m/z peak for a dimeric form of p53 is detected, where z = 17. 
3.4.4. Conformational Landscapes occupied by WT p53-
DBD 
Along with mass spectrometry, ion mobility measurements have been performed on 
the p53 DNA-binding domain sprayed from two different solutions. Collision cross-
sections obtained are tabulated in Table 3.2, 3.3 and 3.4 and plotted as a function of 
charge state in Figure 3.6 and 3.7. The data taken at pH 1.5 (Figure 3.6) shows a 
smooth, near linear increase in cross-section with respect to charge, which can be 
explained by the range of dynamic states of the protein in solution, resulting in 
differently populated protonated states, which have little structure, and are easily 
subject to coulombically driven unfolding once in the gas phase. Faull et al. (46)  
have also used IM-MS to investigate the conformations of p53 in the presence and 
absence of zinc, showing that removal of this zinc ion disrupts the structure of the 
DNA-binding domain.  
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Figure 3.6: Collision cross sections versus charge obtained via the TW IM-MS of 95 µM p53 
DBD at low pH (50 mM ammonium acetate, containing 10% by volume propan-2-ol and 1% 
formic acid). The graph also shows the calculated CCS value for coordinates expected from a 
fully extended form of the p53 DBD. This modelled structure was built using xleap within the 
AMBER molecular modelling package (47) and was found to be 7289 Å
2
. 
Here in the absence of solvent at data taken at pH 1.5, each additional proton added 
to the flexible protein can cause local unfolding due to unfavorable interactions with 
other proximal proton(s). However it also displays some regions of stability seen as 
‘shelving in the cross section values (z = 8 to 10 and z = 12 to 14). For each of the 
three lowest charge states, (z = 9, 10, 11) a single conformation was resolved with 




 and 1805 Å
2
 respectively. At these low charge states, the 
structure is most likely compact but loss of the zinc atom indicates that there is much 
less secondary structure than the conformers reported (see below) from solutions 
buffered at pH = 6.8. For 12 ≤ z ≤ 24 multiple unfoldomers for each charge state 
were observed.  
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Using methodologies established by Jarrold and co-workers (42,43) CCS were 
calculated from coordinates obtained from the X-ray crystal structure of p53 
deposited by Wang et al. (6) for p53-DBD monomer, dimer and extended monomer. 
The results are tabulated in Table 3.1. 
 
Table 3.1: Theoretical calculations of collision cross sections for (a) p53-DBD monomer (b) p53-
DBD dimer and (c) p53 DBD extended monomer. Here values are shown using the Projection 
Approximation, Exact Hard Sphere Scattering and Trajectory Method. TM was not used here 
for the fully extended form of p53 since the size of this molecule was too large for the 
compilation of the MOBCAL software. The less accurate Exact Hard Sphere Scattering (EHSS) 
method gives qualitatively similar results (44) and so the two values are comparable. 
The calculated CCS for coordinates expected from a fully extended form of the p53 
DBD was built using xleap within the AMBER molecular modelling package (47) 
and found to be 7289 Å
2
 (highlighted in Figure 3.6). Even the highest charge state 
experimentally observable has a significantly smaller CCS (by 22%), suggesting that 
the DBD of p53 retains some secondary structure, or at least intermolecular 
interactions, all be they transient.  
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From buffered conditions (Figure 3.7), there are two dominant charge states (z = 9 
and 10). The z = 9 species provides a single resolvable conformer (1657 Å2), 
indicative of a highly compact form of the protein, whereas for z = 10 two species 
are resolved, with the most populated being (1669 Å
2
) and a lower intensity extended 
form (2157 Å
2
). These conformers are not baseline resolved which could be due to 
the resolution of the Synapt HDMS instrument, or alternatively that they are in 
conformational equilibrium on the timescale of these IM-MS experiments (5 - 10 
ms).  
 
Figure 3.7: Collision cross sections versus charge obtained via the TW IM-MS of 95 µM p53 
DBD from buffered solution conditions (50 mM ammonium acetate, containing 10% by volume 
propan-2-ol). 
The low CCS for z = 8-10 are smaller than those calculated from the coordinates 
obtained from the crystal structure deposited by Wang et al. (6), here using the 
Trajectory Method (43) thus indicating that the protein has collapsed somewhat in 
comparison to the X-ray structure. This follows the general trend for monomeric 
proteins previously reported (44), and here reveals conformers which are smaller 
than the equivalent charge state species obtained from the low pH solution, 
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suggesting that the bound zinc has a stabilizing effect. The second much lower 
populated conformational family which starts with the more extended conformer for 
z =10 does coincide with the value calculated from crystal structure coordinates. The 
dimers that are present following n-ESI have significantly lower (by 23%) CCS than 
that obtained from the crystal structure; this form is clearly not stable in the gas 
phase under our experimental conditions.  
For monomeric p53 DBD, with increasing charge, a pathway of unfolding is clearly 
visible, the CCS increase. However there is far more shelving than found at pH 1.5 
suggesting a more concerted unfolding and again more stability to the protein. The 
calculated CCS for each charge state are higher than that the equivalent charge state 
conformers obtained from the physiological pH solution. The data in Figure 3.7 
provide evidence for several stable states on the unfolding pathway. With increasing 
charge (z = 10 to 13 and z = 15 to 18) at least two conformers can be observed. 
Although p53 has unfolded to a more extended structure it still retains some non-
covalent interactions that sustain the protein in these different conformations for the 
duration of the mobility experiment. 
Arrival Time Distributions (ATD) for each charge state, showing the abundance of 
the conformation within the protein under buffered conditions is presented in Figure 
3.8. For 11 ≤ z ≤ 18, multiple unfoldomers (Un) are observed in each charge state, 
and the number of resolvable Un conformers is at least four, albeit at low intensity 
(Figure 3.9). The lack of baseline resolution in the arrival-time distributions suggests 
interconverting conformers for these extended forms over the timescale of our 
experiment. The CCS value of the second, much less populated family of 
conformers, which starts with the more extended conformer (X1) for z = 10 (2157 
Å
2
) coincides with the CCS value calculated from crystal structure coordinates (2072 
Å
2
), but more extended forms are also present, suggesting unfoldomers (Un). 
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Figure 3.8: Waterfall plot representing the in vacuo ‘conformational phenotype’ of p53 DBD 
sprayed from buffered solution conditions (95 µM solution in 50 mM ammonium acetate, 
containing 10% by volume propan-2-ol), obtained via the TW IM-MS. The x, y and z axis show 
the collision cross section (in Å
2
), charge state (range 9 ≤ z ≤ 18), and the relative intensity, 
respectively.  
 
Figure 3.9: Enlargement of the ATDs for charge state range between 11 ≤ z ≤ 18. Here a range 
of extended conformers for higher charge states is observed. 
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The ATDs for the wild type p53-DBD were generated for the non-adducted species. 
In the mass spectrum of the p53-DBD in buffered solution conditions (Figure 3.3) 




 are the heavily adducted species. The adducted populations could 
potentially show different conformational properties than the ‘naked’ protein. The 
comparison of ATDs for a non-phosphorylated protein and a p53-DBD with two 
phosphate adducts is presented in Figure 3.10. The conformational phenotypes 
appear to be comparable and the difference in CCS in only a marginal one, in a range 
of 1 - 2 %. Nonetheless, for the provided ATDs (p53-DBD and mutants presented in 
the subsequent chapter) a mass window corresponding to a ‘naked’ protein (non-
adducted) was used to generate ion mobility profiles.   
 
Figure 3.10: Comparison of ATDs for [M+9H]
9+ 
species (a) non-phosphorylated (b) and doubly 
phosphorylated. Data were acquired via the TW IM-MS at 13 V IMS wave height from buffered 
solution conditions (95 µM p53-DBD solution in 50 mM ammonium acetate, containing 10% by 
volume propan-2-ol), 
3.4.4.1. Collision Cross Sections of WT p53-DBD 






12 2022±52,     2847±1 
2847±1 
13 2296±70,     2888±16 
2888±16 
14 2438±91,     2892±54 
2892±54 
15 2570±61,     3163±32,     3991±0 
3163±32 
3991±0 










Chapter 3: p53 DNA-binding domain in vacuo 
- 98 - 
  
Charge state  Collision Cross Section / Å
2
 
17 2810±0,       3524±27,     4196±22 
3524±27 
4196±22 
18                     3680±34,     4296±20 
4296±20 
19                     3860±73,     4389±44 
4389±44 
20                     4035±96,     4500±67 
4500±67 
21                     4143±89,     4649±2 
4649±2 
22                     4213±66,     4732±18 
4213±66 
23                     4260±80,     4834±18 
4834±18 
24                     4373±27,     4905±10 
4905±10 
25                                      5020±27 
26                                      5101±28 
27                                      5170±23 
28                                      5252±15 
29                                    5366±6 
30                                      5398±24 
31                                      5499±35 
32                                      5568±31 
33                                      5654±43 
34                                    5671±9 
  
 
Table 3.2: Collision cross sections of p53 DBD obtained via the TW IM-MS from pH 1.5 solution 
(95 µM solution in 50 mM ammonium acetate, containing 10% by volume propan-2-ol and 1% 
formic acid). Values are an average of three replicates and stated with the standard deviation of 
the mean. 





10 1669±17,    2157±28 
2157±28 
11 1732±21,    2187±22,    2508±26 
2508±26 
12 1842±42,    2220±9,      2491±42 
2220±9 
2491±42 
13 1918±26,                       2614±23 
2614±23 
14                                       2655±12, 
15                                       2733±7,      3341±12 
3341±12 
16                                       2968±93,    3511±100 
3511±100 
17                                       2875±123,  3681±37 
3681±37 
18                                       2933±83,    3861±56 
3861±56 
 
Table 3.3: Collision cross sections of monomeric p53 DBD obtained via the TW IM-MS from pH 
6.8 solution (95 µM solution in 50 mM ammonium acetate, containing 10% by volume propan-2-
ol).Values are an average of three replicates and stated with the standard deviation of the mean. 
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Table 3.4: Collision cross sections of p53 DBD dimer obtained via the TW IM-MS from pH 6.8 
solution (95 µM solution in 50 mM ammonium acetate, containing 10% by volume propan-2-ol). 
Values are an average of three replicates and stated with the standard deviation of the mean. 
3.5.  Interactions of WT p53-DBD with its 
consensus DNA binding site 
The following section will focus on the use IM-MS to probe the involvement and 
regulation of the p53-DBD in sequence-specific DNA binding. In order to do this, a 
12-mer double-stranded DNA (5’GGAACATGTTCC CCTTGTACAAGG’3 
containing two consensus binding sites MR = 7290.8 Da) and a 20-mer ds DNA 
(5’GAACATGTTCGAACATGTTC CTTGTACAAGCTTGTACAAG’3 containing 
four consensus binding sites MR = 1223.2 Da) was used to examine the binding 
capacity of the WT p53. 
3.5.1. WT p53-DBD dimer bound to ds 12 mer DNA  
As seen in previous section, in the absence of DNA p53-DBD exists mainly as a free 
monomer and is also capable of weak monomer-monomer interactions. In the 
presence of DNA, p53 possesses a remarkable self-organizing ability (mass spectrum 
presented in Figure 3.11). The WT p53-DBD consistently binds consensus double-
stranded 12 mer DNA as a 2:1 complex only (z = 12 - 15). 
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Figure 3.11: n-ESI spectrum of 20 µM p53 DBD with a 10 µM double-stranded 12-base-pair 
DNA fragment in a ratio 2:1 (protein to DNA, based on a protein monomer). Mass spectrum 
was obtained from a solution buffered with ammonium acetate and recorded via the DT IM-
MS. The single spheres on the left represent a p53 monomer, whereas the spheres with DNA 
spirals correspond to the dimeric p53-DNA complex. 
In mobility space, the 2:1 p53-DBD/DNA complex exists only as a single 
conformation, with CCS values only minimally higher (mass corrected) compared to 
the dimeric form without DNA (CCS values are tabulated in Table 3.5). For instance, 
for the z = 14 complex, a CCS of 3194 Å2 was measured, and for the z = 14 dimer, a 
CCS of 2644 Å
2 




















500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5500 6000
m/z
Chapter 3: p53 DNA-binding domain in vacuo 
- 101 - 
  
Charge state Collision Cross Section  
p53 dimer / Å
2
 
Collision Cross Section 
p53 - DNA complex / Å
2
 
13 2520 3113 
14 2644 3194 
15 2712 3191 
 
Table 3.5: Collision cross sections of the dimeric p53-DNA complex obtained via the DT IM-MS 
from buffered solution conditions with ammonium acetate. (20 µM p53 DBD with a 10 µM 
double-stranded 12-base-pair DNA fragment in a ratio 2:1; protein to DNA, based on a protein 
monomer). 
CCS values measured across the observable charge states (z = 13 - 15) for the 
complex are unchanging suggestive of a stable structure in the gas phase. Using 
methods established by Jarrold and co-workers (42,43), the CCS from coordinates 
obtained from the X-ray crystal structure of p53-DBD dimer cross-linked to 16-base-
pair DNA fragment (Figure 3.12) were calculated (deposited by Ho et al. (8)).   
 
Figure 3.12: X-Ray crystal structure of p53-DBD dimer cross-linked to 16-base-pair DNA 
fragment. This structure misses some protein residues (92-96, 114-118 and 290-292) and a few 
basis in the DNA (helix C: G1 helix D: G1, C2 and C16). Representation of PDB 2AC0 file (7) 
rendered orthographically using VMD software. 
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The results are tabulated below in the Table 3.6: 
Method PA EHSS TM 
CCS 3110 4020 3991.5 
 
Table 3.6: Theoretical measurements of collision cross sections for p53-DBD dimer cross-linked 
to 16-base-pair DNA fragment. Here values are shown using the Projection Approximation, 
Exact Hard Sphere Scattering and Trajectory Method. 
All experimentally measured CCS for p53-DBD/DNA complex are smaller (by 25%) 
than those calculated from the coordinates obtained from the crystal structure 
deposited by Ho et al. (8), here using the Trajectory Method (43) thus indicating to 
some extent the structural collapse in comparison to the X-ray structure. This again 
follows the common tendency for proteins we have previously described (44). 
It is interesting to note that in the mass spectrum of p53-DBD with a double-stranded 
12-base-pair DNA fragment, a charge state distribution of the monomeric species is 
also observed.  Overall the charge state distribution is relatively similar to the one of 
p53-DBD sprayed from buffered solution conditions with no DNA present. The most 




 suggesting a 
more compact conformational family. Higher charged species, where 11 ≤ z ≤ 18, are 
also observed at lower abundance (but at marginally higher intensity than those 
observed in the MS in the absence of DNA), indicative of a population of more 
extended states of p53. 
In the mobility view, there are some important differences in the conformational 
landscapes of monomeric p53 observed, when the DNA-target site is available versus 
no DNA present. This is illustrated in the ATDs produced for p53 in Figure 3.13. 
Namely the [M+10H]
10+
 ion exists as a single conformational isomer with a CCS 
value of 1807 Å
2
 in the presence of DNA oligomers but as two distinct 





 respectively).  Further, for the z = 9 species, a CCS of 1762 Å
2 
was 
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measured in the presence of DNA, and for the z = 9 monomer, a CCS of 1659 Å
2 
was 
measured without DNA, which is evident to some degree of preference for more 
extended states of p53 in the presence of DNA-binding target.  
 







 monomeric form of p53-DBD without DNA versus DNA present. 
ATDs were obtained from 20 µM  p53-DBD solution and from 20 µM p53-DBD with a 10 µM 
double-stranded 12-base-pair DNA fragment in a ratio 2:1 (protein to DNA, based on a protein 
monomer), respectively. Both were acquired via the DT IM-MS from buffered solution 
conditions. 
Here it appears that if a DNA-target site is available the equilibrium between the p53 
monomeric conformational isomers is shifted towards more extended structures. This 
depopulation of the more compact form of p53 can be interpreted in at least two 
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different ways. First, the compact forms of p53 have been used to form dimeric 
species required for the p53-DNA complex. Secondly, in contrast in order to 
counteract the reduction in abundance of particular p53 conformers (chaperoned by 
the presence of DNA-target) and to maintain the equilibrium between the different 
dynamic states of p53, concentrations of other p53 conformers would change to 
favour the formation of the conformer with highest affinity for the specific DNA-
binding site - and here this would suggest the more extended or unfolded populations 
are favoured by DNA. And finally, dissociation of p53 protein from DNA complex 
during the desolvation process cannot be ruled out. 
This short argument supports the model for the formation of specific p53-DNA-
binding complexes through a conformational diversity consistent with the hypothesis 
on protein structure known as the ‘new view’ (48,49). In contrast to the traditional 
paradigm of ‘one sequence, one structure, one function’ and a view on proteins as 
structurally restricted, the new view proposes the existence of proteins as an 
ensemble of conformational isomers (48,50). Intrinsically disordered proteins - and 
p53 is one of them - are the most extreme manifestation of protein-conformational 
diversity (51-53). 
3.5.2. WT p53-DBD tetramer bound to ds 20 mer DNA  
In the presence of a longer strand of DNA, the observed spectrum (Figure 3.14) 
displays a wider charge state envelope over the acquired mass range (1000 - 8000 
m/z). However the charge state distribution for p53-DNA complex is very narrow 
compared to monomeric p53. The interaction is highly cooperative and relies on the 
recognition of DNA sequences by the core domain and on the tetramerization of the 
protein, which is heavily mediated by DNA.  
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Figure 3.14:  n-ESI spectrum of 20 µM p53 DBD with a double-stranded 5 µM 20-base-pair 
DNA fragment in a ratio 4:1 (protein to DNA, based on a protein monomer). Mass spectrum 
was obtained from a solution buffered with ammonium acetate and recorded via the DT IM-
MS. The single spheres on the left represent a p53 monomer, double spheres correspond to the 
dimeric form of p53 whereas the spheres with DNA spirals correspond to the dimeric p53-DNA 
complex. 
The WT p53-DBD binds consensus double-stranded 20 mer DNA mainly as a 4:1 
complex where z = 18 - 22. But the dimeric species of p53-DBD bound to DNA also 
exists where z = 14 and 15, which are likely intermediate states between transition 
from monomer (and dimer) to native tetramer. Pagel et al. (54) reports qualitatively 
similar findings where MS of the core-DNA complex shows three species populated 
simultaneously: monomeric p53-DBD, dimeric core bound to DNA and finally 
tetramer p53-DBD bound to DNA.  
In the presence of ds 20mer DNA, the observed ion envelope for monomer is 
significantly much more abundant in comparison to charge states distribution with a 
shorter DNA fragment (with two consensus sites) or in the absence of DNA. The 
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observed charge states ranged from 9 ≤ z ≤ 21. In particular the distribution ranging 
from 15 ≤ z ≤ 21 is more populated than the one ranging from 9 ≤ z ≤ 14 and so it can 
be inferred that p53 under these conditions favours more extended conformations. It 
would be interesting to see what further IM-MS measurements would reveal. 
Especially if the increase in the abundance of higher charge states observed in MS 
would be paralleled by the presence of more unfolded conformations in the ATDs 
produced in the mobility experiments. 
3.6. Summary 
Mass spectrometry provides a compelling, detailed insight into the conformational 
flexibility of this tumour suppressor protein. The plasticity of p53 DNA-binding 
domain is reflected in the existence of more than one conformation, independent of 
any conformational changes prompted by binding. In a complex with DNA, p53-
DBD binds all available consensus binding sites in both DNA constructs. WT p53 
binds to ds 12mer DNA as a dimer and as ‘dimer of dimers’ to 20mer DNA, forming 
a 58 kDa and a 110 kDa complex. The interaction is cooperative, and is dependent on 
the recognition of DNA-target by the p53 and on the tetramerization of the protein, 
chaperoned by the presence of DNA. Conformational diversity of p53 is critical for 
the regulation of different cellular functions such as apoptosis and growth arrest. 
However, in terms of the design of molecules as effective drugs, the conformational 
spread of p53 is understandably an obstacle. A treatment that rectifies one function 
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Common p53 Cancer    
Mutants 
It has become evident that p53 is a molecular node at the junction of an extensive 
and complex network of stress response pathways. Deregulation of this protein has a 
colossal effect on carcinogenesis, as mutated p53 can induce an amplified epigenetic 
instability of tumour cells, facilitating and accelerating the evolution of the tumour. 
In order to understand the mechanism how p53 is inactivated, it is necessary to 
understand its structure and how it responds to mutation. Such knowledge may 
ultimately provide basis for the rational design of novel therapeutics that may 
reverse the effects of mutation in the treatment of cancer. Herein, the conformational 
phenotypes exhibited by common cancer-associated mutations are surveyed. Whether 
the second-site suppressor from loop L1, H115N, could trigger conformational 
changes in p53 hotspot cancer mutations is also tested.  
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4. Common p53 Cancer Mutants 
4.1. Mapping Cancer Mutations on the DNA-
binding Domain 
Tumour suppressor p53 is the most mutated protein in human cancers.  Mutations are 
found in almost every type of cancer. Malignancies with high mutational frequencies 
(40-50%) include ovarian, colorectal, esophageal, head and neck and lung cancers 
whereas tumours of the brain, breast, liver and stomach show intermediary mutation 
frequency (20-30%) (1). A distinctive feature of the p53 mutational map is an 
exceptionally high rate of occurrence of missense mutations which result in the 
expression of a mutant protein. Indeed, these single-point amino acid substitutions in 
p53 lead to abrogation of protein function, rather than deletions or nonsense 
mutations, as it is the case with most tumour suppressor proteins. The latest release 
of the International Agency for Research on Cancer (IARC R16, November 2012) 
TP53 mutation database reports 29575 cases of somatic mutations (2). These 
missense mutations can lead to loss or alteration of p53 binding activity to its 
downstream targets and may thus induce aberrant cell proliferation, with consequent 
malignant cellular transformation. 
The majority of tumour-derived mutations (over 80%) target the core DNA-binding 
domain of p53 (3). There are at least three reasons to explain why the cancer-
associated mutations are predominantly mapped on the DNA-binding domain of p53. 
Firstly, the oncogenic core domain mutants are known to have a phenomenal 
‘dominant-negative effect’ on WT p53 if present (4,5). Since the transcriptional 
function of p53 relies on formation of homotetramers, the mutated p53 proteins may 
interfere with WT by forming hetero-oligomers (containing both mutant and WT 
subunits) malfunctioned in sequence specific DNA-binding (6,7). WT p53 core 
domains in a mixed tetramer may still be able to recognize DNA response elements, 
but binding cooperativity will be progressively lost upon amalgamation of inactive 
mutants (8,9). One of the key findings of the study by Chan et al. (10) study with the 
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R249S and R273H mutants, is that at least three DNA binding-defective mutants are 
required to inactivate the p53 tetramer.  
A second rationale is the low thermodynamic stability of the p53 DNA-binding 
domain, which is just above 37°C (above this temperature p53 DNA-binding domain 
partially unfolds and forms aggregates) (11-13). The intrinsic low stability of core 
domain means that virtually every non-conservative substitution in the core domain 
will reduce the melting temperature below 37°C and have a profound effect on the 
amount of folded protein in the cell. 
The third explanation is that many of the functionally important amino acid residues 
of this domain are arginines. Arginine codons are particularly prone to mutagenesis, 
as they contain CG dinucleotides, which, when damaged, are restored with lower 
fidelity than other dinucleotides (14). 
Approximately 35% of missense mutations in this domain cluster within six so-called 
‘hotspot’ codons detectable in almost every type of cancer (175, 245, 248, 273, and 
282). Four of these codons correspond to arginine resides (175, 248, 273 282) 
involved in direct DNA contact (residues 248 and 273) or in stabilisation of the 
DNA-binding surface (residues 175 and 282) (3).  
4.2. Structural Classes of p53 Core Domain 
Cancer Mutants 
4.2.1. DNA-contact Mutations 
DNA-contact mutations inactivate p53 by removing the critical DNA-contact amino 
acid residues, for instance Arg-248, Arg-273, and Arg-280. Two of the five most 
frequent cancer mutations, R273H and R273C have a minor effect on the 
thermodynamic and kinetic stability of the protein and the overall architecture of the 
DNA-binding surface is not perturbed (15,16). These findings are in accord with the 
results of Ang et al. (17) which show that the R273H mutation displays only residual 
DNA-binding activity in vitro and the binding selectivity is significantly impaired. 
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Crystallographic data confirmed that the mutation has not induced any major 
conformational changes in the adjacent side chains (Asp-281 and Phe-134) (15,16). 
A similar scenario with rather more localized structural changes can be expected for 
DNA-contact mutations Arg-248 and Arg-280. 
4.2.2.  Structural Mutations in the L3 loop 
Another class of mutations corresponds to structural cancer hotspot mutations in the 
L3 loop, G245S and R249S. The G245S mutation prompts minor conformational 
changes that essentially affect residues in the core dimerization interface upon 
binding to a DNA half-site, which weakens DNA-binding, presumably due to 
reduced binding cooperativity (16,17).  
The changes induced by the R249S mutation are much more pronounced as Arg-249 
is essential for stabilizing the conformation of the L3 loop via its guanidinium group. 
This perturbation affects both DNA-contacts (via Arg-248) and the core dimerization 
interface, consequently resulting in substantially weakened DNA-binding in addition 
to a loss of protein stability (15,17). 
4.2.3.  Disruption of the Zinc-binding Region  
Structural mutations in the zinc-binding region are highly destabilizing either due to 
a reduction in zinc-binding (C242S) or in structuring the zinc-binding site (R175H). 
Arg-175 is located in the L2 loop, mutations found in this codon result in complete 
abrogation of DNA-binding activity. Surprisingly the corresponding alanine mutant, 
R175A, is only moderately destabilised as compared to R175H and shows 70% WT 
activity in DNA-binding. Equally, it was found that the R175C mutant essentially 
maintains the WT cell cycle arrest and pro-apoptotic activity, whereas these 
functions are lost upon introduction of large bulky residues (e.g. for mutants R175W 
and R175Y) that presumably cause structural distortion and directly interfere with 
zinc-binding (18).  
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4.2.4.  Structural Mutations at the Periphery of the 
DBD 
One of the most common mutational hot spots is at position Arg-282, located in the 
C-terminal helix H2, which is part of a loop-sheet-helix motif that binds to the major 
groove of DNA response elements. Joerger et al. (16) solved the high-resolution 
crystal structure of several oncogenic mutations, including R282W. The data reveal 
that introduction of the R282W hotspot mutation induces distinct, substantial 
structural distortions in the loop-sheet-helix motif but the overall fold of the protein 
is not compromised. Several stabilizing interactions are also lost which are reflected 
in the observed loss in the thermodynamic stability of the mutant. Importantly, the 
scaffold of the DNA-binding surface, including helix H2, is fundamentally 
preserved, which explains why the mutant is still able to bind to DNA at sub 
physiological temperatures both in vitro and in vivo, at least for high-affinity 
response elements (4,19). 
Similarly, the structure of H168R cancer mutant positioned in the β-turn region of 
the L2 loop shows that the global fold of the protein is maintained but exhibits local 
structural perturbations (19,20).  
4.2.5.  β-sandwich Mutations 
Y220C is the most frequent tumor mutation found outside the structural elements 
that form the DNA-binding surface (loops L2 and L3 and the loop-sheet-helix motif) 
and accounts for approximately 1.4% of somatic p53 missense mutations (2). This 
mutation creates a solvent-accessible crevice at the end of a β-sandwich but leaves 
the overall structure of the core domain intact, as reported by Joerger et al.(16).  
Likewise, other β-sandwich oncogenic large-to-small substitutions, V143A and 
F270L form internal cavities in the hydrophobic core of the protein without collapse 
of the surrounding structure (16,19). Taken together, a common structural feature of 
the β-sandwich mutants appears to be that they induce only minor structural local 
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perturbations, although the effect on the stability of the core is generally much more 
severe than for the hotspot mutations in the DNA-binding area. 
4.3. Rescue of p53 Mutants by ‘Conformational’ 
Drugs 
p53 is mutated or functionally inactivated in the vast proportion of human cancers, 
pharmacological restoration of WT p53 conformation and function by small 
molecules targeting mutant p53 proteins has been proposed as a tactic for the design 
of anti-cancer drugs (21-23). Over the past few years, a number of small molecules 
that reactivate mutant p53 have been identified and characterised. The mechanism of 
action of many compounds remains controversial and has not been fully established 
yet (reviewed by Bykov (24) and Wiman et al. (25). This section will describe only 
some of these molecules and discuss possible mechanisms for mutant p53 rescue. 
A designed nine-residue peptide, CDB3, is derived from p53-binding protein 2 
(53BP2 or ASPP), a known p53-binding protein that interacts with the p53 core 
domain and enhances p53-mediated transactivation (26). NMR measurements have 
mapped the CDB3 docking site to a surface region of p53 that partly intersections 
with the DNA-binding surface (including the loop-sheet-helix motif and parts of β-
strand S8), although the exact binding mechanism of CDB3 is still unclear (27). The 
rationale behind this method is that a peptide binding with a higher affinity to the 
folded state of p53 rather than to the mutated form will shift the equilibrium towards 
the active WT conformation. In vitro studies revealed that CDB3 is able to induce the 
refolding of the denatured p53 core domain, as well as the re-establishment of 
sequence-specific DNA-binding to various p53 mutants (27). Remarkably, CDB3 
was also shown to reinstate the WT conformation transcriptional activity of two 
hotspot p53 mutants, R273H and R175H, in human tumour cells (28).  
Foster and coworkers screened a chemical library for compounds that could stabilize 
the folded conformation of the core domain and identified the first most promising 
small molecule, CP-31398 that can rescue mutant p53 (23). This Pfizer compound 
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was found to stabilize the core domain and enhance the transcriptional activity of 
p53, but the exact mechanism of action of CP-31398 remains still elusive (23). 
Further Rippin et al. (29) showed conflicting data. This NMR study failed to detect 
any binding of CP-31398 compound to the p53 core domain, rather, gel shift assays 
and NMR indicated that the compound binds DNA.  
p53 reactivation and induction of massive apoptosis (PRIMA-1) and and mutant p53 
reactivation and induction of rapid apoptosis (MIRA-1) are two compounds that were 
identified in a cellular screen of a chemical library for compounds that supress the 
growth of tumour cells (21,30). PRIMA-1 and MIRA-1 were found to restore 
sequence-specific DNA-binding and convert the mutant p53 conformation to WT, 
leading to transactivation of p53 target genes (21,30).  
Restoring the DNA binding function of p53 mutant proteins which are highly 
expressed in tumours is a prominent goal in the field. With the emerging detailed 
structural data on mutant p53, rational drug design and virtual screening become 
progressively attractive methods. Nonetheless there is a whole spectrum of different 
p53 cancer mutations, and development of the ‘Holy Grail’, a generic drug that could 
stabilize a range of unstable oncogenic mutants, remains undoubtedly a challenge. 
Whether this is truly feasible, awaits future studies. 
This chapter focuses on the use of IM-MS to probe the conformational diversity of 
common single oncogenic mutations of the p53 DNA-binding domain: R249A, 
R273H, K292I, A276Y, and R175H. The second-site suppressor from loop L1, the 
H115N mutant, is also examined, to determine whether it could trigger 
conformational changes in p53 hotspot cancer mutation, using a double mutant 
approach (R248Q/H115N, R249/H115N, and R273H/H115N). Locations of mutated 
residues used in the studies are depicted schematically on the three-dimensional 
structure of p53 in Figure 4.1. The sequence-specific DNA-binding properties of the 
H115 mutant are also revealed.  
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Figure 4.1: Structure of the DNA-binding core domain of p53 (residues 94 - 312). Locations of 
residues mutated in the experiments are labelled in red, the zinc atom is represented as a a red 
sphere. PDB 2FEJ file (31) was used to generate image in VMD software. 
4.4. Methodology 
4.4.1.  Site-directed Mutagenesis, p53 Expression 
and Purification 
Single-point mutants of p53 DNA-binding domain (R249A, A276Y, K292I and 
H115N) and double mutants (R248Q/H115N, R249A/H115N, and R273H/H115N) 
were expressed and purified by Dr Penka V. Nikolova (King’s College London, UK). 
R175H and R273H mutants were supplied by Dr David J. Clarke (University of 
Edinburgh, UK). All mutants were prepared according to the method outlined here. 
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which was modified so that it did not contain the His tag (20,32,33). p53 mutants 
were generated using the QuikChange® site-directed mutagenesis kit (Stratagene). 
Proteins were expressed at 37°C in Escherichia coli C41 cells and grown up to an 
optical density at 600 nm (OD600) of 0.8. The temperature was reduced to 22°C 
before cell cultures were induced with 1 mM isopropyl β-D-thiogalactopyranoside 
(IPTG) and grown overnight. Cells were harvested by centrifugation and lysed using 
Bug Buster Protein Extraction Reagent. Benzonase nuclease and EDTA-free protease 
inhibitor tablets were also used during this process. The soluble fraction was loaded 
on to an SP-Sepharose column eluted with NaCl gradient followed by gel-filtration 
chromatography using a HP26/60 Superdex 200 column. 
4.4.2.  Sample Preparation 
Protein samples were flash frozen in liquid nitrogen and stored in a -80°C freezer. 
Prior to mass spectrometry and ion mobility mass spectrometry measurements, 
protein samples were thawed and dialysed in 50 mM ammonium acetate for 2 h at 
4°C (with an exception of R175H mutant which was dialysed in 100 mM ammonium 
acetate). Solutions were made up to contain 10% propan-2-ol to aid electrospray 
desolvation. 
4.4.2.1. DNA Oligonucleotides 
Double-stranded 12-mer DNA (5’GGAACATGTTCC CCTTGTACAAGG’3 
containing two consensus binding sites MR = 7290.8 Da) used in this study was 
constructed by annealing purified synthetic oligonucleotides purchased from 
ATDBio (University of Southampton, UK). Annealing was performed by heating the 
oligonucleotides at 95°C for 5 minutes and gradual, slow cooling to room 
temperature to ensure an efficient hybridization. The final concentration of the 
double-stranded DNA used for the binding experiments is based on the assumption 
that all of DNA had annealed completely, however trace amounts of unbound 
DNA/hairpin structures might be still present. 
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4.4.3.  Mass Spectrometry and Ion Mobility Mass 
Spectrometry 
The travelling wave based ion mobility mass spectrometry (TW IM-MS) 
experiments were performed on a Synapt HDMS system (34) (Waters Corporation, 
Manchester, UK) described in detail in Chapter 2, Section 2.5.1. Samples were 
introduced into the source region by nano-electrospray ionisation (n-ESI). The 
instrument was operated in a positive ionisation mode with a capillary voltage of 0.8 
-1 kV, cone voltage of 65 V and source temperature of 30 °C. Source backing 
pressure was elevated to 4 mBar for improved transmission of ions. Travelling wave 
heights of 13, 14 and 15 V and 250 m/s were employed. The ion mobility separator 
containing nitrogen gas was operated at a pressure of 1 mBar. During data 
acquisition, the parameters of the instrument were optimised to obtain the optimum 
ion mobility separation. Equine heart cytochrome c and myoglobin was analysed 
under denaturing conditions to create a calibration curve for cross-section 
measurements versus values obtained from drift tube ion mobility mass spectrometry 
(DT IM-MS) studies. The calibration procedure is described in Chapter 2, Section 
2.5.2. 
Drift tube ion mobility mass spectrometry (DT IM-MS) experiments were performed 
on an in-house modified quadrupole time-of-flight mass spectrometer, the MoQToF 
(35). A more detailed description of this instrument can be found in Chapter 2, 
Section 2.4.1. Ions were produced by positive n-ESI using Z-spray source, within a 
spray voltage range 1.0 to 1.8 kV and a source temperature of 80°C. The drift cell 
was filled with helium buffer gas at the average pressure of 3.5 - 4.0 Torr (4.7 - 5.3 
mBar) and a temperature between 298 - 302 K. The electric potential across the cell 
was varied from 60 to 15 V and ATDs were recorded at eight drift voltages. The 
mobility of the ion of interest was calculated from a linear plot of average arrival 
time versus pressure/drift voltage (P/V) and from this the rotationally-averaged 
collision cross section (CCS) for each resolvable species at a given charge state were 
obtained. 
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4.4.4.  Production of Waterfall Plots for data 
obtained via TW IM-MS 
The waterfall plots for p53 mutants were produced in Origin 8.5.1 software 
(OriginLab, Northampton, MA, USA). Multi-curve waterfall charts were created by 
plotting estimated CCS values (x), calculated as described in Chapter 2, Section 
2.5.2, against peak intensity values (y) and charge (z). The intensities of the peaks 
were obtained from Mass Lynx software (version 4.1, Waters, Manchester, UK). 
4.4.5.  Production of Waterfall Plots for data 
obtained via DT IM-MS 
The waterfall plot for the R273H mutant was produced in Origin 8.5.1 software 
(OriginLab, Northampton, MA, USA). A multi-curve waterfall chart was created by 
plotting the average CCS (x), against peak intensity values (y) and charge (z). The 
intensities of the peaks were obtained from the Mass Lynx software (version 4.1, 
Waters, Manchester, UK). CCS values were calculated from arrival time distribution 
using Equation 4.1 below: 
     









  ⁄   




   
  
   Equation 4.1 
where m and mb are the masses of the ion and buffer gas, z is the ion charge state, e is 
the elementary charge, kB is the Boltzmann constant, T is the gas temperature, N is 
the gas number density, L is the drift cell length, V is the voltage applied across the 
drift cell (here 60 V) and td is the drift time. This relationship uses the drift time (td) 
of each ion: 
Drift Time = Arrival Time - Dead Time   Equation 4.2 
Dead time was calculated by taking an average value of the intercept across the 
arrival time distribution for each charge state. 
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4.5. Insights into the Diverse Conformational 
Nature of Common p53 Cancer Mutants  
This section reports on IM-MS studies on the conformational diversity of common 
cancer-associated p53 mutants. The conformational phenotypes are defined and the 
variation in these, as exhibited by five single-point mutations (R249A, R273H, 
K292I, A276Y, and R175H), are monitored. 
4.5.1.  Structural Mutation in the L3 loop - R249A 
One of the most common mutational hot spots is at position arginine 249, which is 
replaced by serine, thus inducing substantial structural distortions either at the 
periphery of L2 loop or directly at the center of L3 loop of the DNA-binding surface 
(15). This perturbation indirectly affects DNA contacts (via Arg-248) and the core 
dimerization interface, resulting in destabilization of the protein and considerably 
impaired DNA-binding (13,15,17). The far-UV CD spectra revealed that R249S 
mutation has a similar conformation to WT p53-DBD (13). Here the related mutation 
R249A was examined with IM-MS (Figure 4.2 and Figure 4.3 for the mass 
spectrum). When compared to WT p53 (refer to Chapter 3, Section 3.4.4), it is clear 
that this single point mutation inflicts a dramatic change to the conformational space 
occupied by the protein, with the R249A mutant possessing noticeably less 
flexibility.  
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Figure 4.2: Waterfall plot representing the in vacuo ‘conformational phenotype’ of R249A 
mutation sprayed form buffered solution conditions (63 µM solution in 50 mM ammonium 
acetate, containing 10% by volume propan-2-ol), obtained via the TW IM-MS. The x, y and z 
axis show the collision cross section (in Å
2
), charge state (range 9 ≤ z ≤ 18), and the relative 
intensity, respectively.  
The majority of R249A presents as z = 9 and 10 ions, both in a compact form with 
similar CCS (1789 Å
2
 and 1818 Å
2
, respectively) as for the C1 form of the WT p53, 
although the width of the ATDs for the mutant is less than that for the WT, thus 
implying a more ‘molten globule-like’ compact conformer for this single point 
mutant, which is here denoted C2. The z = 9 charge state is also more intense here 
compared to WT p53, which suggests a more compact structure. For 11 ≤ z ≤ 18, 
multiple unfoldomers (Un) for each charge state are observed. However these 
extended conformers are less populated than in WT p53. Overall, the gas-phase 
structure of R249A favours a compact geometry, suggesting that the mutation 
conferred intrinsic stability to a collapsed form, which is significantly smaller (by 
14%) than that found in WT p53. 
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Figure 4.3: n-ESI spectrum of 63 µM R249A mutation obtained via the TW IM-MS from 
buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
 
4.5.2.  DNA Contact Mutation - R273H 
Cancer-associated mutants, such as R273H, are present at the p53 DNA-binding 
interface and are referred to as hotspot contact mutants. R273 is one of the most 
frequently mutated codons, representing about 20% of all cancer mutants in the p53 
database (2). This mutation has a marginal effect on the thermodynamic stability of 
the protein, but affects the conformation required for DNA binding (11,17). The 
introduction of the imidazole ring associated with the histidine residue has been 
reported to perturb the local environment, and to break a salt bridge between R273 
and the carboxylate group of D281 in helix 2 (36). Binding of full-length R273H to 
the gadd45 recognition sequence is weakened approximately 1000-fold in vitro as a 
consequence of mutation, and binding specificity is largely lost (17). The residual 
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binding activity of R273H is too weak to perform a regular transcriptional function 
in vivo (4,37). 
 
Figure 4.4: Waterfall plot representing the in vacuo ‘conformational phenotype’ of R273H 
mutation sprayed form buffered solution conditions (100 µM solution in 50 mM ammonium 
acetate, containing 10% by volume propan-2-ol), obtained via the DT IM-MS.  
Data for this mutation were obtained using DT IM-MS (Figure 4.4 and Figure 4.5 for 
the mass spectrum). The acquired mass spectrum has a high baseline and broad peaks 
in the high m/z range, a common appearance of unstable and aggregated species. 
Here the compact conformation is retained over a large range of charge states (9 ≤ z 
≤ 16) and the more extended forms (X1) are only present at the very high charge 
states. This remarkable stability of a compact conformation and the lack of 
unfoldomers indicate that this mutation favours more compact and rigid 
conformations.  
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Figure 4.5:  n-ESI spectrum of 100 µM R273H mutation obtained via the DT IM-MS from 
buffred solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
 
4.5.3.  K292I Mutation 
Cellular levels of p53 are controlled elaborately through ubiquitylation and 
proteasomal degradation, which are mediated by numerous E3 ubiquitin ligases. 
Interestingly, there are two sequentially located lysine residues in the p53-DBD, 
K291, and K292, which are required for polyubiquitination and degradation of p53 
mediated by makorin ring finger protein 1 (MKRN1) (38). These two highly 
conserved residues are mutated in several different types of human tumors, 
suggesting their critical roles in p53 function (2). The conformational phenotype 
exhibited by one of these cancer-associated mutants, K292I, which is implicated in 
the inhibition of protein-protein interactions was examined (Figure 4.6 and Figure 
4.7 for the mass spectrum).  
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Figure 4.6: Waterfall plot representing the in vacuo ‘conformational phenotype’ of K292I 
mutation sprayed form buffered solution conditions (75 µM solution in 50 mM ammonium 
acetate, containing 10% by volume propan-2-ol), obtained via the TW IM-MS. 
Here a single compact conformation is only exhibited by z = 9 (C2), gradually 
shifting to more extended structures (X1). For 10 ≤ z ≤ 18, multiple unfoldomers are 
observed and their distribution is comparable to that of the WT p53, although the 
intensity varies. 
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Figure 4.7: n-ESI spectrum of 75 µM K292I mutation obtained via the TW IM-MS from 
buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
 
4.5.4.  A276Y Mutation 
Another mutation, A276Y, is an example of a contact mutation as it directly binds to 
DNA (3,39). However, the substitution of the alanine residue with a larger aromatic 
amino acid tyrosine also has a pivotal effect on the function of protein. This mutation 
maps to the binding sites of protein kinases and Mdm2, a major regulator of p53 
levels in the cell (40). In mobility space (Figure 4.8 and Figure 4.9 for the mass 
spectrum) the majority of the protein molecules are located in the z = 9 and 10 
region, and exist as a compact conformational family (C2).  
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Figure 4.8: Waterfall plot representing the in vacuo ‘conformational phenotype’ of A276Y 
mutant sprayed form buffered solution conditions (73 µM solution in 50 mM ammonium 
acetate, containing 10% by volume propan-2-ol), obtained via the TW IM-MS. 
Remarkably, this compact form of the protein is retained over a wide range of charge 
states (9 ≤ z ≤ 14) and its signal intensity is significantly higher than that of all 
previously shown mutants or WT p53 proteins. For 10 ≤ z ≤ 18, multiple 
unfoldomers (Un) are observed. The abundance of the latter is spread over a very 
broad distribution of conformers; for instance for z =17, at least four unfoldomers 






, and 4046 Å
2
. An 
extraordinary feature of this substitution is that both compact forms and more 
extended conformations are highly populated and stable over a longer mobility time, 
which is in marked contrast with other mutants or WT p53 proteins.  
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Figure 4.9: n-ESI spectrum of 73 µM A276Y mutation obtained via the TW IM-MS from 
buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
 
4.5.5.  Disruptions of the Zinc-binding Region - 
R175H  
Arg-175 is located in the loop L2 region and is the hotspot codon for one the most 
common oncogenic mutations, R175H. This mutant is likely to perturb the zinc-
binding site (41) (Arg-175 is directly adjacent to three of the zinc ion ligands Cys-
176, His-179, Cys-238), although there are no NMR or X-Ray crystallography 
records available for this mutant yet. The deleterious effect of this single point 
substitution appear to reside primarily in the fact that an introduction of a bulky 
histidine residue causes structural distortion and may directly interfere with zinc 
binding rather than in the mere loss of WT interactions (42). It results in a complete 
loss of function both at both physiological and sub physiological temperatures in 
vitro and in vivo (4,19,37). This mutation is highly destabilising, but in contrast to 
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the missense mutations found in the β-sandwich region of p53-DBD, DNA-binding 
activity is abrogated in the folded state (4). 
The low thermodynamic stability and associated aggregation susceptibility of this 
mutation is revealed in the mass spectrum obtained (Figure 4.10). Mutation has a 
profound effect on the appearance of the spectrum. High baseline and broad peaks 
are a common trait of unstable and aggregated species (as well as the salt pick up). 
Overall the charge state distribution is qualitatively similar to WT p53-DBD, 
evidence that the native-like structure of the protein has not been completely lost. A 
charge state distribution of monomer is observed with 9 ≤ z ≤ 17 where the most 




. The dimeric form 
[2M+zH]
z+
 is also significantly more pronounced for this mutant, and an ion 
envelope of 14 ≤ z ≤ 17 is observed. Unfortunately no mobility data was recorded for 
this mutant due to limited sample availability. 
Figure 4.10:  n-ESI spectrum of 5 µM R175H mutation obtained via the DT IM-MS from 
buffered solution with 100 mM ammonium acetate. 
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4.6. Mechanism of Rescue of Common p53 
Cancer Mutants by Second-site Suppressor 
Mutations 
The deleterious effects of many common tumorigenic mutations can be reversed by 
intragenic second-site suppressor mutations. Structure-based designs combined with 
yeast and mammalian cell-based screening assays have provided a number of 
second-site suppressors that restore function of various cancer-associated mutants 
(43-45). Global suppressors, N239Y and N268D, act as ‘global stability’ suppressors 
by increasing the overall thermodynamic stability of cancer mutants that can be 
positioned in different regions of p53 core domain (i.e. V143A, G245S, or even 
R175H) (20,43). These two mutations have also been used in Nikolova’s semi-
rational design of a superstable quadruple mutant of human p53-DBD (46). Specific 
suppressors, a second class of second-site suppressor mutations, have been identified 
for the DNA-contact mutants and structural mutants with major distortions of the 
DNA-binding surface. S240R (44) and T284R (45) have been exploited as second-
site suppressor in a double mutation approach for the classic DNA-mutants R273H 
and R273C. Remarkably in both cases, the introduction of an arginine residue close 
to the hotspot of the deleterious mutation potentially creates novel DNA contacts. 
The H168R mutation in combination with a second suppressor mutation, T123A or 
N239Y, was found to rescue a hotspot structural mutant R249S (43,44). The resultant 
core domain of the mutant binds the DNA response elements with WT affinity, 
although the thermodynamic stability of the protein is not fully repaired (15,20).  
An even more detailed picture of possible ways to rescue mutant p53 will emerge 
from additional high resolution structures of cancer mutants in tandem with their 
respective second-site suppressors. 
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4.6.1. Cold Spot Mutations used as Second-site 
Suppressors 
The term ‘mutational cold spot’ describes the region in the L1 loop (amino acids 
112-124) in the core of p53 protein that is known for infrequent mutations in human 
tumours (47-50). Structurally, the L1 loop is a part of the loop-sheet-helix motif of 
the p53-DBD and contains only three amino acid residues that are in direct contact 
with DNA. Multiple studies have shown that the L1 loop is one of the most mobile 
and flexible regions of the core domain indicating an element of intrinsic disorder 
(15,16,39,42,51,52). Computational mutagenesis of L1 loop performed by Pan et al. 
(47) revealed that residues Leu-114, His-115, Ser-116 and Gly-117 make up the most 
flexible region of the loop. Further detailed molecular dynamics simulations which 
analysed human and worm forms of p53 showed that loop L1 has a pivotal role in 
stabilization of p53 structure (53). Several studies reported that some mutations in 
the L1 loop region, such as H115N, S121F and T123P display supra-wild-type DNA 
binding or altered binding-sequence specificity (48,50,54,55). Marabet et al. (13) 
assessed the potential role of H115N and S116M mutations as second-site 
suppressors on the p53 hotspot mutations in terms of their effect on thermal stability 
and DNA binding. The results showed, inter alia, that H115N is capable of rescuing 
the DNA-binding of one of the most common contact mutants, R248.  
H115N is of a special interest here as IM-MS has been used as a tool to test whether 
this mutation could trigger conformational changes in a double mutant approach in 
three p53 cancer-associated mutations: R249A, R273H and R248Q. In addition the 
sequence-specific DNA-binding properties of this mutant were elucidated. 
4.6.2.  Engineered Mutation in the L1 loop - H115N  
IM-MS analysis provided a conformational fingerprint of the H115N p53 mutation, 
in particular a broader distribution of conformers relative to the WT p53 was 
observed. According to the mass spectrometry results (Figure 4.11), the protein has a 
similar range of charge states (9 ≤ z ≤ 19) as the WT p53 protein, however the higher 
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charge states present with higher intensity. The most abundant peak corresponds to z 
= 11, higher by two charge states than for WT p53, which infers a less compact 
structure. The deconvoluted mass of the protein is 24591.8 Da where the reduction of 
mass is due to the change in amino acid residues from a histidine (137.1 Da) to an 
asparagine residue (114.1 Da).  
Figure 4.11: n-ESI spectrum of 97 µM H115N mutation obtained via the TW IM-MS from 
buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
In IM-MS, the conformational diversity of this engineered mutant is remarkable 
(Figure 4.12). For z = 9 and 10, a C1-type conformer with a CCS averaging 1730 Å
2
  
is observed, but for z = 11, the intensity is spread over a wide distribution of 
conformers from C1, with a CCS of 1827 Å
2
, to X1 with a CCS centered on 2184 Å
2
.  
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Figure 4.12: Waterfall plot representing the in vacuo ‘conformational phenotype’ of H115N 
mutation sprayed form buffered solution conditions (102 µM solution in 50 mM ammonium 
acetate, containing 10% by volume propan-2-ol), obtained via TW IM-MS.  
Mass spectrometry data show that the intensity of the more extended populations is 
more pronounced, but IM-MS provides another dimension to this analysis, thus 
indicating that this mutant is intrinsically more plastic and significantly more 
disordered than the WT p53. This diverse conformational phenotype was also seen in 
the detailed far-UV-study at various temperatures, where H115N conformation was 
found to be different from the WT p53 conformation (13). Other results showed that 
the mutant H115N is stabilized intramolecularly and kept more rigid in a 
conformation that is more suitable for DNA binding, as hypothesized in the literature 
(48), potentially it might be suggestive of that the more extended conformations are 
more suitable for DNA-binding. 
When we directly contrast the hard numbers for estimated CCS of H115N mutant 
with WT p53 (Figure 4.13), it can be clearly seen that the mutant favours more 
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extended conformations at higher charge values (17 ≤ z ≤ 19). The CCS values are 
comparable in the more compact native-like conformations (8 ≤ z ≤ 11).  
Figure 4.13: Collision cross sections versus charge of 97 µM H115N mutation compared with 95 
µM WT p53 DBD obtained via the TW IM-MS from buffered solution conditions (50 mM 
ammonium acetate, containing 10% by volume propan-2-ol). The black box highlights the most 
intense charge states of H115N mutation.  
However the most abundant peak for the WT p53 is z = 9 which adopts a single 
conformation, while the most abundant peak for the H115N mutant is z = 11 which 
exhibits three distinct conformational isomers. 
4.6.3.  DNA-binding properties of H115N Mutant  
Binding to DNA of purified H115N protein reported by Ahn et al. (48) was found to 
be superior to the WT p53 by several criteria including gel mobility shift assay, filter 
binding and DNase I footprinting, nonetheless H115N mutant was markedly 
impaired in causing apoptosis when cells were subjected to DNA damage. 
Remarkably H115N also displayed supra-wild-type non-specific DNA-binding. 
Based on the X-Ray crystallography structure of the core domain of p53, the H115 
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residue does not directly contact DNA (3). However, structural studies proposed that 
residues in loop L1 form part of the p53 dimer-dimer interface (56). Hence the 
H115N mutation might contribute to stronger interdomain interactions that stabilize 
cooperative binding of tetramer to DNA. And perhaps mutation of H115 allows for 
greater ease of forming the favourable conformation for DNA-binding. In contrast 
Merabet et al. (13) reported that mutants from the L1 loop (H115N and S116M) bind 
to the DNA with similar affinity to that of the wild-type p53.  
When partnered with DNA, the H115N mutant possesses a remarkable self-
organizing ability, a 2:1 protein/DNA complex is observed, thus implicating that the 
binding is strongly cooperative.  
Figure 4.14: n-ESI spectrum of 97 µM H115N mutant with a 14 µM double-stranded 12-base-
pair DNA fragment in a ratio 7:1 (protein to DNA, based on a protein monomer). Mass 
spectrum was obtained from a solution buffered with ammonium acetate and recorded via the 
DT IM-MS. The single spheres on the left represent a p53 monomer, whereas the spheres with 
DNA spirals correspond to the dimeric p53-DNA complex. 
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Here data does not support the superior DNA-binding ability of this mutant; on the 
contrary it shows rather decreased binding affinity. The p53/H115N-DBD/DNA 
complex has a wider charge-state distribution (z =12 - 18; Figure 4.14). The 
stoichiometry of DNA to protein had to be radically decreased (Figure 4.15) in order 
to remove the excess unbound DNA present in the mass spectrum, thus providing 
clear evidence of reduced DNA-binding activities for this mutation.  
 
Figure 4.15: n-ESI mass spectra of H115N mutation with a double stranded 12-base-pair DNA 
fragment sprayed at different stoichiometric ratios (2:1, 3:1, 7:1, and 10:1; 97 µM : 49 µM, 97 
µM : 33 µM, 97 µM : 14 µM and 97 µM : 10 µM ; protein to DNA, based on a protein 
monomer). All spectra were obtained from ammonium acetate buffered solution and recorded 
via the DT IM-MS. 
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IM-MS data for this mutation show that the 2:1 H115N DBD/DNA complex favours 
a single conformational state. The CCSs are centered around similar values as the 
corresponding charge states of the 2:1 WT p53 complex (CCS values are tabulated in 
Table 4.1). 
Charge state Collision Cross Section  
p53-DNA complex / Å
2
 
Collision Cross Section 




13 3113 2736 
14 3194 3123 
15 3191 3246 
 
Table 4.1: Collision cross sections of the dimeric H115N-DNA complex (97 µM H115N mutant 
with a 14 µM double-stranded 12-base-pair DNA fragment in a 7:1 ratio; based on a protein 
monomer) versus dimeric WT p53-DNA compelx (20 µM p53 DBD with a 10 µM double-
stranded 12-base-pair DNA fragment in a ratio 2:1; protein to DNA, based on a protein 
monomer). Both obtained via the DT IM-MS from buffered solution conditions).  
In the n-ESI spectrum of H115N mutant with a double-stranded 12-base-pair DNA 
fragment (Figure 4.14), a charge state distribution for the monomeric population is 




which is one proton lower than detected in the absence of the DNA partner (Figure 
4.11). Overall the lower charge states are more pronounced in the presence of DNA. 
There is also a drastic decrease in the abundance of ion envelope for the higher 
charged species, where 11 ≤ z ≤ 16. From the MS data it can be inferred that more 
compact conformational family of H115N mutant is favoured in the presence of 
DNA ligand. 
This strong preference towards more compact conformational isomers in the 
presence of DNA in MS is in accord with further mobility measurements. The 
differences in the conformational landscapes of monomeric H115N mutant observed 
when the DNA is available versus no DNA present are illustrated in Figure 4.16. In 
the absence of DNA partner, the H115N molecule assumes two distinct 
conformational isomers for z = 10 with CCS values of 1893 Å
2
 and 2290 Å
2
, but in 
the presence of ligand only a single conformational population was detected of a 
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lower CCS value of 1678 Å
2
. This is similar for the [M+11H]
11+ 
ion which exists as a 
single conformational isomer with a lower CCS when DNA is added. In addition, for 
the z = 9 species, a CCS of 1763 Å
2 
was measured in the presence of DNA, and a 
CCS of 1874 Å
2 
was measured without DNA, again strongly manifesting the 
reduction of more extended states of H115N mutant. 
 




and  [M+11H] 
11+
 monomeric form 
of H115N without DNA versus DNA present. ATDs were obtained from 97µM  H115N solution 
and from 97 µM H115N mutant with a 14 µM double-stranded 12-base-pair DNA fragment in a 
ratio 7:1 (protein to DNA, based on a protein monomer), respectively. Both were acquired via 
the DT IM-MS from buffered solution conditions. 
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The amount of conformational promiscuity and plasticity of the H115N mutant is 
significantly decreased in the presence of DNA. The conformational equilibrium is 
shifted towards more rigid and compact conformational isomers, possibly suggesting 
that the conformer with highest affinity for the DNA-target site is a compact one, 
which allows for greater ease of forming the favourable conformation for DNA-
binding. Remarkably, depopulation in more extended conformations is in a direct 
contrast what was demonstrated for the WT p53 (refer to Chapter 2, Section 3.5.1). 
The shift in the equilibrium towards the more compact conformational state (in the 
presence of DNA-target site) can be explained by at least three principally different 
possibilities. One plausible rationale is that the H115N mutant dynamically samples 
multiple monomeric structural isomers out of which functional states can be selected. 
In the presence of DNA, one of the transient conformers which enables binding with 
the highest affinity, would then be recruited. Addition of DNA would also shift the 
equilibrium of conformers, leading to higher occupancy of the active, here more 
compact conformer. An alternative hypothesis would be that the more extended 
species have formed dimeric species required for the H115N-DNA complex, leaving 
the residual compact conformational isomers. Thirdly, dissociation of H115N protein 
from DNA complex during desolvation processes cannot be ruled out.  
This first model poses a key element of the ‘new view’ (57,58), namely, of having a 
single protein oscillating between a set of structural isomers and forming of the 
specific p53-DNA-binding complexes through a conformational diversity. 
This study exemplifies the usefulness of MS and IM-MS in exploring the dynamic 
landscapes of disordered proteins. The unique advantage of IM-MS over 
conventional ensemble measurements, where multiple conformations are often 
averaged and neglected, is that it is capable of segregating the heterogeneity of a 
complex ensemble, which is of key importance in assigning structure-function 
relationship to proteins that are conformationally mobile, such as IDPs. Single 
molecule techniques are able to capture many distinct dynamic states of protein 
molecules. Fluorescence techniques, such as fluorescence resonance energy transfer 
(FRET), have already revealed the existence of multiple conformations in 
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equilibrium of the full-length p53 protein (59). NMR and pre-steady-state kinetics 
can also provide essential details regarding protein dynamics and the binding process 
- specifics that cannot be obtained by crystal structure analysis alone. Such studies 
are, however, technically challenging and, unfortunately, unachievable in many 
cases.  
4.6.4. Double Mutant R249A/H115N 
IM-MS data for the double mutant R249A/H115N are shown in Figure 4.17 (Figure 
4.18 for the mass spectrum). Here the effect of the ‘second site suppressor’ H115N 
becomes more apparent. 
 
Figure 4.17: Waterfall plot representing the in vacuo ‘conformational phenotype’ of 
R249A/H115N double mutant sprayed from buffered solution conditions (83.2 µM solution in 50 
mM ammonium acetate, containing 10% by volume propan-2-ol). 
In mobility space, the conformational occupancy of this double mutant appears 
highly similar to that presented by WT p53. The highly abundant low charge states 
show an increased width in their ATDs, which is indicative of a C1 conformer as 
opposed to the narrower C2 conformer, but remarkably the extended conformers Un 
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are noticeably more populated than in the WT p53. It appears that the double mutant 
presents a juxtaposition of the conformational space presented by each single mutant, 
providing not just a visual reference but more critically details on the conformational 
spread afforded by the double mutant. According to the variable temperature far-UV 
CD study this double mutant was classified to proteins with a conformation different 
from the WT p53-DBD, nonetheless the introduction of H115N has raised the 
thermal stability, by approximately 1.5 - 2 °C, from 36.5 to 38.5 °C (13), which 
might result in the conformational occupancy of this double mutant highly similar to 
that presented by WT p53 in the mobility profile. 
Figure 4.18: n-ESI spectrum of 83.2 µM R249A/H115N double mutation obtained via the TW 
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4.6.5. Double Mutant R273H/H115N 
Finally the impact of H115N as a ‘second-site suppressor’ on the contact mutant 
R273H (Figure 4.19; Figure 4.20 for the mass spectrum) is considered. Again the 
conformational signature of the double mutant is highly comparable to that of the 
WT p53 and the plasticity of the H115N mutant has increased the population of the 
more extended forms of the protein. These results are certainly in accord with the far-
UV CD study by Merabet et al (13) where the conformation of this mutant was found 
to be highly similar to the WT p53 as well as the overall thermal stability appeared to 
be greater than the cancer-associated mutation. 
 
Figure 4.19: Waterfall plot representing the in vacuo ‘conformational phenotype’ of 
R273H/H115N double mutant sprayed from buffered solution conditions (99 µM solution in 50 
mM ammonium acetate, containing 10% by volume propan-2-ol). 
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Figure 4.20: n-ESI spectrum of 99 µM R273H/H115N mutation obtained via the TW IM-MS 
from buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
 
4.6.6.  Double Mutant R248Q/H115N 
Data for the R248Q mutation in isolation was not obtained but the conformational 
landscape occupied by a double mutant R248Q/H115N was probed.  Arg-248 is a hot 
spot residue in loop L3 for a contact mutation which introduces extensive structural 
changes in the loop L3 and L2 regions, affecting the DNA-binding interface Merabet 
et al. (13) reported that H115N mutation is capable of rescuing the DNA-binding in 
R248Q mutant, as shown by binding of R248Q/H115N to gadd35 (the promoter of a 
gene involved in cell-cycle arrest).  
 
 






Chapter 4: Common p53 Cancer Mutants 
- 146 - 
 
 
Figure 4.21: Waterfall plot representing the in vacuo ‘conformational phenotype’ of 
R248Q/H115N double mutant sprayed from buffered solution conditions (83 µM solution in 50 
mM ammonium acetate, containing 10% by volume propan-2-ol), obtained via the TW IM-MS. 
In addition the variable temperature far-UV CD spectra revealed the conformational 
signature of this double mutant appears to be similar to the WT p53 (13). Here the 
mobility profile is very dynamic, for every charge state the whole spectrum of 
conformations is observed, from a very compact (C1) to unfolded species (Un) 
(Figure 4.21 and Figure 4.22 for the mass spectrum). The compact population exists 
when 9 ≤ z ≤ 13, although the abundance is decreased with each additional proton. 
Extraordinarily, the more extended conformers (X1) are retained over a wide range 
of charge states (9 ≤ z ≤ 18) and the signal intensity is significantly higher than that 
of all previously shown mutants or WT p53 proteins. For 12 ≤ z ≤ 18, multiple 
unfoldomers (Un) are observed in each charge state, and the number of resolvable 
Un conformers is at least four. Overall the mutant exhibits the most unfolded 
structures (the highest values of CCS) in comparison with all other mutants and WT 
p53-DBD. Here speculatively an increase in the more extended populations could 
originate from the addition of second site suppressor H115N.  
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Figure 4.22: n-ESI spectrum of 83 µM R273H/H115N mutation obtained via the TW IM-MS 
from buffered solution with 50 mM ammonium acetate, containing 10% by volume propan-2-ol. 
4.7. Summary 
The application of IM-MS and its capabilities for probing the conformational 
flexibility of p53 carcinogenic mutants has been demonstrated. The data paints an 
intriguingly diverse picture of the effects of common single oncogenic mutations on 
p53-DBD, in particular on the fraction of folded and unfolded protein. The designed 
cold spot mutation H115N was found to inflict a drastic change to the observed 
conformational fingerprint, revealing a very plastic and disordered nature of this 
mutation. The aftermath of introducing H115N mutant as a second-site suppressor on 
the hot spot mutations are demonstrated in the conformational spread afforded by the 
double mutants. 
A technique that is able to rapidly distinguish p53 mutants at low concentrations 
could certainly have marked benefits for cancer screening assays and also for drug 
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discovery. For example, a small-molecule inhibitor that might mimics the function of 
the H115N mutation could be screened by using this IM-MS approach.  Furthermore 
IM-MS could be exploited in elucidation of the relationship between p53 
antineoplastic activities and its structure and functions, as well as in other medically 
important proteins in the human genome. The ability of this method to delineate both 
stoichiometry as well as the conformational spread of this tumour suppressor protein 
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Many structural facets of the function of p53 remain to be unravelled. Of particular 
interest is the mechanism behind the dynamics of disorder-to-order transitions in 
intrinsically disordered regions to explain the structural basis of binding 
promiscuity. Structural studies on p53 bound to domains of signaling proteins and 
partner proteins in the cell cycle and transcriptional pathways are critical to obtain 
a detailed picture of the structural organization of higher-order complexes. Herein 
the conformational diversity of three functional regions of p53 was interrogated: 
natively unfolded N-terminal region, superstable quadruple mutant of DNA-binding 
domain and p53-N-DBD construct, consisting of N-terminus and the core domain. 
The molecular interaction of p53 N-terminus with the oncoprotein murine double 
minute 2, as well as with the antiapoptotic factor B-cell lymphoma-extra-large is 
probed. 
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5. Promiscuous Interactions of p53 
The powerful tumour suppressor protein p53 induces or suppresses the expression of 
an array of target genes engaged in cell cycle control, senescence, and apoptosis in 
response to oncogenic or other cellular stress signals. It exercises its function as 
guardian of genome through a convoluted interplay of independently folded and 
intrinsically disordered functional domains. Furthermore the cellular protein-protein 
interactions play a major role in fine tuning p53 activity at different levels. All steps 
of this regulatory mechanism are controlled by interactions with positive or negative 
modulators, promoting p53 covalent modifications, governing its stability, 
subcellular localization, determining its specificity for selected promoters, or 
modulating its transactivation potential (1). Accordingly, p53 is a highly connected 
protein and can form physical complexes with many cellular proteins. Understanding 
of the greater picture of p53 biology will not be complete until these interacting 
proteins are fully delineated. Moreover, some of these interactions are potential 
therapeutic targets and detailing the basis of interaction will aid in the design of 
molecules as effective drugs. 
In this chapter, insights into the miscellaneous structure of p53 are provided by 
segmenting p53 into individual & multi-domain constructs (shown in Figure 5.1),  
 
Figure 5.1: Domain structure of full-length p53 consisting of an N-terminal domain (NTD), 
followed by the central DNA-binding domain (DBD), the oligomerization domain (residues 318 - 
360) and the extreme C-terminus (residues 360 - 393); Recombinant constructs used herein: 
NTD (residues 1 - 102), DBD (residues 102 - 312) and NT-DBD (residues 1 - 292).  
Chapter 5: Promiscuous Interactions of p53  
- 156 - 
 
as well as interrogating interactions with the most important p53 regulator the E3 
ubiquitin ligase Mdm2 and the BcL-xL which is involved in transcription-
independent apoptotic role of p53. 
5.1. Methodology 
5.1.1.  Protein Expression and Purification 
Protein domain constructs p53-N, superstable mutant of p53-DBD, p53-N-DBD, and 
Bcl-xLΔLΔC were expressed and purified by Ariele Viacava Follis (St Jude 
Children’s Research Hospital, Memphis, USA) according to the method described 
here briefly. Constructs containing p53-DBD (superstable p53-DBD, p53-N-DBD) 
were modified at four residues - M133L/V203A/N239Y/N268D. Each cloned 
plasmid was transferred into Escherichia coli BL21 (DE3) expression strain. Cells 
were grown at 37°C until their optical density at 600 nm (OD600) reached a value of 
0.6, then induced with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 5 
hours and harvested. For expression of superstable mutant of p53-DBD and p53-N-
DBD, the temperature of the media was reduced to 20°C prior to IPTG induction. 
Bcl-xLΔLΔC construct was lysed using osmotic shock in a buffer containing 25 mM 
Tris, 500 mM NaCl, 5 mM imidazole, 20% w/v sucrose, 1 mg/mL lysozime, pH 8. 
Purification was carried out in Tris buffer with either imidazole or NaCl gradient and 
pH 8.0 or 7.0 for the Ni-affinity or anion exchange step respectively. The N-terminal 
domain of p53 was lysed with a microfluidizer in 25 mM Tris, 500 mM NaCl, 5 mM 
imidazole, pH 8.0. Cell pellets containing p53-DBD were lysed sonication in 50 mM 
potassium phosphate, 300 mM NaCl, 2 mM TCEP, 1 mg/mL lysozime, pH 8.0, 
followed by Ni-affinity purification in 25 mM Hepes, 0.5 M NaCl, 2 mM TCEP, pH 




GSHMEEPQSD PSVEPPLSQE TFSDLWKLLP ENNVLSPLPS QAMDDLMLSP 
DDIEQWFTED PGPDEAPRMP EAAPPVAPAP AAPTPAAPAP APSWPLSSSV            
PSQKT  
 
Chapter 5: Promiscuous Interactions of p53  
- 157 - 
 
Superstable p53-DBD (residues 102-312) 
GSHMKTYQGS YGFRLGFLHS GTAKSVTCTY SPALNKLFCQ LAKTCPVQLW 
VDSTPPPGTR VRAMAIYKQS QHMTEVVRRC PHHERCSDSD GLAPPQHLIR 
VEGNLRAEYL DDRNTFRHSV VVPYEPPEVG SDCTTIHYNY MCNSSCMGGM 
NRRPILTIIT LEDSSGNLLG RDSFEVRVCA CPGRDRRTEE ENLRKKGEPH 
HELPPGSTKR ALPNNT 
p53-N-DBD (residues 1-292) 
GSHMEEPQSD PSVEPPLSQE TFSDLWKLLP ENNVLSPLPS QAMDDLMLSP  
DDIEQWFTED PGPDEAPRMP EAAPPVAPAP AAPTPAAPAP APSWPLSSSV 
PSQKTYQGSY GFRLGFLHSG TAKSVTCTYS PALNKLFCQL AKTCPVQLWV 
DSTPPPGTRV RAMAIYKQSQ HMTEVVRRCP HHERCSDSDG LAPPQHLIRV 
EGNLRAEYLD DRNTFRHSVV VPYEPPEVGS DCTTIHYNYM CNSSCMGGMN 
RRPILTIITL EDSSGNLLGR DSFEVRVCAC PGRDRRTEEE NLRKK 
Bcl-xLΔLΔC (residues 1-209, lacking the loop region residues 44-85 and twenty two 
residues at the C-terminus) 
MSMAMSQSNR ELVVDFLSYK LSQKGYSWSQ FSDVEENRTE APEGTESEAV    
KQALREAGDE FELRYRRAFS DLTSQLHITP GTAYQSFEQV VNELFRDGVN 
WGRIVAFFSF GGALCVESVD KEMQVLVSRI AAWMATYLND HLEPWIQENG 
GWDTFVELYG NNAAAESRKG QERLEHHHHH H 
Human wild-type Mdm2-N was expressed and purified by Dr Erin Worrall 
(University of Edinburgh, UK). The amino acid sequence of the N-terminal Mdm2 is 
presented below: 
Mdm2-N (residues 1-126) 
MCNTNMSVPT DGAVTTSQIP ASEQETLVRP KPLLLKLLKS VGAQKDTYTM 
KEVLFYLGQY IMTKRLYDEK QQHIVYCSND LLGDLFGVPS FSVKEHRKIY 
TMIYRNLVVV NQQESSDSGT SVSENR 
5.1.2.  Sample Preparation 
Protein samples were flash frozen in liquid nitrogen and stored in a  - 80°C freezer. 
Prior to mass spectrometry and ion mobility mass spectrometry measurements, 
samples were thawed and dialysed using BIO-RAD micro bio-spin chromatography 
columns (Bio-Rad Laboratories, Inc). Buffer exchange was carried out to 99.99 % 
effectiveness by bio-spin chromatography column washing with four 500 μL aliquots 
of 50 mM ammonium acetate, followed each time by centrifugation for 2 minutes. 
Each of the protein samples was added to the buffer-exchanged chromatography 
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column and centrifuged for further 4 minutes. Protein concentrations were confirmed 
post dialysis spectrophotometrically (NanoDrop Spectrophotometer ND 1000 
Thermo Scientific, USA).  
5.1.3.  Mass Spectrometry and Ion Mobility Mass 
Spectrometry 
Drift tube ion mobility mass spectrometry (DT IM-MS) experiments were performed 
on an in-house modified quadrupole time-of-flight mass spectrometer, the MoQToF 
(2). More detailed description of this instrument can be found in Chapter 2, Section 
2.4.1. Ions were produced by positive n-ESI using Z-spray source, within a spray 
voltage range 1.0 to 1.8 kV and a source temperature of 80°C. The drift cell was 
filled with helium buffer gas at the average pressure of 3.5 - 4.0 Torr (4.7 - 5.3 mBar) 
and a temperature between 298 - 302 K. The electric potential across the cell was 
varied from 60 to 15 V and ATDs were recorded at eight drift voltages. The mobility 
of the ion of interest was calculated from a linear plot of average arrival time versus 
pressure/drift voltage (P/V) and from this the rotationally-averaged collision cross 
section (CCS) for each resolvable species at a given charge state were obtained. 
5.2. Highly Disordered p53-N-Terminal Region 
The N-terminus of p53 consists of an acidic transcription activation domain (TAD) 
and a proline-rich domain. The TAD (amino acid residues 1-63) is often further 
subdivided into ill-defined subdomains TAD1 (residues 1-42) and TAD2 (residues 
43-63) (3,4). The adjacent proline-rich domain (residues 64-92) contains five repeats 
of the sequence PXXP (SH3- domain binding motifs) which contributes to the 
apoptotic function of p53 (3-5). The polyproline regions have conformationally-
constrained backbones indicating a certain degree of structural rigidity. It is possible 
that the prevalence of prolines may facilitate its folding. Such role has not yet been 
experimentally validated for p53, but folding of other proteins has been shown to be 
chaperoned by the proline-rich regions (6,7). The TAD is a promiscuous binding site 
for a multitude of interacting proteins, such as modules of the transcriptional 
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machinery (via BOX-I region) (8-10), negative regulators Mdm2/Mdm4 which 
trigger ubiquitination and ultimately degradation of p53 (11-13), and the 
transcriptional coactivators p300/CBP (14,15).  
The N-terminal region of p53 is intrinsically disordered (16,17), although residual 
secondary structure is observed in functionally essential, conserved hydrophobic 
residues (18). Upon binding of the p53 TAD to partner proteins, regions of nascent 
helical structure that are present in the native state, rigidify and become entirely 
folded. A fragment consisting of residues 15-29 (TAD1), assumes an α-helical 
structure on binding to the N-terminal domain of Mdm2 and Mdm4. While natively 
unfolded segment of TAD2 folds into amphipathic α-helices on binding to 
replication protein A and the Tfb1 subunit of yeast TFIIH. So far, the only known 
atomic high resolution structures of N-terminal p53 have been solved in complex 
with their binding partners, when the p53 fragment forms a helical conformation 
(10,11,19-23). Intrinsic disorder provides a platform for multiple binding of diverse 
target proteins with overlapping binding sites on TAD and, often proteins with 
antagonistic biological effects. The classic sequence-function model is irrelevant 
here. It is estimated that approximately 25% of mammalian proteins are intrinsically 
disordered and the presence of natively unfolded regions is a recurring motif in 
proteins that are at the hub of a plethora of signalling pathways (24,25). 
The N-terminus of p53 is also heavily phosphorylated; it has nine phosphorylation 
sites, seven of which are located within the binding segment of regulatory proteins 
(Ser-15, Thr-18, Ser-20, Ser-33, Ser-37, Ser-46, and Thr-55) (26). Phosphorylation at 
position threonine 18 considerably lessens the affinity of TAD for Mdm2 because of 
electrostatic repulsion between the negatively charged area on the Mdm2 surface and 
the phosphate group (12,27,28). In contrast, there is evidence suggesting that 
phosphorylation at Thr-18 and other sites strengthens p53/p300 binding (14,29,30). 
Multiple phosphorylation of the TAD is able to alter the relative binding affinity of 
p53 for competing binding proteins (for example Mdm2 versus Taz2 domain of 
p300), highlighting how a phosphorylation cascade can provide modulation of p53 
activity in response to stress signals (14). 
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5.2.1. MS of p53-N-Terminus in buffered solution 
conditions 
From the buffered solution, a charge state distribution of p53-N monomer (calculated 
MR = 11162.3 Da, observed MR = 11164.2 Da) is observed with 6 ≤ z ≤ 11 (Figure 







indicative of a compact form of the protein with a limited 
number of charge-accessible residues available for protonation.   
 
Figure 5.2: n-ESI spectrum of 200 µM p53-N obtained via the DT IM-MS from buffered 
solution with 50 mM ammonium acetate. 
The spectrum also displays a less intense populations for dimeric species [2M+zH]
z+ 
and one unique trimer [3M+11H]
11+
, representing higher order multimeric 
association in solution. 
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5.2.2.  Conformational Flexibility of p53-N-Terminal 
Region 
Along with mass spectrometry, ion mobility measurements have been performed on 
p53-N-terminus sprayed from buffered solution conditions. Collision cross sections 
obtained are tabulated in Table 5.1 and 5.2 and plotted as a function of charge state 
in Figure 5.3. The data shows a smooth, near linear increase in cross-section with 
respect to charge to circa 1500 Å
2 
at z = 8, before the CCS values reach a plateau. At 
a given charge state two stable conformational isomers were resolved where their 
CCS varied by 10%, evidence of conformational diversity of the N-terminal region 







displaying the abundance of the conformation with the protein are shown in Figure 
5.4. For z = 7-8 the larger conformer is highly abundant, whereas for the lowest 
observable charge state z = 6 the more compact conformation is more intense. The 
lack of baseline resolution between the dynamic states of p53 can be attributed to the 
resolution of the MoQToF instrument, or rather interconverting conformers over the 
timescale of the experiment. 
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Figure 5.3: Collision cross sections versus charge obtained via the DT IM-MS of p53-N 
monomer and dimer from buffered solution conditions (200 µM p53-N in 50 mM ammonium 
acetate). The black box highlights the most abundant charge states. 
 







 showing at least two species can be resolved for each charge state.  
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The prevalence of intrinsic structural flexibility is signature behaviour of 
transactivation domains of transcription factors, proposed by Liu et al. (31). His 
PONDR analysis revealed that 85% of transcription factors possess extended regions 
of intrinsic disorder. The conformational flexibility of the p53 transactivation domain 
may have been evolutionary carefully chosen to allow p53 to interact with a wide 
array of proteins, since each p53-protein complex may stabilize a specific p53 
conformational isomer suitable for the particular interaction. Further, because of the 
conformational variability and adaptability, the p53 transactivation domain residues 
can adjust to the active sites of various enzymes (kinases, acetylases, etc.), which 
explains why many post-translational modifications of p53 map to the transactivation 
domain. 
Charge state   Collision Cross Section / Å
2
 
6 1142±9,         1252±12, 
7 1304±70,       1469±117 
8 1453±56,       1613±26 
9 1486±132,     1730±113 
 
Table 5.1: Collision cross sections of monomer form of p53-N obtained via the DT IM-MS from 
buffered solution condition (200 µM p53-N in 50 mM ammonium acetate). Values are an 
average of three replicates and stated with the standard deviation of the mean. 
Charge state   Collision Cross Section / Å
2
 
9 1599±300,     1923±240 
10 1702±52,       2145±92 
11 
 
1916±131,     2306±108 
 
Table 5.2: Collision cross sections of dimer form of p53-N obtained via the DT IM-MS from 
buffered solution condition (200 µM p53-N in 50 mM ammonium acetate). Values are an 
average of three replicates and stated with the standard deviation of the mean. 
5.3. Molecular Architecture of p53-N-DBD 
To map possible interactions of the p53 N-terminus with the DBD, mass 
spectrometry and ion mobility mass spectrometry measurements were conducted, 
using a construct comprising the superstable quadruple mutant of p53-DBD (residues 
Chapter 5: Promiscuous Interactions of p53  
- 164 - 
 
102-312) with full N-terminus (residues 1-102). Natan et al. (32) reported that the 
region of the N-terminus interacting with the p53-DBD could be pinpointed to 
residues 86-93, the hinge section between the folded DBD and the proline-rich 
region. These interactions increase the melting temperature of the tetrameric p53 by 
up to 2 °C indicating that p53-DBD tetramer is stabilised through additional 
interactions by its N-terminal region. Light scattering measurements have also 
demonstrated that a short segment from the TAD (residues 89-94) inhibits 
accelerated aggregation of the full-length p53 tetramer. In general this highlights the 
potential repercussions for studies of multi-domain proteins where weak ordered-
disordered domain interactions can regulate the properties of proteins of complex 
structure. 
5.3.1.  MS of p53-N-DBD in buffered solution 
conditions 
The observed spectrum of p53-N-DBD displays a wide charge state envelope over 
the acquired mass range (1000-5500 m/z). Under these conditions the most dominant 
species of p53 corresponds to a monomer (calculated MR = 32613.7 Da, observed MR 
= 32625.9 Da), with a wide-ranging charge state distribution of 10 ≤ z ≤ 20. The 









, suggesting that at least four 
conformational families are present in the solution and transferred into the gas phase 
environment (MS shown in Figure 5.5). The overall charge state distribution of p53-
N-DBD appears dissimilar to the spectrum of isolated superstable p53-DBD (Figure 
5.10). Closer examination of spectra reveals a shift towards higher charge states of 




, perhaps due to the more flexible 
and disordered nature of p53 in the presence of the N-terminus. The intrinsically 
disordered N-terminus also induces an increase in formation of more stable higher 
order multimeric species such as dimers and trimers, in accord with the findings of 
Natan et al. The ion envelope for [2M+zH]
z+
 is 15 ≤ z ≤ 19 along with the less 
intense population for [3M+zH]
z+
, where 20 ≤ z ≤ 22. Even under ‘near native’ 
conditions p53-N-DBD exhibits a wide charge state distribution for monomeric 
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species (10 ≤ z ≤ 20), which is a distinctive behaviour of IDPs in vacuo as reported 
earlier by mass spectrometry (33). 
 
Figure 5.5: n-ESI spectrum of 90 µM p53-N-DBD obtained via the DT IM-MS from buffered 
solution with 50 mM ammonium acetate. 
5.3.2. Conformational Landscapes adopted by p53-
N-DBD  
Collision-cross sections measured for p53-N-DBD from aqueous solution buffered to 
pH 6.8 with 50 mM ammonium acetate versus its charge state are reported in Figure 
5.6. The mean cross-section value of each ion increases with increasing charge, 
which can be attributed to expansion of the protein structure to overcome Coulomb 
repulsion as an increasing number of protons are accepted, a well-established 
phenomenon of gas-phase ions (34,35). The lowest charge state, z = 10 provides a 
single resolvable conformer, indicative of a compact structure, whereas the most 
intense charge state z = 11 adopts two conformations, with the most populated being 
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and a lower intensity elongated form of 2474 Å
2
 (ATDs is shown in Figure 
5.7) With increasing charge, the unfolding pathways of the protein are clearly 
evident and a minimum of two conformational isomers can be resolved for 11 ≤ z ≤ 
19. The majority of the protein for z = 10-15 is present in a compact structure, which 
also exists for z = 16-19, although here the more extended conformational family is 
the more prominent. At the highest charge state z = 20, only the more elongated 
conformer is observed (4092 Å
2
). Remarkably for the dimeric species only a single 
conformation is detected, suggesting that this is the only stable gas phase dimeric 
form of p53, nonetheless still in a collapsed state (CCS only larger by 13% than CCS 
for the equivalent monomeric forms). 
 
Figure 5.6: Collision cross sections versus charge obtained via the DT IM-MS of p53-N-DBD 
monomer and dimer from buffered solution conditions (90 µM p53-N-DBD in 50 mM 
ammonium acetate). The half-filled symbol represents less abundant conformer at a given 
charge state. 
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Figure 5.7: Experimenta ATDs taken at 35 V of p53-N-DBD for z = 10 - 20. 









12 2268±118,     2651±186 
13 2234±38,       2631±35 
14 2318±50,       2879±15 
15 2546±43,       3064±61 
16 2725,             3230 
 
17 2942±74,       3352 
 
18 3018±122,     3694±28 
19 3172±146,     3957±81 
20                       4092±150 
 
Table 5.3: Collision cross sections of monomeric p53-N-DBD obtained via the DT IM-MS from 
buffered solution condition (90 µM p53-N-DBD in 50 mM ammonium acetate). Values are an 
average of two replicates and stated with the standard deviation of the mean. 
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Table 5.4: Collision cross sections of p53-N-DBD dimer obtained via the DT IM-MS from 
buffered solution condition (90 µM p53-N-DBD in 50 mM ammonium acetate). Values are an 
average of two replicates and stated with the standard deviation of the mean. 
 
5.4. The Quest for Stable p53 - Quadruple 
Mutant of p53-DBD: M113/V203/N239Y/N268D 
The low thermodynamic stability and associated aggregation propensity is a known 
Achilles’ heel of human p53 protein that has hampered many biophysical and 
structural studies. By adopting a semi-rational design based on the molecular 
evolution of p53, Nikolova et al. (36) designed a superstable (SS) quadruple mutant 
of the human p53-DNA binding domain. In this approach naturally occurring amino 
acid substitutions were identified by assessing the sequences of p53 homologues 
from more than 20 species and subsequently introduced into p53 core domain to 
measure their effect on the thermodynamic stability of the protein. In addition, a 
N239Y substitution was also introduced although does not occur naturally (37). Four 
most stable point mutations M133L, V203A, N239Y and N268D were combined that 
increased overall rigidity and thermostability of p53. The mutations are positioned in 
different regions of the core domain shown in the Figure 5.8.   
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Figure 5.8: Diagram of the DNA-binding core domain of p53 produced by MOL-SCRIPT 
showing the location of four mutations used to design the superstable quadruple mutant. Image 
and caption taken from Nikolova et al. (36). 
The effect of these point mutations is nearly additive, and the main contribution to 
increased stability arises from N239Y and N268D mutations, both known to act as 
second-site suppressors for various cancer-associated mutations (37). Nikolova et al. 
(36) also measured the DNA binding affinity of the wild-type and quadrupule mutant  
using surface plasmon resonance and reported the apparent binding constants to be 
nearly identical. The crystal structure of the engineered mutant (residues 96-290) 
shows small local structural changes in the loop regions, whereas the overall 
structure of β-sandwich scaffold and the DNA binding surface is maintained (Figure 
5.9) (38). Mutation M133L located in strand S2 of the loop-sheet-helix motif causes 
only minor deviations in the neighbouring residues. Similarly mutation V203A in 
turn between β-strands S5 and S6 induces a local re-packing of the side chains 
around the mutation site. The crystal structure also explains the larger effect of the 
N268D and N239Y substitutions on the stability increase of p53 protein. These 
mutations act on different regions of the core domain. Mutation N268D alters 
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hydrogen bonding network in β-strand S10, which is part of both the β-sandwich and 
the loop-sheet-helix motif.  Contrary to the other three mutations, the N239Y has so 
far not been identified in any known p53 sequence.  
 
Figure 5.9: The X-Ray structure of p53 core DNA-binding domain quadruple mutant 
M113L/V203A/N239Y/N268D. (a) Ribbon image showing the β-sandwich (in yellow), loop 1 and 
2 regions (encircled in blue dashed line) connected via a zinc ion (grey sphere) and a loop-sheet-
helix motif (encircled in green solid line). (b) Stereo view of the Cα trace of the p53 core DNA-
binding domain quadruple mutant (shown in black) superimposed on DNA-free wild type (PDB 
1TSR; chain A, blue) and DNA-bound wild type (PDB 1TSR; chain B, orange). The mutation 
sites in the quadruple mutant are marked by small coloured spheres: M113L (blue), V203A 
(green), N239A (red), and N239Y (magenta). Image and caption taken from  Joerger et al. (38). 
5.4.1.  MS of SS p53-DBD in buffered solution 
conditions 
From the buffered solution, the superstable quadruple mutant p53 monomer is 
observed in a charge state distribution with 9 ≤ z ≤ 18 along with few additional 
multimeric species. Each of the monomer charge states can be assigned  to the zinc-
bound form of the protein (calculated MR = 24245.4 Da, observed MR = 24263.4 Da) 
which suggests that all conformations present in solution retain the zinc binding site, 
and that it is not perturbed by the n-ESI desolvation process or by any subsequent 





indicative of compact conformations 
prevalent in solution as there are few solvent-accessible sites available for 
protonation. Lower intensity monomeric species between charge states 11 ≤ z ≤ 17 
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can be attributed to more unfolded states of p53. The wide charge state distribution 
even under buffered solution conditions is a distinctive signature for IDPs as reported 
previously (33). A less abundant ion envelope for the dimeric form of p53 is also 
observed (z =13-16), representing higher order multimeric association in solution, 
again zinc is bound stoichiometrically. Overall the charge state distribution is 
relatively similar to the de facto WT p53 DBD (refer to Chapter 3, Section 3.4.1, 
Figure 3.3 for the mass spectrum) but the higher charge species appear to be more 
populated manifesting a more disordered  nature for this superstable quadruple 
mutant.  
 
Figure 5.10: n-ESI spectrum of superstable 73 µM p53-DBD obtained via the DT IM-MS from 
buffered solution with 50 mM ammonium acetate. 
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5.4.2.  Conformational Populations occupied by SS 
p53-DBD  
Rotationally averaged CCS obtained from aqueous solution buffered with 50 mM 
ammonium acetate are tabulated in Table 5.5 and plotted as a function of charge state 
in Figure 5.11. Low charge states generally adopt compact conformations indicative 
of native like structure of the protein. The dominant charge states z = 9 and 10
 
assume multiple conformations, where populations with the lowest CCS are the most 
abundant (Figure 5.12 illustrates the abundance of the conformation within the 
protein). Remarkably, this most compact form of the superstable mutant (represented 
as black filled squares) is retained over a wide array of charge states (9 ≤ z ≤ 17), 
whereas for the de facto WT p53-DBD this compact ensemble was found to span 
only charge state z = 9 - 13 (refer to Chapter 3, Section. 3.4.4, Figure 3.7 for the CCS 
plot versus charge state).  
 
Figure 5.11: Collision cross sections versus charge obtained via the DT IM-MS of superstable 
quadruple mutant of p53-DBD monomer from buffered solution conditions (73 µM SS p53-DBD 
in 50 mM ammonium acetate.  The black box highlights the most abundant charge states. 
Chapter 5: Promiscuous Interactions of p53  
- 173 - 
 
 
Figure 5.12: Experimental ATDs taken at 35 V of monomer form of SS p53-DBD for z = 9 - 17. 
This idiosyncratic rigidity and clear resistance to Coulombically-driven unfolding of 
the ‘native like’ structure of superstable p53-DBD perhaps might be an aftermath of 
introduction of four stabilising mutations M133L, V203A, N239Y and N268D. 
Overall the unfolding trajectory of the superstable mutant displays an extraordinary 
extent of stability regions seen as ‘shelving’, cumulating around lower charge states z 
= 9 - 12. The most compact and rigid conformer unfolds minimally, for z = 10, CCS 
of 1611 Å
2 
is measured, whereas for z = 17 the CCS of 2219 Å
2
 is observed (which is 
only larger by 17%). The intermediate conformer (shown as dark grey symbol) is 
only detected at the lower charge states and is entirely lost at z = 13. The third 
conformational family (shown as light grey filled squares) with a CCS of 1937 Å
2
 at 
z = 9 demonstrates two sharp jumps in CCS during the unfolding pathway, occurring 
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Charge state Collision Cross Section / Å
2
 
9 1778±48,       1937 
10 1611±96,       1841±240,     2155±259 
11 1703±9,         1852±2,         2111 
12 1815±45,       2174±99,       2489 
13 1882±51,                             2854±247 
14 1885±5,                               2821±5 
15 1983±48,                             2794±137 
16 2035±54,                             3295 
17 2219±111,                           3665 
 
Table 5.5: Collision cross sections of monomeric SS p53-DBD obtained via the DT IM-MS from 
buffered solution condition (79 µM SS p53-DBD in 50 mM ammonium acetate). Values are an 
average of two replicates and stated with the standard deviation of the mean. 
Overall the IM-MS data paints an intriguing picture of the engineered mutant of p53-
DBD, conformationally diverse with multiple isomers detected, yet exhibiting some 
exceptional intrinsic rigidity of the structure. The design of the superstable mutant, 
which maintains the overall structural features of the WT protein, unquestionably 
supports biophysical and biochemical studies, particularly in tackling the quaternary 
structure of full length p53. Nonetheless, the results should be interpreted carefully 
and when possible the de facto WT p53 construct should be used, especially whilst 
only the isolated p53-DBD is investigated. 
Collision cross sections ranges measured for individual & multi-domain p53 
constructs are plotted in Figure 5.13.  
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Figure 5.13: Comparison of collision cross sections versus charge state measured for monomeric 
p53-N, superstable quadruple mutant of p53-DBD and p53-N-DBD. 
5.5. Architecture of p53:Mdm2 Complex 
Critical to the inhibitory action of the oncogene product, Mdm2, on the tumour 
suppressor p53, is association of the N-terminal domain of Mdm2 with the 
transactivation domain of p53. Much light has been shed on the interaction between 
p53 and Mdm2 by determination of the crystal structure of the N-terminal domain of 
Mdm2 (residues 25-109) bound to 15-residue transactivation domain peptide of p53 
(residues 15-29) by Kussie et al. (11).  
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Figure 5.14: X-Ray crystal structure of human p53-N (residues 15-29, shown in blue colour) in 
complex with Mdm2-N (shown in green); (PDB ID 1YCQ) (11).  
The region of Mdm2 that interacts with p53 consists of an independently-folding 
domain comprising of a four helix bundle flanked on either side by β-sheets. A 
fragment containing residues 15 - 29 of p53 folds as an α-helix that interacts with a 
hydrophobic cleft on the Mdm2 surface (structure shown in Figure 5.14). The 
interaction is interceded by highly conserved amino acids Phy-19, Trp-23 and Leu-
26 of p53 that interact with multiple Mdm2 hydrophobic residues, including Leu-54, 
Met-62, Tyr-67 and Val-93,whose side chains form the cleft on the Mdm2 surface. 
The amphipathic nature of the p53 helix (hydrophobic on the side that interacts with 
Mdm2 and hydrophilic on the side exposed to solvent) is crucial for the binding.  
5.5.1.  Mdm2 N-terminal - MS and IM-MS 
perspective 
The NMR experiment performed by Uhrinova et al. (39) revealed an unstable nature 
and multiple conformations of ligand-free Mdm2-N (residues 2-118). This solution 
structure enabled the hypothesis that upon binding to p53, an N-terminal segment of 
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apo-Mdm2 that occludes contact with the end of the p53-binding cleft is displaced. 
Further, Uhrinova argues that Mdm2-N undergoes expansion upon binding, which is 
attained through conformational rearrangement of its two sub-domains resulting in a 
more ordered, and open conformation of the binding cleft.  
 
Figure 5.15: Solution NMR structure of Mdm2-N (PDB ID 1Z1M) (39) highlighting the C-
terminal end, N-terminal lid region and the hydrophobic p53 binding pocket. 
 
Figure 5.16: PONDR score of disorder for Mdm2-N, showing the disordered lid region at 
residues 4-27 (40). 
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Schon et al. (12) also reported extensive changes in chemical shifts when Mdm2-N 
(residues 2-125) is in complex with peptides from the TAD of p53 (residues 15-29 
and 17-26).  These perturbations were not only restricted to the binding cleft but 
could be mapped to the other parts of the protein, suggestive of extensive 
conformational rearrangement. McCoy et al. (41) also suggested that the N-terminal 
residues of Mdm2-N form a flexible lid over the p53-binding groove (highlighted in 
the structure of Mdm2-N in Figure 5.15 as well as in the  PONDR score in Figure 
5.16), it was therefore important to use a fragment of Mdm2 that contains the 
sequence prior to residues 18, in contrast to some previous studies that employed 
truncated constructs (11,41). 
The mass spectrum obtained for WT N-terminal Mdm2 sprayed from near native 
conditions (50 mM, ammonium acetate) is illustrated in Figure 5.17.  
 
Figure 5.17: n-ESI spectrum of 115 µM Mdm2-N obtained via the DT IM-MS from buffered 
solution with 50 mM ammonium acetate. 
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It displays a wide charge state distribution for monomer (5 ≤ z ≤ 15); characteristic 
behaviour of IDPs. The central spectral peak can be assigned to z = 7 evidence of a 
predominant compact structure to the protein. CCS obtained are tabulated in Table 
5.6 and plotted as a function contrasting experimental CCS values versus charge state 
in Figure 5.18. Multiple conformations are detected; specifically up to two 
conformations can be resolved for each charge state. The data overall shows a 
smooth increase in cross-section with respect to charge. However the unfolding 
trajectory demonstrates some sharp ‘jumps’ in the CCS values, one at z = 6 (from 




and z = 12-13 (2042 to 2245 Å
2




Figure 5.18: Collision cross sections versus charge obtained via the DT IM-MS of monomer 
form of Mdm2-N from buffered solution condition (59 µM Mdm2-N in 50 mM ammonium 
acetate). The half-filled square symbol represents less abundant conformer at a given charge 
state. 
Charge state Collision Cross Section / Å
2
 
5 1047,     1493 
6 1103,     1642 
7 1335,     1839 
8 1405,     2014 
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11 1642,     2107 
12 1723,     2042 
13 1715,     2245 
14 1958,     2472 
15 2003,     2436 
 
 
Table 5.6: Collision cross sections of monomer form of Mdm2-N sprayed from buffered solution 
condition (59 µM Mdm2-N in 50 mM ammonium acetate) obtained via the DT IM-MS. 
 
5.5.2.  Interactions of p53-Mdm2 probed by IM-MS 
Mass spectrometry and ion mobility mass spectrometry was used to study complex 
formation between p53-N (residues 1-105, MR = 11162.3 Da) and Mdm2-N (residues 
1-126, MR = 14926.1 Da) (Figure 5.19 shows the resultant mass spectrum). Proteins 
were incubated up to three hours; an increase in the incubation time did not alter the 
binding strength indicating an instant binding mechanism.  
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Figure 5.19: n-ESI spectrum of 49 µM p53-N in complex with 16 µM Mdm2-N. Mass spectrum 
was obtained from solution buffered with 50 mM ammonium acetate, incubated for five minutes 
and recorded via the DT IM-MS. The single grey spheres represent p53-N monomer, whereas 
the single green spheres represent Mdm2-N monomer. The mixed dimers spheres (green and 
grey) represent the p53-N – Mdm2-N complex. 
The p53-N protein was found to bind Mdm2-N as 1:1 complex only. A charge state 
distribution of 9 ≤ z ≤ 15 for the complex was observed, the dominant peak of the 
complex is assigned to [M+11H]
11+
. In the spectrum, ion envelopes of unbound 
monomeric ensembles for p53-N and Mdm2-N were also detected, which may 
perhaps be a consequence of transient and dynamic character of the interaction 
between the two proteins. There is also a notable depletion of all charge states 
corresponding to N-terminal Mdm2 in the presence of p53-N binding partner. The 
formation of full-length p53-Mdm2 complex was assessed by Funari et al. (42) using 
single molecule atomic force spectroscopy. The binding strength and dissociation 
rate constant was found to fall within a range of values characteristic of dynamical 
protein-protein interactions similar to several other ligand-receptor complexes, such 
as cadherins and selectins (43,44). Indeed, the cellular activity of the p53-Mdm2 
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complex is more likely to require a dissociation rate constant typical of transient, 
dynamic interactions to permit, for instance an ubiquitination and the subsequent 
dissociation of p53 to undergo degradation (45). Moreover, Funari’s findings are in 
close agreement with a stopped-flow fluorimetric study by Schon et al. (12), which 
utilised the two N-terminal domains of both p53 and Mdm2 proteins (rather than full-
length proteins). It can be inferred that the two cognate binding sites of the complex 
experience a bio-recognition process without any steric hindrance effect from the 
presence of the entire milieu of the proteins (42). 
 
Rotationally averaged CCS obtained from aqueous solution buffered with 50 mM 
ammonium acetate are reported in Table 5.7 and plotted as a function of charge state 
in Figure 5.20. The dominant charge states (z = 10 - 12) provide at least two 
resolvable conformers, for z = 13 - 15 three conformational isomers were resolved. 
ATDs of the complex for z = 9-15, displaying the abundance of the conformation 
within the protein are shown in Figure 5.21. Here for z = 10 - 12 and z = 15 the larger 
conformer is highly abundant (arriving later), whereas for z = 9 and 13 the more 
compact conformation is more intense. For z = 14 the intensity of conformers 
appears to be shared equally. 
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Figure 5.20: Collision cross sections versus charge obtained via the DT IM-MS of p53-Mdm2 
complex from buffered solution conditions (50 mM ammonium acetate). The blue box highlights 
the most abundant charge states. 
Additionally the intensity of each conformer switches during different drift voltages, 
the electric potential difference across the drift cell (shown in Figure 5.21a), perhaps 
again suggesting the extraordinary dynamic and transient nature of the complex. To 
simplify, structured, folded proteins with little conformational flexibility in solution, 
would give rise to narrower ATDs (peak width would be expected to be smaller), 
typically presenting one conformation at different drift voltages applied to the cell. In 
turn, less structured or unfolded proteins would give rise to wider ATDs often with 
multiple conformations (as seen here). Analysis of the width of ATDs could 
potentially act as an indicator of intrinsic disorder of proteins, semi quantifying the 
conformational flexibility and spread of structures in a family of the systems.  
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Figure 5.21: a) Experimental ATD of p53-N-Mdm2-N for a single charge state [M + 14H]
14+
 
taken at seven different drift voltages (60, 50, 45, 40, 35, 30, 25 V) showing the switching 
intensity of conformers. At 60 and 45 V the conformer arriving later appears to be more intense 
whereas at 35, 30 and 25 V first conformation is more abundant; at 50 and 35 V intensity of 
conformers seems to be shared equally. b) Experimental ATDs taken at 40 V of p53-Mdm2 
complex for z = 9 - 15.  
Overall the cross-section values are observed to increase upon addition of charge 
attributable to unfolding of the protein structure to minimise Coulomb repulsion (34). 
Interestingly the unfolding pathway of the complex appears to be more 
heterogeneous that that of individual domains of apo-Mdm2 or isolated p53. The 
explicit-solvent molecular dynamics simulations performed for bound and apo-
Mdm2 also showed that their unfolding pathways are different and the transition 
state of bound Mdm2 is more heterogeneous that that of apo-Mdm2 (46).  The 
unfolding trajectory lacks any major stability regions seen as ‘shelving’ of several 
charge states, providing once more evidence of ‘the ephemeral’ and conformationally 
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Charge state Collision Cross Section / Å
2
 
10 1435±138,                  1884±267 
11 1728±135,                  2638±180 
12 1909±23,                    2631±51 
13 1952±81,      2271,     3194 
14 2007,            2770,     3279±189 
15 2410,            2714,     3319±88 




Table 5.7: Collision cross sections of monomeric p53-Mdm2 complex obtained via the DT IM-
MS from buffered solution (50 mM ammonium acetate). Values are an average of two replicates 
and stated with the standard deviation of the mean. 
Collision cross-section ranges measured for the complex and individual components 
are plotted in Figure 5.22.  Cross-section values for the complex range approximately 
between 1450 to 3750 Å
2
, for p53-N between 1150 - 1730 Å
2
 and for Mdm2-N 
between 1050 - 2450 Å
2
, respectively. Remarkably it appears that ‘shape’ of the 
complex is configured by the Mdm2 protein, which has a molecular weight only 
twenty five percent larger than of p53-N. 
 
Figure 5.22: Comparison of collision cross sections versus charge state measured for monomeric 
p53-N (grey triangles), Mdm2-N (green circles) and p53-Mdm2 complex (black squares).  
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The Mdm2-p53 interaction is an example of a protein-protein interaction that is a 
good candidate for inhibition by a small, drug-like ligand (47). Precise structural 
understanding of this compact protein-protein interface will hopefully lead to a 
successful identification of a more specific and potent small molecule drug-like 
antagonist for use in anticancer therapy.  
5.6. BcL-xL-p53 Connection: Alternative Route 
to Cell Death 
The basis for p53’s outstanding apoptotic and tumour suppressive effectiveness lies 
in its pleiotropism that comprises transcription-dependant and -independent 
functions. This p53 transcription-independent apoptosis precedes p53 target gene 
activation and is mediated by the direct interaction of p53 with with Bcl-2 family 
members, the anti-apoptotic members BcL-2 and BcL-xL, and the pro-apoptotic Bax, 
Bak, and Bad. p53 is both a transcription factor and a membrane permeability 
regulator. From genetic and biochemical evidence it has been proposed that p53 
engages apoptotic caspase activation mainly through the intrinsic, mitochondrial 
pathway (48). This pathway is regulated by BcL-2 family proteins, which govern the 
permeability of the outer mitochondrial membrane and the release of death factors 
such as cytochrome c. Chipuk et al. (49) demonstrated that PUMA, a proapoptotic 
BH3-only protein, can release p53 from the p53-BcL-xL complex to bind and 
activate Bax or Bak, in consequence allowing Bax and Bak to prompt mitochondrial 
permeabilization. Another pro-apoptotic protein Bad was shown to be upregulated by 
p53 and form a complex with p53 at the mitochondria inducing apoptosis (50). This 
example describes the function of cytoplasmic p53, which integrates the functions of 
p53 with the Bcl-2 family proteins, and supports the hypothesis that the complex 
formation of p53 and BcL-xL is of high significance in p53 transcription-
independent apoptotic activity. 
The critical interaction between p53 and BcL-2 family members in response to 
apoptotic stimuli has aroused much interest and detailed information on the 
mitochondrial p53 apoptotic mechanism is still accumulating (50-55). Here, in the 
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mass spectrometry study for the molecular interaction between BcL-xL (Figure 5.23 
shows the overall structure) and N-terminal p53 (residues 1-102), a BcL-xL∆L∆C 
construct was used (graphically presented in domain structure in Figure 5.24), in 
which the C-terminal transmembrane twenty two residues as well as the unstructured 
loop region connecting α-helix 1 (α1) to α2 (from residues 44-55) was truncated. 
 
Figure 5.23: X-Ray crystal structure of BcL-xL (PDB 1R2D) (56) adapted to display the long 
disordered loop region (in yellow) connecting α-helix 1 to α-helix 2. 
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Figure 5.24: Domain structure of wild-type (WT) Bcl-xL highlighting the disordered loop region 
connecting α1 to α2; Recombinant construct BcL-xL∆L∆C lacking the loop region as well as the 
twenty two  amino acid residues at the C-terminus. 
 
5.6.1.  MS of BcL-xL∆L∆C in buffered solution 
conditions 
The observed spectrum of BcL-xLΔLΔC (Figure 5.25) displays a wide charge state 
distribution for a monomer, 7 ≤ z ≤ 17 (calculated MR = 20780.9 Da, observed MR = 
20745.1 Da). Under buffered solution conditions the dominant spectral peak can be 
assigned as [M+8H]
 8+
, indicative of a highly compact conformation. In addition a 
less intense ion envelope for [2M+zH]
 z
, is also observed (where 10 ≤ z ≤ 13). 
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Figure 5.25: n-ESI spectrum of 135 µM BcL-xL∆L∆C obtained via the DT IM-MS from 
buffered solution with 50 mM ammonium acetate. 
5.6.2.  Collision cross sections of BcL-xL∆L∆C  
CCS values obtained for the monomeric and dimeric populations are tabulated in 
Table 5.8 and 5.9 and displayed graphically as a function of charge state in Figure 
5.26. The cross-section is observed to increase upon addition of charge and is 
attributed to unfolding of the protein structure to minimise Coulomb repulsion (34).  
However the data also displays some regions of stability seen as ‘shelving’ in the 
CCS values for the lowest charge states (7 ≤ z ≤ 9), providing evidence for several 
stable populations on the unfolding pathway. 
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Figure 5.26: Collision cross sections versus charge obtained on the DT IM-MS of monomer and 
dimer form of 135 µM BcL-xL∆L∆C from buffered solution with 50 mM ammonium acetate. 
The half-filled symbol represents less abundant conformer at a given charge state. 
 
Figure 5.27: Experimental ATDs taken at 35 V of the most intense charge states (z = 7 - 11) for 
monomer form of BcL-xL∆L∆C. 
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The lowest charge state, z = 7 provides a single resolvable conformer, with a CCS of 
1673 Å
2
, whereas for z = 10 two species are resolved, with the most populated being 
1567 Å
2 
and a lower intensity elongated form of 1775 Å
2
 (shown in the ATDs in 
Figure 5.27) With increasing charge two conformational isomers can be elucidated 
for each charge state which indicates that multiple coexisting conformations are 
produced. At the highest charge, z = 14, the observed collision cross-section 




 are obtained. 
The majority of the protein for z = 7-10 is found in a compact conformational 
isomer, which also exists for z = 11-14, although here the more extended 
conformational family is the more pronounced. CCS obtained for dimers are on 
average only 14% larger than CCS of corresponding monomeric conformers (even 
less for z = 13 where the difference is 4%), suggestive of significant collapse of the 
dimeric structure in the gas phase. 
Charge state Collision Cross Section / Å
2
 
7                       1673±1 
8 1567±10,       1775±22 
 
9 1530±42,       1803±93 
10 1720±2,         2038±25 
11 1963±41,       2372±37 
12 2104±108,     2538±23 
13 2508,             3041±125 
14 
 
2746±243,     3553 
 
Table 5.8: Collision cross sections of monomeric BcL-xL∆L∆C obtained via the DT IM-MS 
from 135 µM solution buffered with 50 mM ammonium acetate. Values are an average of two 
replicates and stated with the standard deviation of the mean. 
Charge state Collision Cross Section / Å
2
 
11                       2651±12 
12 2490±110,     2986 
13 2627±101,     2989±74 
 
Table 5.9: Collision cross sections of dimeric BcL-xL∆L∆C obtained via the DT IM-MS from 
135 µM solution buffered with 50 mM ammonium acetate Values are an average of two 
replicates and stated with the standard deviation of the mean. 
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5.6.3.  Molecular Interaction of N-terminal Domain 
of p53 with anti-apoptotic BcL-xL 
A number of researchers have postulated that the anti-apoptotic protein BcL-xL 
interacts only with the DNA-binding region of p53 not with its N- and C-terminal 
regions, and subsequently the proposed molecular interaction has been defined by 
NMR spectroscopy (51,57-59). Controversially, Chipuk et al. (60) reported that the 
amino terminus of p53 including its proline-rich regulatory domain is necessary and 
sufficient to induce transcription-independent apoptosis. Further to that Xu et al. (61)  
characterised the binding interface between p53-N and BcL-xL by employing NMR-
based binding study and a FRET assay in cells. 
        
 
Figure 5.28: n-ESI spectrum of 180 μM p53-N with 135 μM BcL-xL∆L∆C. Mass spectrum was 
obtained from solution buffered with 50 mM ammonium acetate, incubated for five minutes and 
recorded via the DT IM-MS. The single grey spheres represent p53-N monomer, whereas the 
single blue spheres represent BcL-xL∆L∆C monomer. The mixed dimers spheres (blue and 
grey) represent the p53-N -BcL-xL∆L∆C complex. 
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Mass spectrometry was used to study the complexation between p53-N (MR = 
11162.3 Da) and truncated construct BcL-xL∆L∆C (MR = 20745.1 Da) (Figure 5.28 
shows the produced mass spectrum). The preliminary data showed that p53-N binds 
BcL-xL∆L∆C to form 1:1, 31.9 kDa complexes only, where z = 9-13. Notable 
comparable charge states were found for the p53-Mdm2 complex (spectrum shown 
in Figure 5.19, Section 5.5.2) which is not surprising as the Mdm2-binding region in 
the transactivation domain of p53 has also been identified as BcL-xL-binding motif 
(62). In the spectrum shown in Figure 5.21, ion envelopes of unbound ensembles for 
p53-N and BcL-xL∆L∆C were also detected. There is also a notable depletion of all 
charge states corresponding to BcL-xL∆L∆C in the presence of p53-N binding 
partner. These initial results on p53-N-BcL-xL interaction could perhaps be 
improved by lengthening of the incubation time or by employing different 
recombinant BcL-xL constructs, in particular wild-type BcL-xL. A longer incubation 
time would potentially results in strengthened binding (and a decreased amount of 
unbound proteins).  
In conclusion, this study provides introductory information for the elucidation of the 
interaction between p53 and BcL-xL, further work is necessary to determine the 
mechanism and the roles they play in the p53-mediated transcription-independent 
apoptotic functions. 
5.7. Summary 
The past years have brought notable advancements in the understanding of the 
structure and the dynamic behaviour of p53 protein. The challenge now is to 
visualise the structure of multi-domain and full-length p53 in complex with its 
interacting proteins, which will provide further insights into the regulation of p53 
activity via its intrinsically disordered amino- terminus and the crosstalk between 
different domains. The characterisation and quantification of p53 protein-protein 
interactions is essential for understanding the nature and relevance of these 
interactions under physiological and pathological conditions. An important and much 
needed contribution comes from elucidating how the function of a higher-order 
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complex diverges from that of its individual modules, and accurately determining the 
role of each subunit in terms of its identity, stoichiometry, structure, and binding 
constant, and how these might be affected by post-translational modifications. Mass 
spectrometry in tandem with ion mobility mass spectrometry captures the multiple 
populations of protein assemblies and is capable of providing snapshots when 
monitoring the overall activity snapshots in the biogenesis pathway of the protein 
complex. Combing such data from in vivo with that of cellular protein levels will 
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Mass spectrometry and ion mobility mass spectrometry have provided valuable 
insights into the conformational diversity of tumour suppressor, multi-domain 
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6. Conclusions 
In the last ten years mass spectrometry in tandem with ion mobility mass 
spectrometry has blossomed as a powerful biophysical technique capable of 
providing unique insights into the structure and dynamics of proteins. It is an 
attractive tool in the elucidation of IDP structure, capturing detail on the 
conformational range of a polypeptide at a single conformer level, rather than 
averaged data on multiple conformations adopted by the protein, which is of central 
importance in assigning structure-function relationship to proteins that are 
conformationally mobile. This method can test the (many) biophysical assertions and 
predictions made about why they differ from structured proteins. For example, from 
the analysis of the relative intensities of ions in the charge state distribution presented 
by a protein following nano-electrospray ionization, it is possible to infer the range 
of conformational ensembles present in solution and hence the extent of disorder. 
Although it does not provide atomic resolution compared to NMR and X-ray 
crystallography the combination of mass spectrometry with ion mobility delivers 
rotationally averaged collision cross-sections of molecular ions which can be 
correlated with dynamic states of IDPs. 
In this thesis, the structural features and disorder/function relationship for the multi-
talented ‘guardian of the genome’ p53 protein were explored. 
In Chapter Three, the central core of p53, the DNA-binding domain was put under 
the ‘magnifying glass’ of mass spectrometry. The plasticity of this domain was 
reflected in the existence of multiple conformational isomers, independent of any 
binding stimuli. Under ‘near native’ conditions a wide charge state distribution was 
detected, manifesting the signature behaviour of IDPs in vacuo. In the presence of 
DNA, p53-DBD was found to possess a remarkable self-organizing ability, binding 
to double-stranded 12mer DNA as a dimer and as ‘dimer of dimers’ to double-
stranded 20mer DNA, to form 58 kDa and 110 kDa complexes. The importance of 
conformational diversity in binding was also highlighted. 
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In Chapter Four, the in vacuo conformational phenotypes exhibited by most frequent 
single-point carcinogenic mutations of p53 DNA-binding domain: R249A, R273H, 
K292I, A276Y, and R175H were defined. The study on the second-site suppressor 
from loop L1, H115N, showed that this designed mutation inflicts a drastic change to 
the observed conformational fingerprint, revealing a very plastic and disordered 
nature of this mutant. In the double mutant approach, the conformational changes 
triggered by the H115N in the hotspot cancer mutations were also examined, detailed 
in the conformational spread afforded by the double mutants.  
In Chapter Five, insights into the complex structure of p53 were provided by 
segmenting p53 into individual and multi-domain constructs, as well as interrogating 
the molecular interactions of p53 N-terminus with the most important p53 regulator, 
the E3 ubiquitin ligase Mdm2 and with BcL-xL involved in transcription-
independent apoptotic role of p53. The prevalence of intrinsic structural flexibility of 
the N-terminal region of p53 was highlighted via the presence of two persistently 
stable conformers in the unfolding pathway. The intrinsically disordered N-terminus 
induced an increase in formation of more stable higher order multimeric species such 
as dimers and trimers, in the resultant spectrum of p53-N-DBD.  The superstable 
quadruple mutant of the p53 DNA-binding domain was found to inhabit a diverse 
conformational landscape, and showed remarkable rigidity and clear resistance to 
Coulombically driven unfolding of the most compact form which was interpreted as 
a possible aftermath of the introduction of four stabilising mutations. Further, the 
investigation of p53-Mdm2 interaction revealed its extraordinary transient and 
conformationally dynamic character. Multiple conformations were resolved for the 
complex. The unfolding trajectory was found to lack any major stability regions, 
seen as ‘shelving’ of several charge states, and appeared to be more heterogeneous 
that that of individual domains of apo-Mdm2 or isolated p53. 
The p53 system presented here, undoubtedly exhibits a number of mechanistic 
features common to all IDPs: promiscuous interactions, persistent flexibility, partial 
folding in isolation, folding upon binding, conformational diversity and extensive 
regulation by post-translational modifications. Notably, this study has provided 
insights into disorder/function relationships - the functional purposes as to why 
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disorder is utilised.  IDPs are understood only to some extent on a structural level 
and it is expected that the ‘jargon’ of disorder/function relationship is much more 
extensive than is currently known. Further research of the physical properties of IDPs 
and revelation of their links with function are necessary to fully understand the 
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Table A1: Table of amino acids showing their three and one letter code, monoisotopic and average 
masses. 
 












Glycine Gly G C2H5NO2 54.021464 57.05 
Alanine Ala A C3H7NO2 71.037114 71.08 
Serine Ser S C3H7NO3 87.032029 
87.08 
87.08 
Proline Pro P C5H9NO2 97.052764 97.12 
Valine Val V C5H11NO2 99.068414 99.07 
Threonine Thr T C4H9NO3 101.04768 101.1 
Cysteine Cys C C3H7NO2S 103.00919 103.1 
Leucine Leu L C6H13NO2 113.08406 113.2 
Isoleucine Ile I C6H13NO2 113.08406 113.2 
Asparagine Asn N C4H8N2O3 114.04293 114.1 
Aspartic Acid Asp D C4H7NO4 115.02694 115.1 
Glutamic Acid 
AcAcidAcid 
Gln Q C5H9NO4 128.05858 128.1 
Lysine Lys K C6H14N2O2 128.09496 128.2 
Glutamine Glu E C5H9NO4 129.0496 129.1 
Methionine Met M C5H11NO2S 131.04048 131.2 
Histidine His H C6H9N3O2 137.05891 137.1 
Phenylalanine Phe F C9H11NO2 147.06841 147.2 
Arginine Arg R C6H14N4O2 156.10111 156.2 
Tyrosine Tyr Y C9H11NO3 163.06333 163.2 
Tryptophan Trp W C11H12N2O2 186.07931 186.2 
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Appendix 2: Amino Acid R Groups 
Non Polar Amino Acids 
 
 
Polar Amino Acids 
 
Charged Amino Acids 
 
Figure A1: Figures of amino acids from the website of the Department of Biology, Penn State 
University: https://wikispaces.psu.edu/display/bio110/Carbon+and+Life 
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Appendix 3: Properties of Drift Gases 








Effective Radius* / Å 
Helium 4.0026 0.205 1.03 
Neon 20.1797 0.396 n.d. 
Nitrogen 28.0061 1.740 1.73 
Argon 39.9624 1.641 1.67 
 
Table A2: Molecular mass, polarizability volume and effective radius for the neutral drift gases 
utilized in this study. Mass of longest lived isotopes. * Rigid-sphere model. n.d.: not determined. 
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Appendix 4: Metric System Unit Prefixes 
Prefix Symbol Factor 10
n
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Appendix 5: Physical Constants, Symbols and Units  
Symbol Name  Unit 
   
































L distance m 
M mass kg 
MR relative molecular 
weight 
Da 
N number density m
-3
 
P pressure Pa (1 Pa = 10
-5
 bar  = 9.8692 
x 10
-6
 atm = 
   
  7.5006 x 10
-3
 
Torr = 145.04 x 10
-6
 psi)                                
 
  x 10
-6





Torr Torr = 145.04 x 10
-
6
 psi Torr = 145.04 x 10
-6
 psi 
Torr = 145.04 x 10
-6
 psi)                               
Torr = 145.04 x 10
-6
 psi)                                
   
  7.5006 x 10
-3
 
Torr = 145.04 x 10
-6
 psi)                                
 
  Torr = 145.04 x 10
-6
 psi) 
T temperature K ([K] = [°C] + 273.15) 
t0 dead time S 
ta arrival time S 
td drift time S 
v velocity m s
-1
 
V potential difference V 
vd drift velocity m s
-1
 
μ reduced mass kg 
ν RF Hz = s
-1
 










 (Å = 1 x 
10
-10




Table A4: Detailed list of selected physical constants (along with their symbols and units) that were 
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